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ABSTRACT OF THE DISSERTATION 
Genetic Variations in the Regulation and Biosynthesis of Polycyclic Tetramate Macrolactams 
by 
Yunci Qi 
Doctor of Philosophy in Biology and Biomedical Sciences 
Plant and Microbial Biosciences 
Washington University in St. Louis, 2021 
Professor Joshua Blodgett, Chair 
Streptomyces are Gram-positive and filamentous bacteria with high-G+C genomes, which have 
yielded over half of all clinically used antibiotics plus many other useful compounds. Genome 
analyses indicate that these bacteria possess biosynthetic gene clusters (BGCs) encoding for 
many more antibiotic-like compounds than they are known to produce. The apparent silence of 
many BGCs poses a significant roadblock to genome-mining efforts for novel drugs. To 
understand BGC silence, I compared several Streptomyces that harbor the widespread BGC for 
polycyclic tetramate macrolactam (PTM) antibiotics to explore the genetic variations that 
differentiate robustly expressed BGCs from silent BGCs. To test the prevalent hypothesis that 
silent BGCs are transcriptionally downregulated, I specifically compared the promoters of the 
PTM BGCs encoded within closely related members of the S. griseus clade. I found that PTM 
production by S. griseus clade strains indeed varies due to differences in the strengths of their 
PftdA promoters that drive PTM production. A key finding from these experiments was an ‘AG’ 
indel that differentiated strong and ‘silent’ PftdA promoters. This ‘AG’ indel tuned PTM 
production by strongly changing PftdA strength when deleted or reintroduced in wild-type PftdA 
sequences. I also showed that the global quorum-responsive transcription regulator, AdpA, 
xv 
 
upregulated S. griseus clade PftdA promoters. Unexpectedly, I also found that PTM expression in 
the S. griseus clade strain JV180 was dependent on the griseorhodin BGC, which was only 
present in the genomes of S. griseus clade strains having robust PTM expression. This finding 
suggested that strain-to-strain differences in PTM expression is caused by more complex factors 
than just promoter sequence variations alone. Finally, I also explored the diversity of 
biosynthetic genes in PTM BGCs, and the effects of these genes on the structures of PTM 
molecules. These results demonstrate a clear utility for PTM biosynthesis as a model system for 
understanding how genetic variations ranging from the short indels to entire BGCs can tune 
antibiotic production in Streptomyces. 
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Chapter 1: Introduction – Genomics-Guided 
Drug Discovery in Streptomyces and 
Polycyclic Tetramate Macrolactam 
Biosynthesis as a Model System 
1.1 Abstract 
The genomes of Streptomyces and related bacteria contain numerous biosynthetic gene clusters 
(BGCs) for antibiotics and other drug-like compounds. However, the majority of these BGCs 
may be silent, hindering genomics-guided drug discovery. Here, I review numerous approaches 
that have been used to activate silent BGCs. To better understand the underlying biology behind 
BGC silence, I highlight polycyclic tetramate macrolactam (PTM) biosynthesis as a suitable 
model system due to its extensive conservation in Streptomyces and genetic simplicity. 
Additionally, I review recent work that have further elucidated how PTM BGCs produce such 
diverse molecules with numerous potential biotechnological applications. 
1.2  Introduction 
Streptomyces and related actinobacteria have been long studied for their diverse secondary 
metabolism (1) as well as their complex life cycle (2, 3). These bacteria belonging to the order 
Actinomycetales are characterized by Gram-positive cell walls, often filamentous growth, and 
high-G+C genomes (>70%). As non-motile bacteria, Streptomyces are thought to produce 
various specialized metabolites to interact with their environments and nearby organisms (4). 
The diversity of compounds produced by these strains are additionally thought to reflect the wide 
range of ecological niches they occupy, as Streptomyces have been isolated from terrestrial soil 
globally, marine sediments (5, 6), plants (7, 8), insects (9–11), and other sources. 
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The discovery of the antibiotic streptomycin in 1944 (1) illustrated that certain Streptomyces 
metabolites could have extraordinary value in advancing human medicine. This triggered a 
worldwide effort to isolate and screen novel strains of Streptomyces and related genera for new 
antibiotics and other drugs. Actinomycetes have yielded more than half of all clinical antibiotics 
(12, 13) as well as immunosuppressants (14, 15), chemotherapeutics (16), agricultural pesticides 
(17), and veterinary drugs (18, 19) (Figure 1).  
Streptomyces also contribute to biotechnology beyond drug production in several ways. This 
includes the production of many highly stable extracellular enzymes for decomposing 
recalcitrant organic matter with industrial applications such as cellulases and proteases (20). 
There is also significant interest in Streptomyces as biocontrol agents in agriculture, based on 





Figure 1. Streptomyces produce structurally diverse antibiotics that target similarly a diverse 
range of biological processes 
a) Streptomycin; b) Chloramphenicol; c) Thienamycin; d) Amphotericin B; e) Daptomycin; f) 
Tetracycline; g) Lincomycin; h) Fosfomycin; i) Avermectin B1a; j) Tunicamycin A 
 
Many antibiotics from Streptomyces were discovered between 1940’s and the 1970’s by 
screening environmental isolates for their ability to inhibit the growth of target microbes on an 
agar overlay plate, a method sometimes referred to as the Waksman platform (23). However, the 
discovery rate of novel antibiotics decreased greatly in later years, hampered by high rates of re-
discovery of known antibiotics (24, 25). For example, some antibiotics such as streptothricin and 
streptomycin are estimated to be produced by one in ten and one in one hundred Streptomyces 
isolates, respectively (26). As a result, discovery platforms needed to be increasingly complex to 
de-replicate a massive collection of already known molecules and discover new molecules. This 
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trend also created worries that most useful classes of antibiotics from Streptomyces had already 
been discovered (27, 28) and diminishing returns on research investment caused many 
pharmaceutical companies to shift their efforts elsewhere.  
While the development of novel antibiotics has slowed down, the spread of antibiotic resistance 
genes has continued to accelerate due to overuse of existing antibiotics in medicine and 
agriculture (29). In recent years, clinical reports have documented patients infected with “pan-
resistant” pathogens that are resistant to all tested antibiotics (30). Raising fears of a return to 
pre-antibiotic era rife with “superbugs” (31), global health organizations have called for more 
careful stewardship of antibiotic usage and the development of novel antibiotics with unique 
mechanisms of action as well as the exploration of alternative treatments such as phage therapy 
(32).  
Encouragingly, whole-genome sequencing of Streptomyces suggests that these bacteria may be 
able to produce many more antibiotics than previously discovered. Here, I will review recent 
advances in genomics-guided study of Streptomyces secondary metabolism and highlight key 
challenges that remain. Finally, I will introduce the model system we are using to improve our 
understanding of the regulation of Streptomyces secondary metabolite BGCs. 
1.3  Genomics-guided drug discovery in Streptomyces is 
hindered by silent metabolism 
Streptomyces linear chromosomes range in size between approximately 6 to 12 Megabases (33). 
The genome is considered as being divided into three regions. The central core region of the 
chromosome is typically enriched in genes involved in housekeeping processes, while the two 
outer “arm” regions that flank the core tend to encode for more specialized processes including 
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secondary metabolism. The arm regions of Streptomyces genomes exhibit frequent 
recombination, deletion, and duplication events (34, 35). In classical genetic linkage 
experiments, the biosynthetic genes for Streptomyces antibiotics were found to be co-localized in 
biosynthetic gene clusters (BGCs) (36, 37). The co-localization of antibiotic biosynthetic genes 
in these BGCs and the plasticity of Streptomyces chromosomal arm regions likely facilitate the 
acquisition of novel BGCs through conjugal horizontal gene transfer (38).  
The advent of whole-genome sequencing facilitated the identification of BGCs for compounds 
previously discovered through activity-based screening, but also revealed the presence of many 
more BGCs whose products had never been observed (39). Based on bioinformatic predictions, it 
was possible to develop targeted screens for the products of these BGCs, which resulted in the 
discovery of novel compounds (40). These observations suggested that genome-mining of 
Streptomyces and related bacteria should be able to produce many more drug candidates. 
The development of high-throughput sequencing technologies has allowed for many more 
Streptomyces genomes to be sequenced. Sequencing of Streptomyces genomes has continued to 
reveal numerous and diverse BGCs (41). However, factors such as the high G+C enrichment 
(~70%) and repeats in telomeric regions pose challenges in the assembly of Streptomyces from 
shotgun short-read sequencing. Furthermore, two major classes of natural products, polyketide 
synthases (PKSs) and non-ribosomal peptide synthetases (NRPSs), use large assembly-line 
enzyme complexes with repetitive modules with similar enzymatic domains, which can also 
confound draft genome assemblies. As a result of these factors, some BGCs in draft genomes of 
Streptomyces are often fragmented across multiple contigs. Recent improvements in long-read 
technologies such as Nanopore and PacBio sequencing have facilitated the assembly of more 
complete Streptomyces genomes and their BGCs (42). 
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In recent years, bioinformatic tools have been developed to identify secondary metabolite BGCs, 
which have been extensively reviewed elsewhere (43, 44). In brief, representative tools include 
the Natural Product Domain Seeker, NaPDoS (45), the antibiotics and Secondary Metabolite 
Analysis SHell, antiSMASH (46, 47), ClusterFinder (48), and PRediction Informatics for 
Secondary Metabolomes, PRISM (49, 50). These tools scan genome sequences for signatures of 
biosynthetic enzymes and compare the nearby gene neighborhood with documented BGCs. 
Concurrently, several databases have been developed to curate BGC sequences and their 
reported products, such as ClusterMine360 (51), the Integrated Microbial Genomes – Atlas of 
Biosynthetic gene Clusters, IMG–ABC (52, 53), the Minimum Information about a Biosynthetic 
Gene cluster (MIBiG) Data Standard and Repository (54, 55), and the antiSMASH database (56, 
57). Biosynthetic gene cluster identification, annotation, and sequence collection have improved 
in lockstep with the growing number of sequenced genomes and characterized biosynthetic gene 
clusters.  
As new genomes are sequenced, researchers have continued to discover novel clusters encoding 
for potential antibiotics and other drugs. For example, only seven BGCs were conserved between 
the first three completed Streptomyces genomes (58). Unique biosynthetic clusters can typically 
be found even when the genomes of closely related strains are compared, which indicates that 
this trend is likely to continue (59–61). Comparison of orthologous biosynthetic gene clusters in 
databases has also revealed potential chemical diversity from genetic variations in biosynthetic 
gene clusters (62, 63). Similarly, improvements in the ability to grow previously unculturable 
microbes as well as metagenome sequencing has provided access to a larger diversity of bacterial 
genomes to mine for novel BGCs. Continued advances in genome sequencing and bioinformatic 
tools will facilitate the discovery of novel BGCs.  
7 
 
While genomics-guided strategies appear to be a promising new paradigm for drug discovery, 
the characterization of the products of newly discovered BGCs has become a bottleneck. These 
numerous, newly discovered BGCs were termed “cryptic” due to the lack of a known cognate 
product. While there was some success in using targeted metabolomic approaches based on 
bioinformatic predictions of what these BGCs might make (40), this approach failed to yield the 
expected products for the majority of cryptic BGCs. These BGCs are thought to be “silent” due 
to poor transcription (64, 65). Unfortunately for the purposes of drug discovery, many more 
BGCs appear to be silent than actively expressed, severely limiting the accessible candidates in 
drug discovery (66). 
It is commonly hypothesized that these silent BGCs are downregulated in laboratory cultures due 
to the lack of stimulatory signals such as stress or competition (67). Without the necessary 
stimulus, it would be more efficient for the bacteria to not devote resources toward unnecessary 
metabolism, aside from a few BGCs which are expressed to protect the nutrients released by 
autolytic degradation of vegetative mycelia during sporulation (68). As such, significant effort 
has been put into activating silent BGCs by increasing their transcription. 
1.4  Strategies to activate biosynthetic gene clusters 
1.4.1  Regulatory manipulation 
One group of strategies for activating secondary metabolite production focuses on manipulating 
the regulation of BGCs. As Streptomyces are non-motile bacteria commonly found in soil, they 
possess complex gene regulatory networks that allow them to respond to various changes in their 
environment. This is reflected by the fact that strains such as Streptomyces coelicolor encode 
almost 900 transcriptional regulators, of which almost 100 are part of two-component sensor-
histidine kinase systems (69). Some well-characterized transcriptional regulators in Streptomyces 
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include nutrient-responsive regulators such as ppGpp (70), PhoP (71), Crp (72, 73), and DasR 
(74). Many Streptomyces sense and respond to cell density via small molecules such as γ-
butyrolactones (75, 76) and butenolides (77). Many of these are global regulators that regulate 
numerous genes to coordinate morphological development and antibiotic production (68, 78). 
Numerous studies have also shown how these global regulators interact with each other through 
direct regulation or competitive binding (79–81). These global regulators often respond to 
various incoming signals to control expression of cluster-situated regulators (CSRs) within 
BGCs. Many CSRs belong to the SARP (Streptomyces antibiotic regulatory protein), LAL 
(Large ATP-binding regulators of the LuxR family), or PAS-LuxR (Per-Arnt-Sim sensory 
domain-LuxR type HTH domain) family of transcriptional regulators.  
Due to the complex regulatory networks in Streptomyces, various cultivation conditions have 
been tested as a means of activating silent BGCs. Stress factors such as nutrient deprivation, pH, 
heat, rare earth elements, ethanol toxicity, and phage infection have been shown to induce 
various antibiotics (82–84). Additionally, co-culturing Streptomyces with other bacteria or fungi 
has been shown to trigger the production of novel antibiotics, possibly through competition 
sensing (85, 86). Similarly, upregulation of antibiotic production has been reported with the 
addition of chitin, which is a component of fungal cell walls (87). Recent research has also 
shown how signaling molecules, siderophores, and even antibiotics can mediate interspecies 
signaling between Streptomyces strains and other microbes (88–92). Recently, high-throughput 
elicitor screens (HiTES) have been developed to screen libraries of chemicals for potential 
signaling elicitors (93, 94). These approaches typically use promoters from silent BGCs fused to 
reporter genes, but imaging mass spectrometry has also been applied to directly detect 
production of cryptic secondary metabolites (95). 
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Aside from searching for triggers that activate native gene regulatory networks, much research 
has also focused on activating biosynthetic gene clusters by genetically manipulating their 
regulatory network (96). This may involve deletion or overexpression of global regulators or 
CSRs. Recently, transcription factor decoys, originally developed in mammalian systems, have 
also been explored as a method to de-repress BGCs (97, 98). However, manipulating global 
transcription regulators can lead to pleiotropic effects and not all antibiotic biosynthetic gene 
clusters have cluster-situated regulators. Global changes in regulation and gene expression have 
also been induced with spontaneous antibiotic resistance mutations in RNA polymerase or 
ribosome proteins (99). These mutations are easy to generate but have the downside of inducing 
uncontrollable pleiotropic changes like manipulation of global regulators. Although various 
strategies have been demonstrated for activating silent BGCs, no single approach has proven to 
be universally applicable. Further understanding of gene regulatory networks, the signals they 
respond to, and the targets of regulators in Streptomyces may yield new and improved strategies 
for activating silent BGCs (100–102). 
1.4.2  Bypassing regulation 
A different strategy to activating silent BGCs involves applying the synthetic biology toolkit to 
genetically re-engineer BGCs of interest. Rather than relying on potentially insufficient 
regulatory knowledge, these approaches aim to re-wire and deregulate the BGCs. One common 
approach involves replacing the native promoters of BGCs with stronger promoters to upregulate 
their expression. One of the most commonly used promoters in Streptomyces is derived from a 
strong constitutive promoter upstream of the erythromycin resistance gene, ermE, of 
Saccharopolyspora erythraea (103, 104). As Streptomyces gained more interest from synthetic 
biologists, several libraries of constitutive promoters and Shine-Dalgarno sequences have been 
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developed using transcriptomic datasets as well as computational modeling, which can be used to 
fine-tune and balance expression (105–110). Libraries of inducible promoters have also been 
characterized to provide more control over gene expression in Streptomyces (111, 112). 
However, as large biosynthetic clusters can contain dozens of genes, this approach can be 
laborious and requires the ability to rapidly engineer the Streptomyces genome. Additionally, 
many strains can be difficult to genetically manipulate due to native restriction systems, 
hindering direct genetic manipulation of biosynthetic gene clusters of interest. Recently, several 
groups have also explored the usage of CRISPR to facilitate rapid and efficient genome edits 
(113, 114). Some major challenges have included optimizing the efficiency of CRISPR editing in 
Streptomyces and decreasing toxicity from non-specific activity (115). Genome editing 
technologies that have been applied in Streptomyces have been reviewed recently (116). 
The difficulty of editing Streptomyces genomes has often been circumvented by cloning the 
BGCs of interest into large low-copy vectors (117). The resulting plasmids can be readily edited 
in E. coli cloning hosts then be heterologously expressed in more genetically tractable host 
strains. Several studies in recent years have shown improvements such as larger insert sizes and 
assembly of more fragments simultaneously (118). Additionally, several new site-specific 
integrases and their att sites have been characterized from various actinophages (119), providing 
more genomic loci which can host heterologous gene clusters (120–124). This has also been used 
to increase production titers by expressing multiple copies of the BGC of interest. An additional 
benefit of cloning biosynthetic gene clusters into large plasmids is the ability for the BGC to be 
engineered with constitutive promoters more rapidly in E. coli cloning hosts before they are 
conjugated into Streptomyces.  
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Another approach that has been applied to discover new antibiotics is the deletion of other 
BGCs. Deletion of these BGCs can help to identify compounds whose activities were masked by 
the more predominantly expressed antibiotics (125). Additionally, deletion of other biosynthetic 
pathways seems to sometimes cause regulatory and metabolic rewiring, leading to upregulation 
of quiet biosynthetic clusters (126). Furthermore, eliminating competing pathways can increase 
antibiotic titers and also result in a better suited host for expressing heterologous biosynthetic 
gene clusters (127–129). 
1.4.3  Challenges and caveats 
While the described strategies have produced promising results, activating a silent BGC typically 
still involves a significant amount of time and effort to yield. In comparison, improvements in 
genome sequencing and bioinformatic tools have made the discovery of novel biosynthetic gene 
far easier. Taken together, current approaches for activating silent BGCs are unable to keep pace 
with the rate of discovery, preventing genomics-guided discovery from fulfilling its potential. In 
addition, the reasons for why certain BGCs are expressed while others are silent are still poorly 
understood. This question can be difficult to address given the diversity of BGCs in 
Streptomyces strains, which each have their own regulatory pathways. These differences can 
mean that the findings from one BGC may not be broadly applicable to all BGCs.  
An alternative possibility for our inability to detect the products of cryptic BGCs that is 
underexplored that their encoded enzymes could have poor catalytic activity. Even when the 
products of BGCs cannot be detected, transcripts of cryptic BGCs may still be detected at some 
level in transcriptomic studies. Although overexpression of weak enzymes could overcome 
pathway bottlenecks and result in the activation of observable production, the optimization of 
these enzymes through protein engineering could be another approach to increasing production 
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while also being less taxing on the cell. However, examining enzymatic defects would be a much 
more laborious process. Since many BGCs have been activated by regulatory manipulation and 
rewiring, the success of these approaches has encouraged their proponents by demonstrating that 
the enzymes encoded within these silent BGCs are catalytically functional at some level. 
To facilitate the discovery of novel drug candidates, a better understanding of the differences 
between active and silent BGCs is needed. While approaches such as transcriptomics and 
proteomics can be used to identify strongly expressed BGCs, these methods are still relatively 
cost-prohibitive and less accessible. Improved regulatory understanding of BGC promoters could 
create guidelines for identifying BGCs that should already be expressed strongly based on 
genome sequences and also lead to new approaches for engineering weakly expressed 
biosynthetic clusters. 
1.5  Polycyclic tetramate macrolactam biosynthesis as a 
model system for studying BGC silence 
To better understand the underlying differences between strongly and weakly expressed BGCs, 
we turned to polycyclic tetramate macrolactam (PTM) biosynthesis as a model system. The BGC 
for PTM biosynthesis is widely conserved in Streptomyces, other actinomycetes, and even some 
Gram-negative bacteria (Figure 2). At the time the BGC for the frontalamide PTMs were 
originally identified, 10 of the 21 published Streptomyces genome sequences contained a PTM 
BGC (130). Strikingly, many of these strains were not known to produce PTMs. The authors 
demonstrated the pervasiveness of PTM BGCs in Streptomyces by using degenerate PCR primer 
screening to detect 10 PTM-encoding strains from a soil-isolate strain collection (JV176 - JV182 
and JV184 - JV186). The unusually high conservation of PTM BGCs and the discrepancy in 
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PTM production between strains allows for the comparison of directly orthologous BGCs that 
are strongly or weakly expressed.  
 
 
Figure 2. Representative PTM BGCs and their products. 
 
Another advantage of PTM biosynthesis as a model system is that PTM BGCs are very simple 
and compact, typically containing only 3 to 6 genes and spanning less than 20 kilobases. Most 
PTM BGCs appear to be organized as single operons controlled by one promoter, although some 
PTM BGCs have been reported to have two promoters (64). Since the precursors for PTMs, 
ornithine and malonyl-CoA, are common metabolites, they do not require additional genes 
encoding for specialized precursor units. As such, PTM regulation should be less complex than 
other BGCs, which can contain many more genes and promoters. Interestingly, many PTM 
BGCs do not appear to be associated with a CSR.  
PTM molecules are also of interest for potential applications in agriculture and healthcare. One 
highly studied PTM, dihydromaltophilin (also known as heat-stable antifungal factor, HSAF), is 
an effective broad-range fungicide (131). Lysobacter strains which produce HSAF have been 
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tested as biocontrol agents to control crop pathogens in several studies (132, 133). HSAF is 
thought to disrupt the function of ceramide synthases in filamentous fungi, and further studies 
are still being performed to better understand its mechanism of action (134–136). In additionally, 
ikarugamycin, which was originally isolated as an anti-protozoal metabolite (137), and PTM 
molecules with similar structures have attracted recent interest for their ability to inhibit cancer 
cell line proliferation (138, 139). 
Since the identification of the PTM BGC, several groups have attempted to characterize the 
PTMs produced by BGCs found in previously sequenced genomes. The first such study targeted 
the PTM BGC in Streptomyces griseus subsp. griseus strain IFO13350 (140). This S. griseus 
strain has been a model strain for studies in the AdpA quorum-responsive global regulator as 
well as streptomycin biosynthesis (141). Despite S. griseus being a well-studied strain, there had 
been no reports on any PTMs being isolated from S. griseus. Upon observing no PTM 
production, the authors reconstructed the PTM BGC with strong constitutive promoters inserted 
in front of each gene and heterologously expressed the refactored BGC in S. lividans strain 66. 
This study suggested that the native IFO13350 PTM BGC was silent, and that promoter rewiring 
could be an effective way to activate silent PTM BGCs PTMs. A further study in 2015 by the 





Figure 3. Maximum likelihood phylogenetic tree of selected S. griseus clade strains. S. griseus 
strain IFO13350 and Streptomyces sp. strain JV180 are highlighted red. atpD, gyrB, recA, rpoB, 
and trpB sequences of previously established S. griseus clade strains were taken from previous 
published lists (142, 143). S. griseus clusters I-IX, as defined by Rong et al (142, 143) were 
represented in the tree. Sequences were aligned with MUSCLE and the alignments were 
concatenated. The maximum likelihood tree was built using the GTR+I+G model using CLC 
Main Workbench. Branches supported by less than 50% of 500 bootstrap simulations were 
collapsed.  
 
Interestingly, one of the soil-derived Streptomyces strains isolated by Blodgett et al. that 
exhibited robust PTM production, strain JV180, is phylogenetically closely related to S. griseus 
strain IFO13350, with >99% identical 16S rRNA sequences (Figure 3). These strains both 
belong to the S. griseus clade, a large group of strains with highly identical 16S rRNA, which 
have been heavily sampled in drug-discovery screens (142, 143). Many S. griseus clade strains in 
the Northern Regional Research Laboratory (NRRL) culture collection run by the U.S. 
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Agricultural Research Service had their genomes sequenced and published in 2015 as part of a 
project working to mine actinomycete genomes for phosphonate natural products (144). Many of 
these genome-sequenced S. griseus clade strains also possess PTM biosynthetic clusters on their 
chromosomes, further demonstrating how widespread this biosynthetic cluster. Indeed, when 
PTM production by strains IFO13350, JV180, and eight other S. griseus clade strains from 
NRRL (JV251-JV258) were compared, four strains had active PTM BGCs while the others, 
including strain IFO13350, had silent PTM BGCs (Figure 4A). Similarly, when I characterized a 
panel of strains containing the newly discovered clifednamide-type PTM BGC, I found that some 
strains barely produced trace amounts that could only be detected by highly sensitive LC-
MS/MS while other strains produced over 20 µM (Figure 4B). These observations show that 
PTM biosynthesis may be a highly suitable model system for studying the underlying differences 
between active and silent BGCs. Recently, a similar study demonstrated the potential of such 
comparative approaches by using comparative transcriptomic analysis to study factors that 
caused differences in the expression of conserved BGCs in four strains belonging to the marine 
actinomycete genus Salinispora (145). However, this study highlighted changes in CSRs as 
possible causes for the observed differences in transcription of BGCs, and such a model likely 





Figure 4. PTM BGCs may be active or silent. LC-MS chromatograms of PTM production by (A) 
a panel of strains with clifednamide BGCs and (B) S. griseus clade strains with ftdABCDEF 
BGCs, including strains IFO13350 and JV180. Panel A was adapted from reference (146). 
 
1.6  Regulation of PTM biosynthesis 
Due to the recent discovery of the PTM BGC, there is relatively scant knowledge regarding how 
these BGCs are regulated. While many other BGCs in Streptomyces are regulated by CSRs, 
which are in turn regulated by global transcriptional regulators, PTM BGCs do not appear to 
contain a conserved CSR. The lack of CSRs may be due to the genetic simplicity of PTM BGCs, 
which eliminates the necessity for such proteins. Here, I will review prior studies related to the 
regulation of PTM BGCs. 
1.6.1 AdpA, a global quorum-responsive regulator, may regulate the PTM 
BGC of S. griseus strain IFO13350 
A genome-wide survey of AdpA binding sites suggested that the PTM biosynthetic cluster of S. 
griseus strain IFO13350 was directly regulated by the global transcription factor AdpA, which is 
part of the A-factor regulatory cascade (147). In addition to an AdpA binding signal from ChIP-
Seq, transcription of the PTM biosynthetic gene cluster was reduced in a ΔadpA mutant. 
However, as S. griseus strain IFO13350 was not known to produce PTMs, this connection went 
ignored. A-factor (2-isocapryloyl-3R-hydroxymethyl-γ-butyrolactone) was originally discovered 
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in 1967 as a diffusible extracellular molecule that caused sporulation and streptomycin 
production in bald mutants of S. griseus (148).  
As the concentration of A-factor molecules increases, they bind ArpA (A-factor receptor protein 
A), which is a transcriptional repressor of adpA (Figure 5). Binding of A-factor to ArpA causes a 
conformational shift and causes it to dissociate from the adpA promoter, allowing for the 
expression of AdpA (A-factor dependent protein A). AdpA then binds to numerous promoters 
and acts as a transcriptional activator. In S. griseus, AdpA is estimated to directly bind to and 
regulate transcription from hundreds of promoters (147). These promoters control genes involved 
in numerous processes including differentiation and secondary metabolism. AdpA also appears 
to repress its own transcription. This is supported by AdpA binding to its own promoter in vitro 
and repressing transcription in an in vitro runoff transcription experiment (149). AdpA may also 
repress A-factor production, as evidenced by a ΔadpA mutant producing ten times more A-factor 
than the wild-type strain (150). However, transcription of afsA was not affected, so the 
mechanistic link is still unclear. AdpA also forms a positive feedback loop with bldA, which 




Figure 5. The A-factor regulatory cascade. 
 
A-factor is produced in a growth-dependent manner and reaches maximum concentration during 
late stationary phase, after which it rapidly disappears (152). A-factor is produced from 8-
methoxy-3-oxononanoyl-ACP (a fatty acid derivative) and dihydroxyacetone phosphate (a 
glycolysis intermediate) and involves the enzymes AfsA (A-factor synthase A) and BprA 
(butenolide phosphate reductase A), which appear to form a two-gene operon, and a non-specific 
phosphatase (153). A BprA-independent pathway has also been observed in cell-free lysate and 
feeding experiments of ΔbprA mutants. Since the discovery of A-factor, numerous other 
diffusible signaling molecules have been characterized in various other Streptomyces strains, 
including similar γ-butyrolactones, butenolides, and 2-alkyl-4-hydroxymethylfuran-3-carboxylic 
acids (154). 
AdpA contains a N-terminal ThiJ/PfpI/Dj1-like dimerization domain and a C-terminal 
AraC/XylS-type DNA-binding domain. Consistently, AdpA dimerizes in solution and usually 
binds as a dimer to its target promoters (155). AdpA binds the consensus sequence 
TGGCSNGWWY. A structural study has shown that AdpA only directly interacts with the 
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second and fourth nucleotides in its operator consensus sequence, which explains the high degree 
of degeneracy in its consensus sequence (156). This is likely related to the large number of 
promoters that AdpA regulates.  
AdpA homologs are found in many Streptomyces strains, though not all. Although the full extent 
of the AdpA regulon in other Streptomyces strains have not been explored as thoroughly as in S. 
griseus, many studies have shown that AdpA homologs directly control the expression of 
biosynthetic gene clusters in many Streptomyces. For example, S. coelicolor A3(2), the most 
extensively studied Streptomyces model strain, contains one AdpA homolog, AdpA-c. adpA-c 
(also known as bldH), is required for morphological differentiation and production of the 
antibiotic actinorhodin (157, 158). However, AdpA-c also appears to inhibit production of 
undecylprodigiosin. Furthermore, adpA-c is not controlled by γ-butyrolactones. These 
observations show how AdpA homologs in various Streptomyces have evolved to occupy 
different roles in their gene regulatory networks.  
1.6.2 Other studies on PTM regulation 
Recently, the ikarugamycin PTM BGC of S. xiamenensis strain 318 was reported to be regulated 
by the AdpA homolog of this strain (159, 160). The authors observed that the AdpA protein of S. 
xiamenensis appears to have diverged from its well-studied homologs in S. griseus and S. 
coelicolor by sequence-based phylogenetic analysis. Furthermore, while AdpASg and AdpASc 
upregulate genes for morphological differentiation, AdpASx appears to repress morphological 
differentiation genes as well as transcription of the PTM BGC. In another study in S. 
xiamenensis strain 318, three genes were found to upregulate PTM BGC transcription when they 
were overexpressed (161). However, these proteins did not directly bind the promoter region of 
the PTM BGC, so it is unclear how they indirectly upregulate PTM production. Finally, several 
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studies have examined the regulation of the HSAF BGC in Lysobacter enzymogenes, which will 
not covered here in detail as it is unlikely that similar regulatory mechanisms are conserved 
across bacterial phyla (162–168). 
Several studies have used commonly applied synthetic biology strategies such as promoter 
replacement and heterologous expression to activate silent PTM BGCs (Table 1). One example is 
the PTM BGC belonging to S. albus strain J1074. This strain is a derivative of S. albus strain G, 
lacking the SalI restriction and modification enzymes, which makes it more genetically tractable, 
and has a compact genome of 6.8 Megabases (169). S. albus strain J1074 has been used as a 
heterologous host for antibiotic production in numerous studies, which have been reviewed 
elsewhere (127). A PTM BGC was identified in the genome sequence of S. albus strain J1074 in 
2010 (130), but this strain had not been reported to produce PTMs previously, like S. griseus 
strain IFO13350. Insertion of the strong constitutive promoter PermE* in front of either the first 
ORF, encoding the sterol desaturase, or the second ORF, encoding the iPKS-NRPS, resulted in 
strongly increased production of 6-epi-alteramide A and 6-epi-alteramide B (170). This led the 
authors to also realize a small peak for 6-epi-alteramide A could also be found in extracts from 
wild-type S. albus strain J1074. Additionally, a gene encoding for a LuxR-type transcriptional 
regulator was found approximately 7.6 kilobases upstream of the cluster. When this protein was 
overexpressed on a high-copy number plasmid, PTM production was strongly upregulated. 
However, the gene encoding the LuxR-type regulator is not co-localized with PTM biosynthetic 
gene clusters in strains aside from S. albus, and further studies would be required to investigate 





Table 1. Previous studies focused on activation of silent PTM biosynthetic gene clusters. 
Source of PTM BGC Strategy used Ref 




S. albus J1074  Promoter replacement or overexpression of 
LuxR-family regulator sshg_05706 
Transposon library screening with PTM 




S. pactum SCSIO 02999 Promoter replacement  (171) 
S. roseosporus NRRL 
15998 
Promoter replacement by CRISPR (114) 
S. sp. S10 Heterologous expression in S. sp. LZ35-
derived host and promoter replacement 
(172) 
Umezawaea sp. RD066910 Co-culture with Tsukamurella pulmonis 
TP-B0596 
(173) 
S. somaliensis SCSIO 
ZH66 
Media optimization (174) 
 
Another study in S. albus strain J1074 examined transcriptomic data and found that the PTM 
BGC appeared to be poorly transcribed compared to the overall transcriptome (64). Transposon 
mutagenesis was used to identify genes that affected expression of a reporter gene fused 
downstream of the PTM promoter. This resulted in the identification of XNR_3174, which 
encodes a transcriptional regulator which appears to downregulate several secondary 
metabolites. The protein encoded by XNR_3174 may be part of a butanolide-sensing regulatory 
system in S. albus. However, further experiments are needed to determine if the product of 
XNR_3174 directly regulates the S. albus PTM BGC.  
1.7 An introduction to PTM biosynthesis 
In the course of collecting PTM biosynthetic gene cluster sequences for promoter comparisons, I 
noticed a marked difference in the gene content between certain strains. I hypothesized that 
closer analysis of the enzymes encoded by different PTM biosynthetic gene clusters and the 
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molecules produced by these strains could help shed light on the biosynthetic pathway of PTMs 
and identify novel PTM-modifying enzymes. These findings can contribute to engineering of 
novel PTM structures molecules by combining PTM genes from various BGCs. This could 
produce PTMs with increased inhibitory activity or novel targets. Here, I will briefly summarize 
the results of publications by other groups on the roles of various enzymes on PTM biosynthesis. 
In Chapters 4-6, I will detail the hypotheses I developed from my own analyses and the 
experiments that were performed to test some of the hypotheses using available strains. 
1.7.1 PTM biosynthesis begins with an iterative polyketide synthase/non-
ribosomal peptide synthetase fusion protein  
PTM biosynthesis begins with an iterative polyketide synthase/non-ribosomal peptide synthetase 
fusion protein (iPKS-NRPS), which has been named FtdB, IkaA, CbmA, or PtmA in various 
systems. Polyketide synthases (PKSs) and non-ribosomal peptide synthetases (NRPSs) are 
modular enzymes which work like assembly lines to combine and modify various precursors to 
produce the scaffold of many natural products. PKSs are evolutionarily and functionally related 
to fatty acid synthases and polymerize acyl-CoA precursor molecules, and NRPSs function 
similarly but use amino acid substrates. Unlike fatty acid synthases and ribosomes, PKSs and 
NRPSs can use various acyl-CoA molecules and non-proteinogenic amino acids precursor 
molecules. Additionally, PKS modules may omit some of the domains required to completely 
reduce the carbon-carbon bonds between each subunit unlike fatty acid synthases, which usually 
produce completely saturated fatty acids. Finally, both PKSs and NRPSs can have domains for 
further chemical modifications. These features allow them to produce complex and diverse 
chemical structures. Iterative polyketide synthases are very similar to fatty acid synthases and 




Figure 6. The iterative polyketide synthase module uses twelve malonyl-CoA molecules to build 






This protein is notably one of few iterative polyketide synthase found in Streptomyces, although 
recent genomic analyses suggest that more exist than previously thought (175). In vitro studies 
on the iPKS-NRPS of the Lysobacter enzymogenes strain C3 HSAF cluster has shown that one 
L-ornithine and twelve malonyl-CoA precursor molecules are used to produce a polyene 
intermediate, which has been named lysobacterene A (176). The iPKS module uses one set of 
acyltransferase (AT), acyl carrier protein (ACP), ketosynthase (KS), ketoreductase (KR), and 
dehydratase (DH) domains to create two 12-carbon polyene chains (Figure 6). After the first 
polyene chain is formed, the condensation (C) domain of the NRPS module forms a peptide bond 
between it and the amine group in the side chain of the nonproteinogenic amino acid L-ornithine 
loaded on the peptidyl carrier protein (PCP) domain by the adenylation (A) domain (Figure 7). 
The iPKS module then produces a second polyketide chain, which interestingly retains an extra 
unreduced ketone group. A second peptide bond is formed between the second polyketide chain 
and the backbone amine group of the ornithine. Finally, the thioesterase (TE) domain catalyzes 
an intramolecular cyclization between the carboxyl group of the ornithine and the second 





Figure 7. The iPKS-NRPS attaches two polyene chains to an L-ornithine molecule, which 





1.7.2 The PTM cyclization cascades  
After the production of the intermediate lysobacterene A, a series of oxidoreductases catalyze the 
cyclization of the two polyene chains. PTMs can have systems such as 5-5, 5-5-6, 5-6-5 carbon 
ring systems with differing stereochemistry, which was recently shown to be dependent on the 
oxidoreductase enzymes encoded for by their BGCs  (177, 171, 172, 178). A recent study 
showed that a 5-6-5 ring system PTM producer could be engineered to produce 5-5-6 ring 
system PTMs by replacing the oxidoreductases in its BGC with those from a 5-5-6 ring system 
producing PTM BGC (179). 
Ikarugamycin, the first PTM to be discovered, is a prototypical 5-6-5 carbon ring system PTM 
(137). Ikarugamycin was found to be produced by a three-gene BGC, ikaABC, where IkaA is the 
iPKS-NRPS which produces the intermediate lysobacterene A (180). IkaB is an oxidoreductase, 
whose homologs are often annotated as phytoene dehydrogenases, and contains a Rossman-fold 
NAD(P)H binding domain. IkaC is another oxidoreductase, whose homologs are often annotated 
as alcohol dehydrogenases. The functions of IkaB and IkaC were tested in mutant studies by 
cloning the ikaABC biosynthetic gene cluster of Streptomyces sp. strain ZJ306 and 
heterologously expressing truncated biosynthetic gene clusters in S. lividans strain TK64 (177). 
These experiments revealed that IkaB catalyzes the formation of a 5-6 carbon ring intermediate 
(Figure 8). In an NADPH-dependent mechanism, IkaC forms the final 5-carbon ring through a 
Michael addition mechanism, which also results in the isomerization of a trans C=C bond to a cis 
C=C bond. There are examples of PTM biosynthetic gene clusters which contain ikaAB 
homologs in addition to other tailoring enzymes. The strains containing these clusters would 





Figure 8. Proposed biosynthetic pathway for ikarugamycin. 
 
Dihydromaltophilin, which is also known as Heat-Stable Antifungal Factor (HSAF), is the 5-5-6 
carbon ring system PTM whose biosynthesis has been studied the most extensively is. The 
HSAF biosynthetic gene cluster in Lysobacter enzymogenes strain C3 encodes for a sterol 
desaturase, an iPKS-NRPS, and four oxidoreductase genes, OX1-OX4. In addition, two genes 
encoding for a ferrodoxin reductase and an arginase upstream of the sterol desaturase and on the 
opposite DNA strand appear to support increased HSAF production but are not required for 
HSAF biosynthesis. Extensive genetic and biochemical studies have shown how OX1-4 produce 
the 5-5-6 carbon ring system of HSAF (131, 181, 178, 182) (Figure 9). OX1-OX3 are similar in 
amino acid sequence to IkaB. Genetic studies have shown that OX3 acts first and forms a 5-
carbon ring with loose stereospecificity. Depending on the stereochemistry of the 5-carbon ring, 
either OX1 or OX2 form a second 5-carbon ring. Finally, OX4, is a homolog of IkaC, and gives 





Figure 9. Proposed biosynthetic pathway for 5-5-6 ring system PTMs in Lysobacter 
enzymogenes strain C3. 
 
The biosynthetic clusters for many other 5-5-6 carbon ring system PTMs which have been 
characterized such as frontalamides, pactamides, and combamides contain two IkaB homologs. 
FtdD, PtmB2, and CbmC are all homologs of OX3 and presumably carry out the same function 
to form the first 5-carbon ring. FtdC, PtmB1, and CbmB are all homologs of OX1 and OX2, and 
presumably form the second 5-carbon ring. Finally, FtdE and PtmC are homologs of OX4 and 
presumably form the final 6-carbon ring. Some biosynthetic gene clusters lack OX4 homologs, 
such as the combamide biosynthetic gene cluster (172). It is also noteworthy that the 5-5-6 
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carbon ring systems of frontalamides, pactamides, combamides, and HSAF have some differing 
stereochemistries, suggesting slight differences between the oxidoreductases in these BGCs. 
Another interesting difference is that while OX1, OX2, and FtdC add a hydroxyl group adjacent 
to the 5-5 carbon ring system in a cylization-coupled mechanism, PtmB and CbmB do not appear 
to (183).  
1.7.3 PTM tailoring reactions 
After their cyclization, PTMs can be modified by various tailoring enzymes. One of the most 
commonly found modifications on PTM molecules is the addition of the hydroxyl group on the 
macrolactam ring, adjacent to the tetramic acid. This hydroxylation has been found in PTMs with 
5-5, 5-5-6, and 5-6-5 carbon ring systems. This modification is added by a sterol desaturase, 
which is often encoded for by the first gene in PTM biosynthetic gene clusters (Figure 10). The 
role of this enzyme was first demonstrated in HSAF production by Lysobacter enzymogenes 
strain C3 (184). This hydroxylation was required for the antifungal activity of HSAF against test 
organisms such as Penicillium avellaneum, which demonstrates the importance of this 
modification and may explain why the sterol desaturase is so widely conserved in biosynthetic 
gene clusters that produce diverse PTM molecules. They also found that the product of the 
ferrodoxin reductase gene that is co-localized with the HSAF biosynthetic gene cluster 




Figure 10. A sterol desaturase (FtdA) adds a commonly found hydroxylation to PTMs. 
 
In the subsequent study, the sterol desaturase homologs of Lysobacter capsisi strain DSM 19286 
and Saccharophagus degradans strain DSM 17024 were shown to add the same hydroxylation to 
the 5-6-5 carbon ring system PTM, ikarugamycin (185). These experiments also demonstrated 
the promiscuity of the sterol desaturases as the sterol desaturase from a biosynthetic gene cluster 
for a 5-5-6 carbon ring PTM was functional on a 5-6-5 carbon ring PTM substrate. The sterol 
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desaturases in other PTM biosynthetic clusters have been named FtdA, PtmD, CbmE, and such. 
However, some PTM clusters lack a sterol desaturase homolog. 
Aside from FtdA, many PTM biosynthetic gene clusters encode for cytochrome P450 enzymes 
such as FtdF, IkaD, CftA, and CbmD. Some of these cytochrome P450 enzymes, such as CftA 
and IkaD, have been reported to modify PTMs in various ways (Figure 11). The functions of 
other cytochrome P450 enzymes have not been fully characterized, but they may add slightly 
different modifications. Aside from other cytochrome P450 enzymes, there are likely other PTM-
tailoring enzymes that have yet to be discovered, such as halogenases and methyltransferases, 
based on published structures of PTMs (186, 187). A more comprehensive understanding of 
PTM biosynthesis could allow for the engineering of PTM BGCs with genes from different 
strains, which could be tailored for new structures.  
 
 




1.7.4 PTM metabolomics 
Due to structural similarities between PTMs, similar methods can be used to analyze PTMs 
produced by a variety of organisms. PTMs are commonly detected by UV absorbance in HPLC 
analysis. All PTMs with either 5-6-5 or 5-5-6 carbon ring systems have absorbance maxima at 
approximately 222 nm and 322 nm. On the other hand, PTMs with 5-6 or 5-5 carbon ring 
systems, which may be intermediates or terminal products depending on the oxidoreductases 
encoded by their BGCs, have absorbance maxima at approximately 270 and 365 nm instead. 
Such methods for PTM detection tended to be used in earlier studies of PTMs and were useful in 
identification of PTMs by matching peak absorbance spectra to known compound libraries (130, 
188). Liquid chromatography coupled mass spectrometry (LC-MS) has also been frequently used 
for PTM detection. 
As part of this thesis, we developed several metabolic tools for improved detection of novel 
PTMs in uncharacterized strains. Firstly, since all PTMs require the non-proteinogenic amino 
acid L-ornithine, we could add deuterium or 13C-labeled L-ornithine to growth media. Our lab 
has found that many actinomycetes are able to uptake exogenous ornithine and directly 
incorporate them into NRPS products (189). The appearance of additional peaks in the mass 
spectra due to the heavier isotopes helped identity putative PTM peaks as ornithine-incorporating 
molecules. Secondly, we also took advantage of the fact that the tetramic acid-containing 
macrolactam ring of most PTMs is the same in almost all PTMs and that diversification of PTM 
structures mostly occurs in the polycyclic portion of PTMs, except for a commonly found 
hydroxylation adjacent to the tetramic acid moiety. Using tandem mass spectrometry (MS/MS), 
were able to identify common daughter ions produced from both hydroxylated and non-
hydroxylated PTMs by collision-induced dissociation (Figure 12). This method greatly improved 
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sensitivity for PTMs by filtering out most parent ions that did not fragment into daughter ions 
that were indicative of PTM structures. This method was also compatible with the previously 
described isotopic L-ornithine feeding, as the tetramic acid is derived from the ornithine 
precursor. One caveat to the usage of LC-MS/MS filtering is that changes to the tetramic acid-
containing fragment would result in different daughter ions. A few PTMs are known to undergo 
a N-methylation on the tetramic acid, which would make the molecules undetectable by the 
current version of the method (186). However, to this day, the BGC for these PTMs have not 
been characterized, and none of the PTM BGCs described in this thesis have nearby N- or O-
methyltransferases. Nevertheless, the precursor ion scan method should be adaptable to include 
N-methylated PTMs, should the need arise. 
 
 
Figure 12. LC-MS/MS can be used to identify diverse PTMs through common daughter ions 
produced in collision-induced dissociation. Atoms derived from ornithine, which can be fed in 





Streptomyces and related bacteria were once the focus of intense screening by pharmaceutical 
companies, which yielded over half of all clinically used antibiotics and numerous other drugs. 
Recent advances in whole-genome sequencing and bioinformatic tools has revealed that the 
genomes of these organisms contain many more BGCs for drug-like compounds than previously 
known. However, many of these BGCs are apparently silent in laboratory cultures, posing a 
major roadblock to genomics-based drug discovery. Researchers have developed various 
approaches to activate these BGCs, which are thought to be downregulated. These include 
screening for various factors which can trigger increased expression from these BGCs as well as 
leveraging the growing synthetic biology toolkit to replace the native regulatory elements of 
these BGCs.  
Although these approaches have resulted in the discovery of numerous new molecules, none of 
them are universally applicable to all BGCs and activating a silent BGC can still be a laborious 
process. Additionally, the reason some BGCs are silent while others are active remains largely 
unaddressed. A better understanding of why active and silent BGCs are different could 
streamline genomic-based discovery by predicting which BGCs should be expressed as well as 
help develop new engineering strategies to activate silent BGCs. In this work, I used the widely 
conserved BGC for PTMs as a study system to try to address this and other questions: 1) How do 
mutations in promoter sequences result in active and silent PTM BGC expression? 2) Are there 
other genetic changes that affect PTM BGC expression? 3) How do genetic changes in PTM 
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Chapter 2: Genetic Variations in 
Transcriptional Regulation of Polycyclic 
Tetramate Macrolactam Biosynthesis 
This chapter was previously submitted in the journal Proceedings of the National Academy of 
Sciences, and is currently in revision after undergoing peer review: 
Qi Y., Nepal K. K., and Blodgett J. A., A Comparative Metabologenomic Approach Reveals 
New Mechanistic Insights into Streptomyces Antibiotic Crypticity, PNAS (In revision).  
2.1 Personal contribution 
S. griseus strain IFO13350 and eight other S. griseus clade strains (JV251-258) were obtained 
from the Agricultural Research Service culture collection (NRRL – Northern Regional Research 
Laboratory). Strains JV180 and SP18CM02 are soil isolates (see Chapter 6). Dr. Nepal, who 
joined the Blodgett lab postdoc in late 2018, and I each designed and generated roughly half of 
all strains, plasmids, and oligonucleotides described in this manuscript (see Tables S1-S3). I 
performed the phylogenetic, LC-MS/MS, and RT-qPCR analyses. Dr. Nepal cloned, expressed, 
and purified AdpA and performed the EMSA assays. Dr. Nepal, Dr. Blodgett, and I wrote the 
manuscript. 
2.2 Abstract 
Streptomyces genomes harbor numerous biosynthetic gene clusters (BGCs) encoding for drug-
like compounds. While some of these BGCs readily yield expected products, many do not. 
Biosynthetic crypticity represents a significant hurdle to drug discovery, and the biological 
mechanisms that underpin it remain poorly understood. Polycyclic tetramate macrolactam (PTM) 
antibiotic production is widespread within the Streptomyces genus, and examples of active and 
cryptic PTM BGCs encoded by Streptomyces griseus are known. To reveal new insights into the 
55 
 
causes of biosynthetic crypticity, we employed a PTM-targeted comparative metabologenomics 
approach to analyze a panel of S. griseus strains that included both poor and robust PTM 
producers. By comparing the genomes and PTM production profiles of these strains, we 
systematically mapped PTM promoter architecture within the group, revealed that these 
promoters are directly activated via the global regulator AdpA, and discovered that small 
promoter indels differentiate weaker PTM producers from stronger ones. We also revealed an 
unexpected link between robust PTM expression and griseorhodin pigment co-production, with 
weaker S. griseus PTM producers being unable to produce the latter compound. This study 
highlights promoter indels and biosynthetic interactions as important genetically encoded factors 
that impact BGC outputs, providing mechanistic insights that will undoubtedly extend to other 
Streptomyces BGCs as well. We highlight comparative metabologenomics as a powerful 
approach to expose genomic features that differentiate strong antibiotic producers from weaker 
ones. This should prove useful for rational discovery efforts and is orthogonal to current 





Many therapeutics derive from natural products and their synthetic analogs (1). Historically, 
Streptomyces and related actinobacteria were heavily screened for these molecules, which 
resulted in numerous essential medicines. These include many clinical antibiotics (2), and there 
is an urgent need for new anti-infectives to counter increasing drug-resistance (3). A massive 
reservoir of uncharacterized biosynthetic gene clusters (BGCs) encoding drug-like molecules 
resides within Streptomyces genomes, which has triggered resurgent interest in these organisms 
(4). However, a large proportion of these BGCs fail to produce detectable expected compounds 
under laboratory conditions. This phenomenon of cryptic or silent metabolism thus poses a 
significant hurdle to genomics-driven drug discovery (5, 6). Silent BGCs are often thought to be 
transcriptionally deficient, and synthetic biology, cell signaling, and stress mechanisms are 
commonly used to activate silent BGCs for molecule discovery (7). However, a deeper 
mechanistic understanding of Streptomyces silent metabolism is still needed to access the full 
biosynthetic potential of these organisms to overcome the drug discovery gap (8). 
Here, we employed a comparative metabologenomic approach to dissect why certain 
Streptomyces strains are ready antibiotic producers while others have apparently silent BGCs. 
Polycyclic tetramate macrolactam (PTM) antibiotics were specifically targeted in this study 
because they provide an opportune model system for multi-strain comparative analyses. This is 
because PTM BGCs are atypically common within Streptomyces genomes compared to most 
other antibiotic families, and this commonality is leverageable for deep trait comparisons 
between several individual producers. The environmentally and biotechnologically- important 
Streptomyces griseus clade (9) was identified as a particularly advantageous cohort for these 
comparisons; multiple strains within it have established active or cryptic PTM BGCs (10, 11), 
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plus several additional family members with sequenced genomes and yet-unstudied PTM 
clusters were available from public collections. Finally, PTM biosynthesis is increasingly 
understood, and this foundational knowledge was necessary to enact a targeted metabolomics 
approach to document sensitive production differences. PTMs have experienced intense study 
towards understanding their unusual hybrid non-ribosomal peptide/polyketide origins, 
investigating PTM therapeutic potential, and leveraging their ease of manipulation via synthetic 
biology (12).  
This study was initiated by comparing the genomes and PTM production profiles among a cohort 
of PTM locus-bearing S. griseus strains, which included known examples of both strong and 
poor PTM producers. This led to the discovery a S. griseus phylogenetic subclade that has 
consistently higher PTM production and PTM BGC promoter strengths compared to the rest of 
the test strains. Despite the exceptional commonality of PTM biosynthetic loci in Streptomyces 
bacteria, PTM regulation remains poorly understood. To reveal how promoter sequence 
variations might underpin the observed PTM phenotype differences, the promoter driving 
production in the robust producer Streptomyces sp. strain JV180 was thus mapped and compared 
against the rest of the clade. Overall, many promoter features appeared to be largely conserved 
within the group, regardless of host-strain PTM capability. Additionally, the global regulator 
AdpA was confirmed to play a direct positive role on PTM locus control through gene deletion, 
binding site mutation, and in vitro binding experiments. AdpA binding sites were detected in the 
PTM promoters of all tested clade members, where they display a contextually unusual 
arrangement downstream of promoter -10 boxes. Critically, comparisons of strong and weak 
PTM promoters from several S. griseus clade members identified a 2-3 bp indel, located between 
the −10 box and AdpA operator site, that strongly influences PTM production strength. Yet 
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another PTM control mechanism that differentiates weak from stronger PTM producers was 
discovered following the mutagenesis of strain JV180’s griseorhodin BGC. Weak S. griseus 
clade PTM producers natively lack griseorhodin BGCs, and loss the JV180 cluster severely 
curtailed PTM production. Further dissection revealed that strain JV180s PTM production likely 
benefits from PTM-griseorhodin co-expression via a yet-uncharacterized transcriptional 
mechanism. In sum, this work revealed two new mechanisms by which stronger and weaker 
PTM producers are differentiated, and it highlights the application of targeted comparative 
metabologenomics to cohorts of highly related strains to successfully reveal otherwise difficult-
to-detect genomic features that tune antibiotic production.  
2.4 Results 
2.4.1  The S. griseus clade is an ideal model group to compare and reveal 
genetic underpinnings of PTM crypticity 
Several features of the S. griseus clade make the group attractive for comparison-based 
approaches to reveal BGC silencing mechanisms. Clade-member Streptomyces sp. strain JV180 
is a ready producer of the compounds (10, 13), while S. griseus subsp. griseus strain IFO13350 
harbors a silent PTM BGC (11, 14). The PTM production status of most other clade members 
remained unknown, and to benefit from the increased analytical depth afforded by expanded 
cohort sizes, several additional clade-members having PTM loci in their sequenced genomes (15) 
were obtained from public strain repositories (JV251-JV258). To complete the cohort, the 
environmental clade-member Streptomyces sp. strain SP18CM02, whose genome was recently 
reported by our group was also added (13) (Table S1). The close phylogenetic relationships of 
these strains were confirmed through multi-locus phylogeny (9) (Fig. S1). Further, the exact 
synteny observed among their PTM coding regions (Fig. 1A) and the high pairwise PTM enzyme 
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sequence identities encoded within each strain indicate that their PTM BCGs are orthologous 
(Table S4).  
 
 
Figure 1. Differences in S. griseus PTM production correlate with putative PTM promoter 
region sequence variation. (A) In all tested S. griseus strains, the PTM locus is comprised of a 
conserved set of genes ftdA-F. The non-PTM upstream and downstream genes in all test strains 
respectively encode a cysteine desulfrase (ORF -1) and mandelate racemase (ORF +1). (B) PTM 
production is most robust on solid media (blue bars, n = 3) versus when strains are grown liquid 
(brown bars, n = 4) media. PTM quantification in each was obtained by normalizing the sums of 
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LC-MS/MS PTM peak areas by protein content, and then plotted relative to the PTM production 
by strain JV180 grown on solid media. n.d. = not detected. (C) Neighbor-joining tree of PftdA 
region sequences extracted from the intergenic region upstream of each strain’s ftdA gene. This 
tree indicates that PftdA sequences of JV180-like strains form a separate group from the other 
(IFO13350-like) PftdA’s. The analogous PftdA region of Streptomyces albus strain J1074 was used 
as an outgroup. These intergenic region sequences were aligned with MUSCLE and the tree was 
built using the Kimura substitution model in CLC Main Workbench. Branches supported by less 
than 50% of 500 bootstrap simulations were collapsed. (D) PTM production resulting from non-
JV180 PftdA regions (source strains on X axis) swapped into JV180 for functional analyses (n = 
3). (E) Relative ftdB transcript abundance from JV180 promoter-swapped strains in panel D (n = 
6, except JV1178 where n = 3). From these data, a clear trend emerges where strains and their 
PftdA-region promoters sourced from the S. griseus group that includes JV180 (green highlights, 
panels A-D) yield higher PTM production and transcription compared to the rest of the tested S. 
griseus most closely related to IFO13350 (red highlights, panels A-D). 
 
To assess and compare PTM production in these strains, the robust PTM-producing strain JV180 
served as an archetype. Strain JV180 PTM production was extensively analyzed using 
approaches similar to those reported for clifednamide-type PTM analyses in other Streptomyces 
by our group (16). Putative PTM peaks were identified using 13C5-labeled ornithine precursor 
incorporation and diagnostic daughter-ion production following collision-induced dissociation in 
liquid-chromatography coupled tandem mass spectrometry (LC-MS/MS). These target the 
conserved ornithine-derived tetramate region, which has two possible hydroxylation states (see 
Fig. S2B-E, S3). As expected, all PTM peaks identified through these methods were absent when 
the JV180 PTM BGC was deleted (ΔftdABCDEF; Fig. 1A, S2A), yielding a high-confidence set 
of S. griseus clade PTM congeners for quantitative production comparisons. 
The remaining S. griseus clade strains were then grown under several growth conditions, and 
their extracts were analyzed via LC-MS/MS and UV spectrometry for PTM production (see 
Methods). As expected from orthologous PTM BGC’s, all producing strains gave PTM signals 
that largely overlapped with those established in JV180, but strain-to-strain differences in 
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quantity and relative PTM congener ratios were observed. From these comparative PTM 
production data, an interesting trend emerged. Strains JV180, SP18CM02, and JV251-253 
displayed robust PTM production while the remaining strains generally showed little production 
(Fig. 1B, S4-S6). We noted that these strains belong to a distinct subclade on the S. griseus 
phylogenetic tree (Fig. S1, group VI in green), suggesting they might share a conserved genetic 
basis for increased PTM production versus the other studied clade-members. Interestingly, these 
comparative production analyses revealed a clear bias for higher PTM production on solid media 
over shake-flask cultures for all tested strains (Fig. 1B). The strongest PTM producers continued 
to have the highest production in liquid media as well. Throughout, to obtain consistent 
transcriptional information, liquid media was used. Further, in agreement with prior publications, 
PTM production could be detected by UV absorbance in JV180 (10), while strain IFO13350 
produced insufficient PTMs for detection using this method (Fig. S7A). In contrast, our PTM 
targeted LC-MS/MS analyses revealed detectable production in all tested clade members, but the 
amounts varied widely by strain. This suggests prior efforts to characterize weak PTM producers 
may have overlooked scant actual production due to inherent UV limitations, overcome here by 
MS/MS methodology (Fig. S7B, C).  
2.4.2  PTM promoter sequence heterogeneity contributes to differences in 
antibiotic production 
Because the most robust PTM production was found in strains of the JV180 subclade, we 
hypothesized that comparing these genomes against other S. griseus strains could reveal specific 
differences that underpin the observed production disparities. PTM BGC transcriptional 
differences were immediately targeted as a potential mechanism. While weak transcription is 
often implicated in the cryptic biosynthesis literature, this assertion is often speculative or left 
without mechanistic investigation (17). The possibility of PTM biosynthetic enzyme defects in 
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some strains was ruled out as a potential cause. This is because all tested strains have high PTM 
BGC protein-sequence identity (Table S4), and previous transcriptional refactoring experiments 
were able to successfully activate the cryptic PTM BGC of strain IFO13350 in heterologous 
hosts as a demonstration of BGC functionality (11, 14). 
Possible strain-linked differences in PTM BGC transcription were initially explored by 
comparing the presumed PTM promoter regions of each strain tested here. S. griseus PTM BGCs 
have a simple and conserved gene arrangement with minimal intergenic gaps, suggestive of a 
single operon (Fig. S8A). PCR amplification of cDNA intergenic junctions confirmed that the 
JV180 PTM BGC is transcribed as a single operon (Fig. S8B).  
Phylogenetic analysis of the ~500 nt located upstream of the first gene in each studied PTM 
BGC, ftdA, formed two groups: one by JV180-like strains and one by the remaining strains 
(these sequences are hereafter referred to as JV180- or IFO13350-like PftdA’s, respectively; Fig. 
1C, S9). To test if the sequence differences in PftdA regions are transcriptionally relevant, we 
leveraged the strong PTM producer JV180. JV180 represents a uniform background to eliminate 
complicating metabolic and genetic variables inherent to strain-to-strain comparisons. After 
replacing the native promoter region of JV180 with the corresponding region of the other 10 S. 
griseus strains in this study, we observed higher PTM production and ftdB transcription from 
JV180-like PftdA’s than IFO13350-like PftdA’s (Fig. 1D, E). This supports the idea that stronger 
PTM producers might result from inherently stronger promoters. Surmising that the basic 
transcriptional machinery of all S. griseus strains should be highly similar, we also hypothesized 
that if JV180-like PftdA’s are stronger than IFO13350-like PftdA’s, then introducing the former 
promoter type into strain IFO13350’s PTM BGC should increase PTM production and 
transcription. However, exhaustive attempts to introduce the necessary plasmids to engineer 
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increased production in IFO13350 (and other group member JV257; Fig. S1) failed by both 
conjugation and protoplast transformation. Instead, the effects of PftdA sequence variation were 
assayed in strain IFO13350 using a xylE (18) reporter gene chromosomally integrated into the 
ΦC31 site. Controls testing the efficacy of colorimetric XylE assays in both strains JV180 and 
IFO13350 were successful when using the strong- constitutive promoter PermE*, but both 
PftdA_JV180 and PftdA_IFO13350 failed to drive observable XylE in both strains. However, RT-qPCR 
assays to detect xylE transcripts were successful in making the desired comparison, confirming 
PftdA_JV180 to be stronger than PftdA_IFO13350 in both JV180 and IFO13350 hosts (Fig. S10). 
Together, the above data support the initial idea that PftdA sequences from strong and weak PTM 
producers determine PTM production. 
2.4.3  Mapping promoter regions of the JV180 PTM BGC enables structure 
function comparisons 
Existing PTM regulatory knowledge is sparse (19, 20), including within the S. griseus clade. Our 
above results suggested that S. griseus PTM regulation involves cis-regulatory elements located 
directly upstream of ftdA (~500 nt). To define the PTM promoter architecture of these strains, the 
transcriptional start site (TSS) of strain JV180 was mapped via circular Rapid Amplification of 
cDNA Ends (5’-cRACE). The putative TSS was a cytosine residue 195 nt upstream of the 
predicted start codon of ftdA (Fig. S11). Likely −10 and −35 boxes were assigned based upon 
established spacing (21, 22) (Fig. 2A). The high sequence conservation between the −35 box and 
the TSS (82.4% - 100% pairwise sequence identity) suggested that all examined S. griseus 
strains share the same core promoter (−35, −10 and TSS).  
To better resolve PftdA promoter architecture and probe for the presence of cis-regulatory 
signatures upstream of the predicted −35 boxes, a series of nested deletions in this region were 
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created in JV180 (Fig. 2A). PTM transcription and production in these deletions were largely 
unaffected, except where the putative −35 box was disrupted (Fig. 2A, Δ−528_−31). This 
confirmed the position of the JV180 −35 box, and suggested this region lacks any critical 
regulatory residues (Fig. 2B, C). Further, we observed generally low sequence conservation 
within this region upstream for all studied S. griseus strains (38.2% - 97.8% pairwise sequence 
identity). This contrasts with the high conservation seen for the core promoter region (−35, −10 
and TSS).  
 
Figure 2. Mapping of PftdA and identification of cis-regulatory elements by deletion analysis. 
(A) Diagram of the JV180 PftdA region, with the zones deleted upstream of PftdA diagrammed 
below. Inset: alignment of the core promoter sequence (note: the sequences are identical in 
JV180-like PftdA’s). (B) Relative PTM production from JV180 mutants with deletions in the 
upstream region of PftdA (n = 3). (C) Relative ftdB transcript abundance from JV180 mutants with 
deletions in the upstream region of PftdA (n = 6). (D) Diagram of the PftdA untranslated region 
(UTR) downstream of the transcript start site. Regions deleted downstream of PftdA are 
diagrammed below. Inset: cartoonized representation of the JV180 PftdA UTR secondary structure 
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predicted by mFold. (E) Relative PTM production from PftdA UTR truncation mutants (n = 3). (F) 
Relative ftdB transcript abundance from PftdA UTR truncation mutants (n = 6). 
 
The –10 boxes and TSS residues of all examined strains are perfectly conserved, but several 
single nucleotide polymorphisms (SNPs) differentiate the −35 boxes of the IFO13350-like PftdA’s 
(Fig. 2A, red box) from the strictly conserved −35 boxes of the JV180 group (Fig. 2A, green 
box). Because these SNPs could contribute to PftdA strength variations, a panel of JV180 mutants 
carrying each observed −35 box SNP in the IFO13350 group was created and tested for PTM 
production and transcription (Fig. S12A). These IFO13350 group −35 box SNPs failed to 
significantly change PTM production and only slightly decreased transcription in the chimeric 
JV180 hosts (Fig. S12B, C). These differences were subtle compared to the far more substantial 
ones seen in our ~500 nt replacements upstream of the ftdA gene (Fig. 1D and E), indicating PftdA 
strength differences must originate through mechanisms other than −35 box differences.  
2.4.4  AdpA positively regulates S. griseus PTM BGCs 
Many Streptomyces mRNAs contain long 5’ untranslated regions (5’ UTRs)(21, 22), which can 
contribute to regulatory tuning. The DNA regions encoding 5’ UTRs can modulate gene 
expression through direct regulator binding (23), and their corresponding mRNAs can further 
modulate expression via riboswitches (24) or other RNA secondary structures (25). A series of 
~20 nt deletions were constructed (Fig. 2D) across the 195 nt 5’ UTR region of JV180 to probe 
contributions to PTM regulation. This revealed multiple lesions with strongly decreased PTM 
production and transcript levels, while others had little effect (Fig. 2E, F). mFold (26) modeling 
to reveal possible 5’UTR mRNA secondary structures across S. griseus strains yielded several 
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energetically favored outputs, and we surmise some of the deleterious mutational effects seen in 
JV180 might stem from the disruption of these types of structures (Fig 2D inset, Fig. S13-17).  
While S. griseus PftdA 5’ UTR folding remains to be further explored, the above deletions were 
particularly useful for identifying a critical region that we subsequently characterized as an 
AdpA binding site (Fig. 2D-F; Δ29_48, Fig. S9). AdpA is a global regulator that is well-studied 
in strain IFO13350, where it is known to bind >500 chromosomal sites via its weak consensus 
sequence TGGCSNGWWY (27). S. griseus AdpA is involved in the hierarchical control of 
morphological differentiation, the production of streptomycin and other antibiotics, and several 
other important processes (28). Prior ChIP-Seq and RNA-seq data indicated that AdpA might 
bind upstream of IFO13350’s PTM BGC (29), but because prior efforts to elicit PTM production 
from wild-type IFO13350 were unsuccessful (11, 14), the biological significance of AdpA’s 
interaction with the gene cluster was tenuous. Our searches for potential AdpA consensus motifs 
within the PftdA regions of the studied S. griseus clade strains revealed an imperfect inverted 
repeat 29-48 nt downstream of the TSS in the JV180 PftdA (within the 5’ UTR region) that was 
conserved in all S. griseus strains examined. Because our nested deletions revealed that this 
sequence is essential for JV180 PTM production (Fig. 2D-F, Δ 29_48, Fig. S9), it renewed the 
notion that AdpA might positively regulate PTM expression.  
Several experiments were carried out to investigate whether AdpA regulates PftdA, including 
adpA deletion and complementation analysis, mutating the putative AdpA binding site in PftdA, 
and in vitro binding assays. As expected from prior adpA studies in strain IFO13350 (30), 
deletion of the JV180 ortholog (ΔadpA) led to the loss of morphological differentiation and 
pigmentation (Fig. S18). PTM production and BGC transcription were also abrogated in JV180, 
and these defects were rescued by ectopically expressing either native adpA, its IFO13350 
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ortholog (97% amino acid identity vs JV180 AdpA) or by replacing PftdA with the strong 
constitutive promoter PermE* to drive PTM BGC expression independent of AdpA (Fig. 3A, B, 
S19). These results were consistent with AdpA being a transcriptional activator for PftdA. 
However, in bacterial regulation, regulators binding downstream of the RNA polymerase 
complex typically cause transcriptional down-shifts. Thus, the location of the putative AdpA 
operator site downstream of the conserved –10 box is unusual for a transcriptional activator. 
Importantly, another AdpA-activated promoter with a downstream operator site controls S. 
griseus IFO13350 adsA, encoding an extracytoplasmic function sigma factor (23). This 
precedent thus supports the idea that AdpA could positively regulate PTM expression despite its 





Figure 3. AdpA is required for PTM expression and directly binds PftdA in vivo and in vitro. 
(A) Relative PTM production from JV180, its ΔadpA mutant, and complementation of PTM 
production by adpA or replacement of PftdA with the constitutive PermE* (n = 3). (B) Relative ftdB 
transcript abundance from JV180, its ΔadpA mutant, and complementation of PTM transcription 
by adpA or replacement of PftdA with the constitutive PermE* (n = 6). n.d. = not detected. (C) 
Alignment of the PftdA AdpA binding sites, with non-conserved nucleotides highlighted in red 
(note: the sequences are identical in the JV180-like PftdA’s). (D) Relative PTM production from 
JV180 PftdA AdpA binding site mutants (n = 3). (E) Relative ftdB transcript abundance from 
JV180 PftdA AdpA binding site mutants (n = 6). EMSA assays for His-tagged JV180 AdpA 
interaction with the (F) JV180 PftdA binding site, (G) IFO13350 PftdA binding site, or (H) a JV180 
PftdA binding site containing a transversion mutation in one of the nucleotides (red, underlined) 
directly interacting with AdpA, which was necessary for protein-DNA interaction. The lane 
marked by the + sign is a positive control using wild-type JV180 probe sequence. 
 
AdpA-DNA co-crystallization studies indicate that the protein binds target operators as a 
homoduplex that recognizes a highly variable motif, containing four core invariant guanosine 
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and cytosine nucleotides (Fig. 3C, bold residues in gray box) (27). In all S. griseus PftdA 
promoters studied here, these invariant residues were perfectly conserved, and introducing a 
transversion mutation at any one of these nucleotides abrogated JV180 PTM production and 
transcription (Fig. 3C-E). This additional evidence further suggests that the identified region acts 
as a functional AdpA operator. Exchanging the JV180 AdpA operator site with that from 
IFO13350 was PTM proficient although it showed a slight decrease in PTM titer and ftdB 
transcription (Fig 3C-E). AdpA-PftdA interactions were further examined via electrophoretic 
mobility shift assays (EMSA) using operator sequences from JV180 and IFO13350, plus the 
critical point mutants that disrupt essential DNA-AdpA interactions. As expected, recombinant 
histidine-tagged AdpA bound the JV180 and IFO13350 PftdA AdpA binding sites (Fig. 3F, G) but 
failed to shift operators with the in vivo tested point mutations (Fig. 3H, S20). Together, our in 
vivo and in vitro data strongly suggest that AdpA directly binds PftdA in both JV180 and 
IFO13350, but also indicate that the native SNPs (Fig. 3C, red residues) in the non-essential 
residues of the AdpA operator sites are not the main cause of PTM expression differences seen 
between PftdA_JV180 and PftdA_IFO13350 (Fig. 3D,E).  
2.4.5  Comparative promoter analyses reveal an indel “switch” that tunes 
PftdA strength and PTM production 
Aside from the AdpA operator, the JV180 PftdA 5’ UTR truncation experiments revealed that the 
28 nucleotides between the TSS and the AdpA binding site are also critical for PTM expression 
(Fig. 2B-F, Δ2_28). Nucleotide alignments between promoters in this region revealed generally 
high conservation, except for two nucleotides (AG) that are present in all JV180-like PftdA’s but 
are missing from IFO13350-like PftdA’s (Fig. 4A, S8). The effects of this indel on PTM regulation 
were tested by deleting this AG dinucleotide from JV180, and by introducing the dinucleotide at 
the corresponding position in PftdA_IFO13350 (PftdA_IFO13350+AG). PftdA_IFO13350+AG was tested 
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heterologously in strain JV180. Strikingly, the dinucleotide deletion led to strongly reduced PTM 
production and transcription, while the amended PftdA_IFO13350+AG insertion variant led to a 
substantial increase in JV180 PTM production and transcription compared to the wild type 
PftdA_IFO13350 sequence (Fig. 4B, C). To test if the indel’s effect was sequence specific, a JV180 
transversion (ΔAG::CT) mutant was created, which exhibited reduced PTM production and 
transcription compared to wild-type, but was much less deleterious than ΔAG (Fig. 4B,C). This 
region is seemingly prone to sequence plasticity within the S. griseus clade; the recently isolated 
strain SP18CM02 contains an additional guanosine in this region compared to other JV180-like 
PftdA’s (Fig. 4A). Despite having otherwise high overall identity to all other JV180-like PftdA’s, 
PftdA_SP18CM02 drove slightly less transcription and resultant PTM production when heterologously 
introduced into JV180 (Fig. 1D, E). Together, these data suggest that of the natural sequence 
variants in this region, having the AG dinucleotide is important for PTM production. These data 
clearly reveal this indel region as a key factor in modulating natural S. griseus PftdA strength. 
Further work is necessary to discern how this indel region modulates promoter strength, possibly 
via mechanisms such as perturbed AdpA-RNA polymerase interactions or recruitment of another 




Figure 4. A conserved AG(G) indel tunes strong and weak PftdA’s. (A) Alignment of the PftdA 
UTR section containing the conserved AG(G) indel between the TSS and the AdpA binding site. 
Non-conserved nucleotides are indicated in red. (B) Relative PTM production from JV180 
PftdAΔAG mutants and JV180 ΔPftdA::PftdA_IFO13350±AG mutants (n = 3). (C) Relative ftdB 
transcript abundance from JV180 PftdAΔAG mutants and JV180 ΔPftdA::PftdA_IFO13350±AG mutants 
(n = 6, except for JV1032 where n = 3).  
 
2.4.6  Discovery of an unexpected griseorhodin biosynthetic interaction that 
strengthens PTM production in strain JV180 
Our data thus far illustrated how leveraging within-clade comparative metabologenomics can 
assist regulatory region mapping, and how small easily overlooked nucleotide changes in these 
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regions can tune antibiotic production. The use of comparative genomics to understand 
Streptomyces antibiotic production, particularly at the species level, is a relatively recent 
development in natural products functional genomics. Studies in this area tend to focus on BGC 
conservation and differentiation (e.g. comparison of the S. albus clade, see (31)). From these 
comparisons, we anticipated that our S. griseus strains would share several BGCs (beyond 
PTMs), and that some antibiotic BGCs in these strains would not be conserved clade-wide. We 
found that our S. griseus strains share a core set of 13 conserved BGCs. Some BGCs were found 
in only a few strains, and several BGCs were unique by strain (Fig. S21). Strikingly, strain 
IFO13350 is one of the oldest known producers of streptomycin (32), but all members of the 
JV180 group were found to lack this BGC. Likewise, we noted that JV180 group strains produce 
red pigments that are absent from the other studied S. griseus strains (Fig. S22). Through 
comparative BGC analysis and subsequent cluster deletion in strain JV180, we attributed this 
pigment to the production of griseorhodin polyketide congeners (33) (Fig. 5A; ΔgrhR2-V, S23A-
C). Unexpectedly, this griseorhodin BGC deletion mutant exhibited several additional 
phenotypes, including abrogated PTM production, downregulated PTM BGC transcription, and 






Figure 5. Deletions in the JV180 griseorhodin (grh) BGC often negatively impact PTM 
production and transcription by PftdA. (A) Diagram of the JV180 griseorhodin BGC with gene 
ranges deleted in various mutants mapped below as corresponding colored bars. (B) Relative 
PTM production from various grh mutants in JV180 rpsL (white background) and JV180 
ΔPftdA::PermE* background strains (grey background, n = 3). n.d. = not detected. (C) Relative ftdB 
transcript abundance from various grh mutants in JV180 rpsL and JV180 ΔPftdA::PermE* 
background strains as noted in panel B, (n = 6).  
 
The loss of PTM production in the JV180 ΔgrhR2-V mutant was wholly unexpected, and the 
mutant’s pleiotropic phenotypes suggested griseorhodin might act as a signaling molecule. To 
test this, four adjacent genes encoding griseorhodin polyketide synthase (PKS) assembly-line 
enzymes were deleted (ΔgrhQSAB) (Fig. 5A). This was done to specifically eliminate 
griseorhodin production, while leaving all other grh BGC genes intact. Interestingly, this mutant 
was PTM-proficient, arguing against the signaling idea. To further probe how the griseorhodin 
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BGC exerts its influence, we tested a griseorhodin-enriched JV180 growth extract (see methods, 
Fig. S25A) and authentic γ-rubromycin (34) (a griseorhodin analog) for their ability to 
chemically complement the ΔgrhR2-V strain. Neither sample could restore PTM production in 
the ΔgrhR2-V mutant in flask cultures (Fig. S25B), and disk diffusion tests on agar plates failed 
to restore sporulation in the diffusion zone (Fig. 25C). These experiments together ruled out the 
griseorhodin signaling hypothesis. 
To continue probing the grh locus for key PTM-influencing genes outside of grhQSAB, multiple 
groups of genes were deleted from the BGC (grhR1-E, grhFGH, and grhI-P; Fig. 5A). All three 
mutations caused complete loss of red griseorhodin pigmentation and showed reductions in PTM 
production and transcription (Fig. 5B, C, S23D, S26B). Homology-based annotations of the 
genes in these regions (33) led us to focus on a subset which might affect PTM biosynthesis 
through transcriptional or metabolic mechanisms. Genes grhR2 and grhR3 encode transcriptional 
regulators, which could influence regulatory crosstalk, grhF encodes a phosphopantetheinyl 
transferase (essential for posttranslational modification of NRPS and PKS enzymes), and grhGH 
encode β and ε subunits of acetyl-CoA carboxylase (ACC) essential for malonyl-CoA, a 
common precursor for fatty acid, griseorhodin, and PTM biosynthesis. PTM production in JV180 
ΔgrhR2-V was not complemented by grhR2, grhR3, or grhF, but grhGH was able to restore 
some PTM production and transcription (Fig. 5B, C, S26A). Interestingly, expressing either 
grhG or grhH alone were sufficient to restore PTM production, similar to grhGH when 
expressed together (Fig S26A). A ΔgrhGH mutant was thus created, leading to partial 
griseorhodin pigmentation and reduced PTM production comparable to the initial ΔgrhFGH 
mutant (Fig. S23D, S26B). How the ΔgrhR1-E and ΔgrhI-P mutations caused decreased PTM 
production remains unclear. Because these lesions led to loss of putative regulatory genes (grhR2 
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& grhR3, see (33), their phenotypes could be entangled with concomitant grhGH 
downregulation. 
In addition to the griseorhodin BGC’s grhGH, several other Streptomyces PKS clusters are 
known to harbor additional non-housekeeping copies of ACC genes. These include cpkKL in the 
coelimycin BGC of S. coelicolor (35) and jadN in the jadomycin BGC of S. venezuelae (36), and 
it can be reasoned that these ACC copies likely assist polyketide biosynthesis through increased 
malonyl-CoA. Because JV180 PTM production decreased in the ΔgrhR2-V and ΔgrhGH 
mutants, but not the ΔgrhQSAB mutant (Fig. 5C), we likewise hypothesized that PTM 
downshifts in these mutants might be caused, at least partially, by reduced intracellular malonyl-
CoA concentration. We thus tested several additional S. griseus ACC subunit genes for their 
ability to rescue PTM production in the JV180 ΔgrhR2-V strain to discern if these effects were 
specific to grhGH or are more broadly attributable across ACC subunit homologs. The tested 
ACC genes included housekeeping accBE alleles cloned from JV180 and IFO13350 (whose 
functions were assigned by sequence homology and gene neighborhood synteny to the accBE 
genes in S. coelicolor (37)) plus the previously-uncharacterized PKS-associated ACC genes 
SGR3280-3281 of strain IFO13350, all of which encode ACC β and ε subunits like grhGH. All 
of these ACC homologs partially restored PTM production in the ΔgrhR2-V strain (Fig S26A), 
further supporting a role for malonyl-CoA in the PTM production defects of the ΔgrhR2-V and 
ΔgrhGH mutants.  
To test if JV180 could still produce PTMs independent of the griseorhodin BGC, we 
constitutively expressed the strain’s PTM BGC by replacing PftdA with PermE*. This ΔPftdA::PermE* 
promoter replacement in both of the ΔgrhR2-V or ΔgrhGH backgrounds led to increased PTM 
production and PTM BGC transcription, similar to a JV180 ΔPftdA::PermE* control (Fig 5B, C). 
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Our data show that PTM transcription and its production is affected by the lack of grhR2-V and 
grhGH. It is possible that the griseorhodin BGC may affect the PTM BGC through biosynthetic 
malonyl-CoA availability. It is also likely that an as yet-undefined transcriptional regulatory 
interaction also connects the two BGCs. Malonyl-CoA responsive regulators are well-
characterized in other model organisms such B. subtilis (38), but no such regulators are known in 
Streptomyces. Further inquiry is underway to characterize this unusual cross-cluster interaction 
more fully.  
Intrigued by the finding that ectopic expression of just grhG or grhH could rescue PTM 
production in the JV180 ΔgrhR2-V mutant, we tested if the PTM BGCs of weak-PTM producing 
S. griseus strains might be similarly stimulated for production. This was done by heterologously 
expressing grhG in strains IFO13350, JV254, and JV258 (the grhGH construct had low 
conjugation efficiency). This resulted in increased PTM production from these natively low-
producing strains on agar media and also increased PTM BGC expression when tested in strain 
IFO13350, showing that ACC subunit overexpression can stimulate PTM production in natively 
poor producers (Fig. S27A, B). Combined with the above data, these observations support a 
model where S. griseus PTM production differences have complex origins. In the case of poor 
PTM producers, promoter indels and insufficient positive BGC interactions likely dampen 
potential production via low transcription. In contrast, better PTM producers appear to benefit 
from cross-BGC interactions that increase transcription from a more active PftdA variant (+AG), 
resulting in PTM production. Strain JV180, and possibly other members of its subclade, do not 
seem to be bottlenecked for PTM production at the transcriptional level based on several findings 
throughout this study. This includes failure of grhG merodiploids to boost WT JV180 PTM 
production (Fig. S27A) and evidence from several recombinant strains where PTM BGC 
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transcription was significantly upregulated by 2 to 9 fold, but PTM production increased by only 
up to 1.4 fold (ΔgrhQSAB, adpA complementation, and ΔPftdA::PermE* strains; Fig. 3A, 3B, 5B, 
5C). The above findings also highlight ACC enzyme overexpression as a way to potentially 
upregulate certain silent BGCs, adding a new dimension of utility for these genes in synthetic 
biology, where they are currently used for increasing fatty acid and polyketide titers via malonyl-
CoA overproduction (39). 
2.5 Conclusions 
Streptomyces genomes contain many BGCs encoding for drug-like compounds, and to harness 
their full biosynthetic capacity for discovery, it is crucial to understand what underpins the 
differences between active and silent BGCs (8). Cryptic metabolism is a well-recognized 
problem in the field, and poor BGC transcription is often implicated as the predominant 
mechanism behind biosynthetic silence. However, this supposition is increasingly challenged by 
a growing body of research that suggests all cryptic clusters aren’t necessarily transcriptionally 
silent (40). Further, it only addresses how biosynthetic silence could originate in a given 
organism but does little towards explaining why affected BGCs show little activity to begin with. 
A common but difficult-to-prove hypothesis is that axenic laboratory growth deprives 
microorganisms of signals needed to upregulate quiescent BGCs (17). This idea is based on the 
complex lifestyles of Streptomyces bacteria, which are known to be heavily influenced by 
molecular and environmental cues (41). Indeed, chemical elicitor screening, co-culturing, and 
other regulatory manipulation strategies continue to yield new molecules from apparently silent 
BGCs, bolstering this idea (7, 41, 42). However, the number and types of molecular signals these 
organisms can sense and respond to must have a finite limit, constrained by the characteristics 
and capacities of their genetically encoded signal transduction pathways (8). If true, then 
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extracellular signals can only explain one part of antibiotic crypticity, highlighting the need to 
understand how basic strain-to-strain genetic differences also contribute to the phenomenon. 
Towards this, we leveraged the unusual commonality of PTM BGCs in Streptomyces to compare 
several highly related S. griseus strains to discover genomic features that differentiate strong and 
weak producers. These efforts led to the first sequence-defined PTM promoter in the genus, 
confirmation that the global regulator AdpA acts directly on S. griseus PTM production by 
binding PftdA promoter regions in an atypical way, and that 2-3 bp lesions between -10 promoter 
regions and AdpA operator sites can cause substantial differences in transcription strength and 
biosynthetic output. To our knowledge, this type of inquiry is largely absent from the 
biosynthetic-regulatory literature, but similar promoter heterogeneity, with resultant tuned 
transcription, has been documented to control phase variation in bacterial pathogenicity (43). 
Further, because the AG indel discovered here resides in a poly-guanosine rich region, poly-N 
strand slippage (43) or a similar mechanism might plausibly explain how these promoter variants 
arise in S. griseus populations. As more Streptomyces are sequenced and characterized, it is 
likely that additional promoter region sequence variations will emerge as drivers of silent 
metabolism in other biosynthetic pathways. In proof, scientists working at WarpDrive Bio, Inc 
patented a method for activating silent BGCs encoding rapamycin-like antibiotics by “reversing” 
naturally-occurring short indels within LAL-family regulator binding sites (44). Those regulatory 
indels were discovered through large-scale actinomycete genome sequence and molecule 
production comparisons at that company. Such knowledge is thus highly desirable to streamline 




Finally, we also found that in strain JV180, a BGC encoding griseorhodin production was 
required for both PTM production and transcription. Part of this relationship seems to implicate 
malonyl-CoA, whose biosynthesis is encoded for by grhGH, but further research is clearly 
needed to reveal a definitive mechanism. The deletion of unwanted BGCs is commonly used to 
engineer “clean” chassis strains (45) or to uncover the metabolites of BGCs (35, 46). In light of 
this, our discovery of PTM dependence on griseorhodin was surprising and provides a rare 
cautionary example of how genome-minimization can have unintended consequences on broader 
strain-wide BGC function. Together, our results show that the seemingly simple monocistronic 
PTM BGC of strain JV180 appears is under highly complex control, adding to a growing body of 
similarly complex BGC regulatory circuits and mechanisms in other Streptomyces (47, 48). 
Much remains to be learned about these types of regulatory networks in Streptomyces, and 
continued inquiry is required for a more comprehensive understanding to support rational drug 
discovery and production.  
2.6 Materials and Methods 
2.6.1 Strains, Plasmids, Primers, Enzymes, Chemicals and General Methods 
Strains, plasmids, and primers are described in Tables S1-3. Strains IFO13350 and JV251-258 
were obtained from the Agricultural Research Service Culture Collection (NRRL). All primers 
were purchased from Integrated DNA Technologies. All restriction enzymes, Taq polymerase, 
and T4 ligase were purchased from New England BioLabs. PCR was generally carried out using 
KOD Hot Start DNA Polymerase (EMD Millipore) in FailSafe PCR 2X PreMix G (Epicentre). 
Taq polymerase was used for colony PCR to verify cloning and genome editing. Streptomyces 
genomic DNA was prepared for PCR by grinding a colony in DMSO as described by Van Dessel 
et al (49). Most media components and chemicals were purchased from Sigma Aldrich or Fisher 
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Scientific unless specified. γ-rubromycin was purchased from Abcam. 13C5-L-ornithine was 
purchased from Cambridge Isotope Laboratories. Standard protocols for manipulating E. coli 
were based on those of Sambrook et al (50). Streptomyces cultures were routinely propagated on 
ISP2 agar and Trypticase Soy Broth (Difco) at 28˚C. Glass beads were added to liquid cultures to 
disrupt mycelial clumps.  
2.6.2 Streptomyces conjugations  
Conjugations were performed using JV36 as the general E. coli donor as previously described 
(51). Streptomyces sp. strain JV180 spores were collected from lawns plated on 8340 agar (1% 
Proflo cottonseed meal (ADM); 2% D-mannitol; 0.1% yeast extract; 0.01% KH2PO4; 0.01% 
MgSO4-7H2O; 0.002% CaCl2-2H2O; 0.2% (v/v) R2 trace elements solution (52); 2.067% MES 
hemi-sodium salt; 2% agar; pH 6.5) using sterile cotton swabs into TX Buffer (53). Strain JV254 
and JV258 spores were collected from lawns plated on SFM (52) and ISP-S (1.5% malt extract; 
0.5% soluble starch; 0.5% yeast extract; 0.3% CaCO3; 2% agar; pH 7.4; T. A. Voeikova personal 
communication, 2007), respectively. Exconjugants were selected with 50 µg/mL colistin and 50 
µg/mL apramycin. Successful integrations by ΦC31 integrase-based vectors were verified by 
colony PCR as previously described (16).  
2.6.3 Marker-less gene deletion/promoter replacement  
All gene deletions and PftdA mutants were constructed using double homologous recombination as 
previously described (16). To avoid undesired recombination between the wild-type and the 
mutant PftdA sequences, an intermediate ΔPftdA::tsr mutant was constructed, with specifics 
provided the Supplementary methods. This ΔPftdA::tsr mutant was used as the parent strain for the 
construction of most PftdA mutants. Some plasmids for genome editing were cloned using 
overlap-extension PCR instead of Gibson assembly as described previously (54) (see Table S2). 
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2.6.4 PTM production and analysis 
Strains were streaked from −80˚C glycerol stocks onto ISP2 plates and incubated at 28˚C for 2-3 
days. A plug was cut from the plate and used to inoculate 3 mL of Trypticase Soy Broth in 24-
well deep well plates, which were shaken at 300 rpm at 28˚C. One 4 mm glass bead was added 
per well to disrupt mycelial clumps. After 2 days of growth, 200 µL of cultures were either 
inoculated into 20 mL ATCC-MOPS (adapted from ATCC172: 1% dextrose; 2% soluble starch, 
0.5% yeast extract; 0.5% N-Z amine; 0.63% MOPS; pH 7.2) in a 125 mL flask with 6 mm glass 
beads for disrupting clumps or plated on 8340 agar overlaid with cellophane and incubated at 
28˚C. Flask cultures were shaken at 250 rpm. After 4 days of growth, 1 mL was collected in 
RNALater for protein and RNA analyses (see RT-qPCR section below) and the rest of the 
cultures were extracted twice with equal volumes of ethyl acetate. Solid media (plate) cultures 
were incubated for 6 days and the mycelia and spores were collected from the cellophane for 
protein extraction by trichloroacetic acid as described by Bose and Newman (55) and 
quantification by Bradford assay. The remaining agar was diced and extracted with ethyl acetate 
by soaking overnight.  
The ethyl acetate extracts were dried at low pressure and re-suspended in 500 µL of LC-MS 
grade methanol and syringe filtered before LC-MS analysis. PTM analysis was performed using 
a Phenomenex Luna C18 column (75 x 3 mm, 3 µm pore size) installed on an Agilent 1260 
Infinity HPLC connected to an Agilent 6420 Triple-Quad mass spectrometer. For each run, 10 
µL sample was injected and the chromatography conditions were as follows: T = 0, 5% B; T = 4, 
45% B; T = 12, 53% B; T = 16, 100% B, T = 20, 100% B; A: water + 0.1% formic acid, B: 
acetonitrile + 0.1% formic acid; 0.8 mL/min. The diode array detector was set to measure 
absorbance at 320 nm. The mass spectrometer was set to precursor ion scan mode with the 
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precursor ions m/z: 450 – 550, collision energy = 30 V, fragmentor = 70 V, and daughter ions 
m/z: 139.2 or 154.2. The resulting data was analyzed offline with Agilent MassHunter 
Qualitative Analysis software. Chromatograms were extracted for each parent-daughter ion mass 
transition, and the integrated areas for major PTM congeners were used to compare PTM 
production. The sums of PTM peak areas were normalized by total protein, and the relative PTM 
production was calculated relative to the appropriate control strain, typically JV180 rpsL. PTM 
production experiments were generally carried out in triplicates, unless specified. The statistical 
significance in the differences observed was calculated by two-tailed Student’s T-test, typically 
relative to JV180 or its rpsL mutant, JV307 or otherwise indicated. *p < 0.05, **p < 0.01, ***p < 
0.001. Error bars represent standard deviation. 
Generally, the PTM production data reported were based on liquid media cultures that were used 
to collect the corresponding RT-qPCR data. Relative PTM production trends were consistent 
between solid and liquid media. Some figures in the SI show relative PTM production on solid 
media, where flask culture/RT-qPCR data was not collected. 
2.6.5 RT-qPCR 
Strains were cultivated in flasks as described above. After 4 days, 1 mL of culture added to 2 mL 
of RNAlater and vortexed to stabilize RNA. The mixture was centrifuged at 3,214 X g for 10 
minutes and the supernatant was discarded. The RNA-stabilized pellet was resuspended in 250 
µL of 10 mg/mL lysozyme (Sigma) and incubated at 37˚C for 30 minutes. To the lysate, 750 µL 
of Trizol reagent (Fisher) was added and protein and RNA were extracted following the 
manufacturer’s protocol from this point. Protein concentration was measured by Bradford assay. 
The RNA was resuspended in 84 µL of nuclease-free water. DNase treatment was carried out by 
adding 10 µL 10X Turbo DNAse buffer, 4 µL Turbo DNase with 2 µL of RNAsin (Promega) for 
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approximately 6 hours at 37˚C. Removal of leftover DNA was confirmed by PCR and gel 
electrophoresis before the DNase inactivation reagent from the Turbo DNAse kit (Fisher) was 
added. RNA concentration was measured with a NanoDrop and 5 µg of RNA was used for 
reverse transcription with Superscript II (Thermo) following the manufacturer’s protocol.  
Primers for qPCR were designed using the IDT primerquest tool. Real-Time PCR was performed 
on a CFX Connect Real-Time PCR Detection System (BioRad) with the following program: 1 
cycle at 95°C for 3 min, 40 cycles of 95°C for 10 s and 55°C for 30 s. Each reaction contained 5 
µL of iTaq Universal SYBR Green Supermix (BioRad), 2 µL of nuclease free water, 1 µL of 10 
µM forward primer, 1 µL of 10 µM reverse primer, and 1 µL of template cDNA. The relative 
transcript abundance was calculated using the ΔΔCT method and hrdB was used as the 
housekeeping gene (56). The primer efficiency was determined as described by the qPCR 
instrument manufacturer for several pairs of PTM BGC probes, and the ftdB primers YQ376-
180ftdB1153 and YQ377-180ftdB1278 were chosen for subsequent experiments as they had the 
highest efficiency and produced the most consistent results. Data shown represent at three 
technical replicates each for at two biological replicates. The statistical significance in the 
differences observed was calculated by two-tailed Student’s T-test, typically relative to JV180 or 
its rpsL mutant, JV307 or otherwise indicated. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars 
represent standard deviation. 
2.6.6 Expression and purification of His-tagged AdpA 
The full-length adpA gene of Streptomyces sp. strain JV180 was amplified by PCR using 
primers pET11a-AdpA-F and pET11a-AdpA-R. The PCR product was cloned into the 
expression plasmid pET11a. The expression recombinant plasmid, pKN052, contained the 
sequence adpA-CTC-GAG-(CAC)6-TGA under the control of the T7 promoter, similar to the 
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construct reported by Yamazaki et al (23). E. coli BL21 (DE3) Rosetta harboring pKN052 was 
cultured in LB medium with 100 µg/mL ampicillin at 37˚C overnight. 1 mL of seed culture was 
transferred to 150 mL of LB medium with 100 µg/mL ampicillin and incubated by shaking at 
37˚C at 250 rpm. When OD600 reached 0.6-0.8, the cells were chilled on ice for 1 h. After adding 
IPTG to 1 mM, the culture was continued for shaking at 250 rpm for 22 h at 18˚C. The cells were 
harvested by centrifugation at 5000 rpm for 30 min, resuspended in Tris-HCl buffer (20 mM 
Tris-HCl, 200 mM NaCl and 10% glycerol: pH:8.0) and stored at −80˚C. To purify the protein, 
cells were disrupted by sonication (3 min: 10 sec on/10 sec off at 20% amplitude) and His-tagged 
AdpA was purified with nickel-nitrilotriacetic acid (Ni-NTA, Qiagen) resin by eluting with 250 
mM imidazole. Protein expression was verified with SDS-PAGE before downstream 
experiments. 
2.6.7 Electrophoretic mobility shift assay  
Double-stranded DNA probes containing the 20 bp putative PftdA AdpA binding site plus 15 bp 
additional flanking sequences were synthesized by IDT. The DNA was resuspended in TEN 
buffer (10 mM Tris, 1 mM EDTA, 0.1 M NaCl, pH 8.0). For each probe, 50 nM probes were 
prepared using the Dig Gel Shift Kit, 2nd generation (version 10, Roche) with the following 
conditions: 20 µl DNA (from 100 nM stock), 8 µl 5X labeling buffer (1 M potassium cacodylate; 
125 mM Tris-HCl; 1.25 mg/ml bovine serum albumin; pH 6.6), 8 µl CoCl2 (25 mM), 1.5 µl 
Digoxigenin-11-DDUTP (1 mM), 1.5 µl terminal transferase, and water up to 40 µl. After brief 
mixing and centrifugation, reactions were incubated at 37˚C for 30 min and then chilled on ice. 
The reaction was quenched by adding 2 µl of 200 mM EDTA (pH 8.0).  
The protein-DNA interaction assay protocol was based on that described by Ming et al(27). 
Purified AdpA-His was serially diluted in protein buffer (10 mM Tris-HCl, pH7.5; 100 mM 
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NaCl; 2.5% (w/v) glycerol; and 0.25 mM DTT). The reaction mixtures contained 2 µl of binding 
buffer (200 mM Tris-HCl, pH 7.5; 1 M KCl; 2.5 mg/mL bovine serum albumin (BSA); and 1% 
nonidet P-40), 1.2 µl of 1 ng/µl poly[d(I-C)], 1.8 µl DNA probe (4.5 nM), the desired volume of 
purified protein, and water up to 20 µl. Samples were incubated for 1 h on ice. Gel 
electrophoresis was performed with a 5% native acrylamide gel (Bio-RAD, mini protein TBE 
precast gel) in 0.5X Tris-borate-EDTA buffer (TBE, 10X concentration: 890 mM Tris; 80 mM 
boric acid; and 20 mM EDTA, pH 8.3) at 85 V for 145 min. Electro-blotting was performed 
using a BioRad Turbo Transfer System (Trans-Blot TurboTM System) on positively charged 
nylon membrane (Sigma-Aldrich). Crosslinking was performed by baking the nylon membrane 
at 120˚C for 30 min. Subsequently, the chemiluminescent detection was done as mentioned in 
the DIG-KIT protocol with very slight modification (overnight blocking, 2 hrs anti-digoxigenin-
AP treatment, and washing for 30 min each time) and the imaging was done with a LICOR 
(ODYSSEY Fc) imaging system (model # 2800). 
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Chapter 3: Genetic Variations in PTM 
Biosynthetic Genes 
3.1 Abstract 
Since the discovery of ikarugamycin in 1972, numerous polycyclic tetramate macrolactams 
(PTMs) have been discovered and characterized. PTMs show remarkable diversity in their 
structures aside from certain eponymous features that define PTMs, which include the tetramate-
containing macrolactam ring and the polycyclic ring system. The structural diversity of PTMs is 
reflected by their ability to bind various targets, as PTMs have been reported to inhibit various 
organisms and disrupt cellular processes. These results indicate numerous potential applications 
for PTMs in healthcare, agriculture, and research. Structural changes in PTMs are the result of 
changes in the enzymes encoded for by their biosynthetic gene clusters (BGCs) or off-target 
effects by other enzymes encoded in the genomes of PTM-producing strains. Here, I describe my 
efforts to document the genetic diversity encoded within PTM BGCs and the functions of various 
enzymes which differentiate certain PTM BGCs. A clearer and more comprehensive 
understanding of PTM biosynthesis could lay the foundation for engineering PTM BGCs tailored 





Polycyclic tetramate macrolactams (PTMs) are a class of antibiotics produced by numerous 
Streptomyces and other bacteria (1). The high conservation of PTM biosynthetic gene clusters 
(BGCs), especially in Streptomyces, makes it a suitable model system for comparative studies of 
BGC regulation and silencing. In addition, PTMs are also of interest due to their chemical 
diversity, which results in the ability of PTMs to inhibit various targets. These properties present 
potential applications for PTMs in healthcare, agriculture, and basic research. 
One well-characterized PTM is ikarugamycin, which was originally isolated in a screen for 
inhibitors of Tetrahymena (2). It and structurally similar PTMs like clifednamides and 
capsimycins have recently garnered attention for their cytotoxic properties, which have potential 
applications in healthcare (3–5). Recently, ikarugamycin was shown to bind and inhibit hexose 
kinase 2 (HK2) to inhibit tumor growth (6), but other glycolysis-independent effects are also 
thought to be involved (7). Ikarugamycin also inhibits clathrin-dependent endocytosis in animal 
and plant cells, and has been used to study related processes in basic research (8, 9). 
Another well-characterized PTM is dihydromaltophilin, which is was originally isolated as heat-
stable antifungal factor, HSAF (10). The producer of HSAF, Lysobacter enzymogenes strain C3, 
inhibits a wide range of phytopathogenic fungi and been tested as an biocontrol agent in several 
field experiments (11, 12). The mechanism of function for HSAF is not clearly understood and 
may vary in different species. In one study, HSAF was been reported to disrupt ceramide 
synthase activity in Aspergillus nidulans (13). Another study reported that HSAF induced ROS-
mediated apoptosis in Candida albicans, possibly by disrupting β-tubulin polymerization like 
another PTM, alteramide B (14, 15).  
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These diverse functions are related to the various modifications of PTM molecules, which should 
arise from differences in the enzymes encoded for by their BGCs. Better understanding of the 
functions of various PTM biosynthetic enzymes lay the foundation for researchers to engineer 
PTM BGCs producing novel structures, which could inhibit a wider range of pathogens or have 
increased efficacy (16). To date, numerous PTM molecules with diverse structures have been 
isolated and characterized. However, the genomes of many of the source organisms have not 
been sequenced. Similarly, many Streptomyces and actinomycetes possessing PTM BGCs have 
been genome-sequenced, but not evaluated for their ability to produce PTMs.  
When I began my thesis project in 2014, three PTM BGCs had been linked to their products: the 
HSAF BGC in Lysobacter enzymogenes C3 (17), the frontalamide BGC from Streptomyces sp. 
SPB78 (1), and the ikarugamycin BGC of Streptomyces sp. Tü 6239 (18) (Figure 1). Since then, 
several other PTM BGCs have been characterized, such as the pactamide BGC of S. pactum 
strain SCSIO 02999 (19), the combamide BGC of S. sp. strain S10 (16), and the somamycin 
BGC of S. somaliensis strain ZH66 (20).  
Thus far, the functions of several enzymes encoded within PTM BGCs have been deduced. PTM 
biosynthesis is initiated by the iterative polyketide synthase non-ribosomal peptide synthetase 
fusion protein. This protein has been reconstituted in vitro to demonstrate how it uses to use one 
L-ornithine and twelve malonyl-CoA precursors to produce the skeleton of PTMs (21).  
The cyclization of PTMs have been shown through gene deletions to be dependent on a series of 
oxidoreductases. Differences in the polycyclic systems of PTMs are determined by the 
oxidoreductases responsible for the first two rings, which are often annotated as phytoene 
dehydrogenases (19, 22, 23). The final ring is formed by another NADPH-dependent 
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oxidoreductase, which is often annotated as an alcohol dehydrogenase (24). Finally, a commonly 
found PTM-tailoring hydroxylase, which is often annotated as a sterol desaturase, has been 
shown to be promiscuous for different PTM substrates in vitro (25). 
 
 
Figure 1. Previously characterized PTM BGCs and their products. The ikaABC BGC of 
Streptomyces sp. strain ZJ306 was shown as the ikaABC BGC of Streptomyces sp. Tü 6239 was 
not published in its entirety. 
 
As I collected PTM BGC sequences from online databases such as GenBank and IMG for 
promoter comparisons, I noticed a greater diversity in the genes encoded by various PTM BGCs 
than previously reported. Using homology-based annotations and meta-analysis of known PTM 
compounds and PTM-producing strains, I formed several hypotheses on the functions of some 
previously uncharacterized PTM BGC genes. Some genes I initiated genetic and metabolomic 
studies on include FtdF, which is a cytochrome P450 found in the most widely distributed type 
of PTM BGC, and FtdG, which is a Rieske 2Fe-2S domain protein found is some FtdF-less PTM 
BGCs. Additionally, I identified an unusual group of PTM BGCs that may be responsible for 
producing cylindramide-type PTMs. Finally, I also identified a group of PTM BGCs as being 
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likely clifednamide-type PTM BGCs. To support this hypothesis, we sequenced the genome of 
the original source organism of clifednamides, Streptomyces sp. strain JV178, which was 
published in Genome Announcements (see Chapter 5). We confirmed the identity of the 
clifednamide PTM BGC and the role of novel cytochrome P450, CftA, which we published in 
ACS Synthetic Biology (see Chapter 6).  
In addition, the Blodgett lab has also conducted selective isolation of actinomycetes from local 
soil samples. Dr. Blodgett’s BIO3493 class at WUSTL also conducts selective isolation of 
actinomycetes each year. The majority of these strains have been screened via LC-MS/MS or 
PTM biosynthesis or via PCR for key PTM BGC genes. We had the opportunity to sequence the 
genomes of 96 strains, of which roughly half contained PTM BGCs. Two of these strains were 
Streptomyces sp. strains JV180 and SP18CM02, which were used in comparative studies of PTM 
regulation (see chapter 7). Preliminary analyses of the PTM BGCs encoded in these genomes 







3.3.1 FtdF, a CYP450 found in the most common type of PTM BGC 
A majority of PTM biosynthetic gene clusters have a similar genetic content as the frontalamide 
biosynthetic gene cluster. These clusters contain ftdA, encoding the sterol desaturase; ftdB, 
encoding the iPKS-NRPS; ftdCD, encoding two phytoene dehydrogenases; ftdE, encoding an 
alcohol dehydrogenase; and ftdF, encoding a cytochrome P450. By sequence similarity, FtdF 
would be considered a member of a different subfamily of cytochrome P450 enzymes than CftA. 
Additionally, frontalamides do not bear a ketone group at the same site as clifednamides. These 
observations suggested a different role for FtdF. To investigate the function of FtdF, I deleted the 
ftdF gene from Streptomyces sp. strain JV180, whose PTM BGC has the same gene content as 
the ftd cluster, through markerless homologous recombination. The resulting strain, JV1171, was 
grown on 8340 agar along with the parent strain JV307 (JV180 rpsL), extracted with ethyl 
acetate, and analyzed for PTM production by LC-MS/MS (Figure 2). Compared to JV307, the 
extract from JV1171 was missing the peaks for compounds 1, 4, 5, 6, and 7. Conversely, the 
peaks for compounds 2, 3, and 8 were either unaffected or grew larger, suggesting that these 
were intermediate compounds that accumulated due to the absence of FtdF. The lost peaks could 
be complemented by ectopic expression of ftdF under the constitutive promoter PermE*. However, 
the relative ratios of the PTM peaks was still different from wild-type JV180. Additionally, 
overexpressing ftdF from the same construct in wild-type JV180 also caused a skew in the 
relative ratios of the various peaks. More of compounds 1 and 7 appeared to be produced than in 








Table 1. List of PTM compounds produced by strain JV180 and their mass transitions. 
compound # RT (min) m/z1 m/z2 ftdF dependent? 
1 7.1 511 139 Y 
2 7.8 513 154 N 
3 8.8 497 139 N 
4 10.5 495 139 Y 
5 9.1 511 154 Y 
6 6.2 509 139 Y 





























As the JV180 PTM BGC contained two phytoene dehydrogenases, FtdC and FtdD, I predicted 
that JV180 would produce PTMs with 5-5-6 carbon ring systems. Additionally, the as the JV180 
PTM BGC contained the sterol desaturase, FtdA, I predicted that some of its products would 
have the commonly found tetramate-adjacent hydroxylation. These hydroxylated PTMs are 
distinguishable from non-hydroxylated PTMs by their fragmentation. I obtained authentic 
maltophilin isolated from Stenotrophomonas maltophilia, a Gram-negative bacterium, from 
EMC microcollections GmbH. I was able to match compound 5 in the extracts from JV180 to the 
maltophilin standard by retention time, m/z, and collision-induced dissociation (Figure 3). These 
data strongly indicated that JV180 produced maltophilin or a stereoisomer, which could not be 





Figure 3. Strain JV180 produces maltophilin. (A) LC-MS/MS chromatograms of JV180 extract, 
the extracted ion chromatogram of the 511.2 → 154.2 mass transition, and a maltophilin 
standard. (B) Product ion spectra of maltophilin and compound 5 in the extract of JV180 






A few compounds could be identified as FtdA-hydroxylated PTMs due to their fragmentation 
into a m/z 154 daughter ion. Using these observations, I proposed a role for FtdF as well as 
possible structures for compounds 1-5 based on structures of previously characterized PTMs. I 
hypothesize that FtdF oxidizes a pre-existing hydroxyl group on carbon 12 to a ketone group. 
This hydroxyl group appears to be originally added by FtdC and there are homologs of FtdC 
such as PtmB1 that do not appear to add this hydroxylation (23). I also predicted that FtdF can 
carry out a subsequent addition of a hydroxyl group at carbon 14. I predicted that FtdF carried 
out multiple rounds of oxidation on its substrates due to the number of peaks that were lost when 
ftdF was deleted, and the skewed distribution of ftdF-dependent peaks when ftdF was 
overexpressed. A similar model was recently proposed by researchers studying the PTM BGC of 
Streptomyces sp. strain SCSIO 40010, which has a similar BGC (20). Multiple PTM-associated 
cytochrome P450 enzymes appear to carry out multiple rounds of oxidation, including IkaD, 
CftA, and CbmD (4, 26, 16). Additionally, I was unable to predict a structure for compounds 6 
and 7. Based on their mass transitions, they may be derivatives of compounds 1 and 2, 
respectively, where a bond was oxidized into a double bond. Additionally, there should likely be 
a FtdA-hydroxylated product of compound 1, but this compound appears to be barely produced 










Spencer Stumpf, a former technician in the Blodgett lab, generated a ftdA deletion in JV307 as 
well as JV1171. This eliminated a widely conserved and characterized sterol desaturase, which 
adds a hydroxyl group adjacent to the tetramic acid. The loss of peaks in these mutants further 
supported my proposed PTM tailoring pathway in JV180. The ΔftdA ΔftdF double mutant 
predominantly produces compound 3, which should also help in the purification of this 
compound for structural elucidation experiments.  
 
 




























3.3.2 FtdG, a 2Fe-2S Rieske domain protein 
Through bioinformatic analyses, I discovered a clade of PTM BGCs which contained ftdABCDE, 
but not ftdF. Instead of the cytochrome P450 enzyme, these PTM BGCs encoded a 2Fe-2S 
Rieske domain protein, which I will refer to as ftdG (Figure 6). Since a 2Fe-2S Rieske domain 
could function as an electron carrier, I reasoned that this enzyme could have a redox-related 
function. Interestingly, in S. pactum SCSIO 02999, this gene was considered to be part of the 
adjacent xiamycin BGC and named xiaA (27). However, the authors reported that they were 
unable to delete xiaA and could not investigate whether it affected xiamycin production. Based 
on the start-stop codon overlap of ftdE-ftdG in S. olivaceus strain NRRL B-3009, I determined 
that this gene should actually be part of the PTM BGC. To investigate the function of FtdG, I 
obtained several genome-sequenced Streptomyces strains with ftdG-containing PTM BGCs from 
the NRRL collection (Table 2). I grew each strain on several different media and their extracts 
were analyzed via LC-MS/MS. JV820 seemed to be the only strain that naturally produced 
PTMs on the media tested. 
 
 
Figure 6. S. olivaceus strain NRRL B-3009 (JV820) contains a PTM BGC with a novel Rieske 





Table 2. List of obtained strains containing FtdG-type PTM BGCs. 
Strain  Description Media tested (underlined: PTM+) 
JV819 Streptomyces griseus subsp. griseus NRRL B-
2621 
ISP2, YMS, SMMS, HT, 8340, 
JBFM1 
JV820 Streptomyces olivaceus NRRL B-3009 ISP2, ISP4, YMS, SMMS, HT, 
8340, JBFM1, ATCC172, SFM 
JV823 Streptomyces atroolivaceus NRRL ISP-5137 ISP2, YMS, SMMS, JBFM1 
 
Compared to JV180, the extract of JV820 appeared to contain many identical peaks (Figure 7). 
The JV820 extract also contains putative PTM peaks which are novel and not present in the 
JV180 extract. Two peaks eluting at 15.8 minutes (m/z 479) and 16.4 minutes (m/z 481) may 
correspond to compounds similar to lysobacterene A or a 5-carbon ring intermediate. The JV820 
extract also contained several novel PTM-like peaks do not appear in the extract of JV180 
(Figure 8A, 8B). Two of these peaks eluting at 5.5 minutes and 6.4 minutes had similar UV 
absorbance spectra as known PTM compounds, with absorbance maxima at approximately 222 
nm and 322 nm (Figure 8C). The peak eluting at 6.4 minutes had an additional absorbance 




Figure 7. Strain JV820 produces some PTMs also produced by JV180. LC-MS/MS 
chromatograms of extracts of JV180 and JV820. 
 
To further verify if these compounds were PTMs, Edward Ding, a former undergraduate student 
in the Blodgett lab, grew JV820 on YMS media supplemented with 50 μg/mL d7-L-ornithine, 
which could be directly taken up and incorporated into PTMs. As expected, a +7 m/z shift was 
observed in the mass transition for the peak eluting at 6.4 minutes (Figure 8D). However, at the 
point when this experiment was carried out, I had an incorrect model for how PTMs fragmented 
to produce a m/z 154.2 daughter ion. Therefore, I looked for the wrong m/z shift in the mass 
transition for the peak eluting at 5.5 minutes. LC-MS/MS analysis of these novel peaks by their 



























Figure 8. Strain JV820 may produce novel PTMs. Novel PTM-like peaks can be seen in the 
extracted ion chromatograms for the (A) 495.2 -> 139.2 and (B) 511.2 -> 154.2 mass transitions. 
(C) Absorbance spectra at 5.5 minutes and 6.4 minutes. (D) Precursor ion spectra at 6.4 minutes 
for JV820 grown on YMS supplemented with 50 μg/mL L-ornithine (blue) or d7-L-ornithine 
(red). 
 
To investigate whether FtdG was responsible for modifying PTMs into these novel compounds, 
Edward set out to delete the ftdG gene from JV820 (Table 3). Edward also ectopically expressed 
ftdG in the parent rpsL mutant (JV1047), the ΔftdG mutant (JV1208), as well as the JV180 ΔftdF 
mutant (JV1171) to test if he could complement loss of novel PTM compounds or cause JV180 





Table 3. List of JV820 mutants and ftdG-expression strains 
Strain Genotype Strain Genotype 
JV1047 JV820 rpsL_K43R JV1171 JV180 rpsL_K43R ΔftdF colony a 
JV1048 JV820 rpsL_K43M JV1201 JV1171 + pJMD2-ftdG_819 colony 
2 
JV1049 JV820 rpsL_K88R JV1202 JV1171 + pJMD2-ftdG_820 colony 
1 
JV1208 JV1047 ΔftdG colony #1 JV1203 JV1171 + pJMD2-ftdG_820 colony 
2 
JV1227 JV1047 + pJMD2-ftdG_820 colony 
#1 
JV1204 JV1171 + pJMD3-ftdG_820 colony 
1 
JV1228 JV1047 + pJMD2-ftdG_820 colony 
#2 
JV1206 JV1171 + pJMD2-ftdG_823 colony 
1 
JV1229 JV1047 + pJMD3-ftdG_820 colony 
#1 
JV1207 JV1171 + pJMD2-ftdG_823 colony 
2 
JV1230 JV1047 + pJMD3-ftdG_820 colony 
#2 
 
JV1231 JV1208 + pJMD2-ftdG_820 colony 
#1 
JV1232 JV1208 + pJMD2-ftdG_820 colony 
#2 
JV1233 JV1208 + pJMD3-ftdG_820 colony 
#1 
JV1234 JV1208 + pJMD3-ftdG_820 colony 
#2 
 
Interestingly, no PTM peaks seemed to be lost when ftdG was deleted in JV820, but the sizes of 
various PTM peaks increased or decreased (Figure 9A). Similarly, when ftdG was heterologously 
expressed in JV1171, no new PTM peaks were added, but the relative amounts of PTM peaks 
changed. After closer analysis, I noticed a pattern where FtdA-hydroxylated compounds 







Figure 9. FtdG does not create new PTM compounds but changes the amount of ratio of 
hydroxylated and non-hydroxylated compounds. (A) LC-MS/MS chromatograms of JV1047 
(JV820 rpsL_K43R) and JV1208 (JV1047 ΔftdG) and (B) PTM production by JV1171 
expressing ftdGJV820 (n = 3, p values calculated by Student’s T-test relative to JV1171). 
 
Therefore, I hypothesize that FtdG may somehow interact with FtdA and improve its catalytic 
efficiency. In a similar case, a ferrodoxin reductase gene (FNR) encoded upstream of the HSAF 
BGC in Lysobacter enzymogenes C3 appears to have a similar function, as its deletion caused a 
similar reduction in HSAF (dihydromaltophilin) and accumulation of the precursor 3-deOH 
HSAF (17). The FtdA-catalyzed hydroxylation appears to be necessary for the ability of HSAF 
to inhibit some fungal targets, which may explain why mechanisms to increase its catalytic 
efficiency may be selected for. To further test this hypothesis, Spencer Stumpf, a former 
technician in the Blodgett lab, deleted ftdA from several strains. We hypothesized that if FtdG’s 
function is to increase FtdA’s activity, then the JV820 ΔftdA (JV1521) and ΔftdA ΔftdG (JV1559) 
double mutants should have the same PTM production profiles. While the mutants were 
constructed, they were not analyzed in the same experiment, and may have been affected by 
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batch-to-batch variation in PTM production profiles. These strains should be re-grown on the 
same batch on media in triplicates to  
 
Figure 10. Preliminary LC-MS/MS analysis of JV820 ΔftdA and ΔftdA ΔftdG mutants. 
 
3.3.3 Sea-sponge associated PTMs 
In 1991, a novel PTM compound named discodermide was isolated from the marine sponge 
Discodermia dissoluta (28). Since then, the PTMs cylindramide A and geodin A were also 
isolated from sea sponges (29, 30). If a marine sponge was able to produce PTMs, this could 
have been an interesting example of horizontal gene transfer. However, I hypothesized that it 
may be more likely that these PTMs were produced by symbiotic bacteria, similar to how the 
Altermonas sp. strain that was isolated from the sea sponge Halichondria okadai produces 
























contain two fewer carbon atoms (Figure 11). Due to their cytotoxic properties, these molecules 
became the subject of numerous synthetic chemistry studies (32, 33).  
 
 
Figure 11. Sponge-derived PTMs have two less carbon atoms. Atoms highlighted in red in 
alteramide A and HSAF are missing in discodermide and cylindramide A. 
 
I noticed that several PTM BGC sequences collected during bioinformatic analyses contained 
several different open reading frames, including one predicted to encode a thioesterase (Figure 
12). This was unusual as the iPKS-NRPS gene already encodes a thioesterase domain. I also 
noticed that many of the strains containing these PTM BGCs were sea-sponge associated Gram-
negative bacteria. Therefore, I hypothesize that these could be the BGCs responsible for 
producing discodermide-like PTMs. It may be possible that the additional thioesterase enzyme 
111 
 
prematurely terminates the elongation of the second polyketide chain, resulting in the omission 
of two carbons. As these thioesterase genes are short, it may be possible to synthesize codon-
optimized versions of these genes for ectopic expression in PTM-producing Streptomyces strains 
in the future to test whether discodermide-like PTMs can be produced. The Pseudoalteromonas 
flavipulchra strain JG1 PTM BGC also contains additional ORFs which may be involved in 
PTM production (Figure 12). In place of the commonly found ftdA, the first ORF encodes an 
acetylornithine deacetylase. This enzyme may help to supply additional ornithine precursor for 
PTM production, similar to the arginase found upstream of the HSAF BGC in Lysobacter 
enzymogenes strain C3. Two ORFs encoding a transmembrane protein and an efflux protein 
likely help to provide self-resistance by exporting PTMs into the environment. A short ORF 
encoding a flavodoxin may provide a redox partner for the phytoene dehydrogenases that are 
responsible for the cyclization of the PTM. 
 
 





3.3.4 Genome sequencing of 96 Actinomycetes  
The Blodgett lab has two ever-growing collections of environmentally isolated Actinomycetes. 
The BE (Blodgett Environmental) strain collection contains strains isolated from enrichment 
cultures of local soil samples by undergraduate students, technicians, and rotating graduate 
students, while the BIOL3493 strain collection contains strains isolated by WUSTL students in 
the BIOL3493: Bacterial Prospecting and Biotechnology course. A large proportion of the BE 
strain collection were screened for their ability to inhibit the growth of Pseudogymnoascus 
destructans, the causative agent of bat white-nose syndrome (WNS) (34). Many strains which 
produced strong inhibitory activity were PCR-screened with degenerate primers for signatures of 
ftdB, the PTM iPKS-NRPS, or pzbB, which produces the non-proteinogenic amino acid L-
piperazate (26, 35). All strains in the BIOL3493 collection also undergo the ftdB degenerate PCR 
screen as part of the coursework. The Blodgett lab received funding to sequence the genomes of 
96 strains with 2 x 150 bp Illumina sequencing and to complete the genomes of 10-15 strains 
with 2 x 300 bp Illumina sequencing and long-read PacBio sequencing. Of the strains chosen for 
sequencing, 56 strains originated from the BE collection, 23 originated from the BIOL3493 
collection, and 14 strains originated from a collection of strains (JV176, JV177, JV179-JV190) 
isolated by Dr. Blodgett at Harvard in 2010 (Table 4). Additionally, 3 strains (S. jamaicaensis 
NCIMB 10166, Kutzneria buriramensis DSM 45791, and S. malaysiense DSM 100712) 
originated from public culture collections and were chosen for sequencing in an attempt to close 






Table 4. List of strains chosen for 2 x 150 bp Illumina sequencing and assembly results 
Strain Reason for sequencing Length (bp) Contig # N50 (bp) 
AL04 BIOL3493, rare species, strong broad-spectrum inhibitor 11,301,112 782 164,142 
BAT2 BE strain, Tyler isolate contaminated (2 Streptomyces) 
BAT24 BE strain, Tyler isolate, PzbB positive 9,486,057 357 256,527 
BAT26 BE strain, Tyler isolate, PzbB positive 9,506,583 411 281,640 
BAT42 BE strain, Tyler isolate, PzbB positive 9,492,239 375 256,527 
BB07 BIOL3493, PTM-positive 10,676,817 376 183,423 
BB09 BIOL3493, PTM-positive  10,395,563 501 203,602 
BE10 Pamamycin 9,603,600 301 348,969 
BE12 Pamamycin 9,580,770 237 356,864 
BE121 PzbB positive  10,610,326 608 230,468 
BE128 PTM producing 8,918,868 326 183,478 
BE13 PTM producing 8,533,920 305 264,667 
BE132 WNS inhibitor F 8,064,299 341 436,993 
BE133 PzbB positive, WNS inhibitor J 9,930,516 746 105,986 
BE137 PTM producing 7,763,681 343 153,795 
BE147 WNS inhibitor A1 9,284,533 405 277,560 
BE148 PTM producing 9,218,342 305 215,089 
BE174 PTM producing 9,739,818 390 285,901 
BE185 PTM producing 9,793,097 584 131,456 
BE188 PTM producing 8,076,758 285 266,673 
BE20 PTM producing, WNS inhibitor A2 10,271,073 1,260 105,095 
BE206 PTM producing, WNS inhibitor A2 9,914,897 943 121,580 
BE225 PTM producing 10,031,912 1,066 116,972 
BE227 PzbB positive  9,049,326 335 263,218 
BE228 WNS inhibitor C2, 9,820,179 254 315,646 
BE230 PzbB positive  9,001,909 307 254,675 
BE237 PzbB positive  contaminated (Streptomyces + Kocuria) 
BE24 PTM producing 7,971,324 798 141,216 
BE277 Strongly anti-C. neoformans 9,017,290 302 277,108 
BE28 PTM producing 8,043,392 272 457,457 
BE282 PzbB positive, WNS inhibitor F 8,598,617 306 370,259 
BE284 WNS inhibitor 9,833,168 481 288,600 
BE29 PTM producing 8,075,161 370 376,521 
BE303 PTM producing 9,891,409 970 116,825 
BE304 PzbB positive  contaminated (2 Streptomyces) 
BE308 WNS inhibitor B1 9,261,303 423 215,089 
BE313 PTM producing 8,724,148 419 174,959 
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BE315 PzbB positive  9,562,638 372 280,975 
BE319 PTM producing 8,558,901 263 331,196 
BE32 PTM producing 8,219,217 250 284,361 
BE320 PTM producing 8,493,263 498 170,937 
BE323 broadly anti-fungal 9,756,673 391 387,221 
BE327 PTM producing 8,500,088 246 404,390 
BE33 PTM producing 10,217,343 936 100,891 
BE34 PTM producing 10,166,712 1,023 117,209 
BE345 anti-C. neoformans 8,744,333 664 157,290 
BE350 PTM producing 8,066,878 344 374,272 
BE356 PzbB positive, WNS inhibitor O 9,304,540 768 123,559 
BE38 WNS inhibitor 10,012,355 366 290,019 
BE39 PzbB positive  10,003,645 334 286,490 
BE42 WNS inhibitor B2 9,195,459 396 234,316 
BE45 PTM producing 9,454,890 1,019 110,999 
BE48 WNS inhibitor 10,015,493 369 290,003 
BE54 WNS inhibitor 9,979,542 264 351,252 
BE76 WNS inhibitor 9,931,428 349 281,144 
BE78 WNS inhibitor 9,876,433 391 285,745 
BE83 PTM producing 7,831,504 403 152,811 
BE87 PTM producing 10,934,189 1,349 105,073 
BM10 BIOL3493, rare species, possible PTM 8,907,934 693 206,289 
BM11 BIOL3493, rare species contaminated (E. coli) 
BM12 BIOL3493, rare species 8,368,232 113 718,560 
CM02 BIOL3493, PTM producer 8,032,753 362 431,047 
CM03 BIOL3493, PTM-positive 9,441,162 523 192,487 
CS02 BIOL3493, PTM-positive  7,792,961 309 344,841 
CS05 BIOL3493, PzbB positive  9,946,654 356 301,199 
CS06 BIOL3493, PzbB positive  8,682,499 361 238,624 
EM04 BIOL3493, PTM-positive  7,423,092 715 167,922 
EM07 BIOL3493, PzbB positive  8,347,011 420 162,775 
EM08 BIOL3493, PTM-positive  7,102,563 485 288,813 
ENG2 BE strain, Tyler isolate 7,437,980 197 285,969 
ENG35 BE strain, Tyler isolate 7,437,360 198 285,834 
ES09 BIOL3493, PTM-positive 8,004,884 384 350,916 
JA06 BIOL3493, possible PTM 10,251,260 434 168,112 
JA07 BIOL3493, rare species 7,602,102 229 550,036 
JA12 BIOL3493, possible PTM 8,628,358 387 263,986 
JA17 BIOL3493, possible PTM 8,242,768 569 166,691 
115 
 
JG07 BIOL3493, PzbB positive  8,697,082 403 291,113 
JV176 HSAF screen #8 9,180,255 297 395,164 
JV177 HSAF screen #23 9,094,990 685 252,002 
JV179 HSAF screen #33 9,158,385 234 413,960 
JV180 HSAF screen #38 8,082,789 391 385,067 
JV181 HSAF screen #42 7,826,196 256 355,395 
JV182 HSAF screen #44 10,924,231 3,819 240,575 
JV183 HSAF screen #45 9,210,398 447 164,957 
JV184 HSAF screen #69 9,471,885 470 206,890 
JV185 HSAF screen #71 8,952,695 458 210,935 
JV186 HSAF screen #75 7,236,288 397 223,038 
JV187 HSAF screen #32 11,784,417 441 149,906 
JV188 HSAF screen #47 9,392,901 504 254,039 
JV189 HSAF screen #60 9,429,214 611 211,373 
JV190 HSAF screen #65 8,992,785 507 343,451 
JV974 S. jamaicensis 10,325,532 765 208,728 
JV995 Kutzneria buriramensis 8,125,896 662 156,601 
JV996 Streptomyces malaysiense 8,094,488 570 156,601 
KL33 BIOL3493, strong clifednamide A producer 10,339,804 482 189,496 
MRY08 BIOL3493, PzbB positive  9,339,871 708 92,810 
 
Jennifer Greif, a former undergraduate student in the Blodgett lab, extracted the genomes of 95 
of these strains with a Qiagen DNeasy UltraClear microbial kit. Spencer Stumpf and I extracted 
the genomes of the strains chosen for PacBio sequencing using a phenol-chloroform protocol. 
The library preparation, sequencing, and genome assembly were carried out by a team at the 
McDonnell Genome Institute (WUSTL). Based on research relevance and draft genome 
assembly, roughly 20 strains were chosen to receive additional 2 x 300 bp Illumina sequencing 
or long-read PacBio sequencing. Out of these strains, the 10 strains which yielded abundant 
genomic DNA sample by phenol-chloroform extraction were chosen for PacBio sequencing, 
while another subset of 15 strains received additional 2 x 300 bp Illumina sequencing (Tables 5 
and 6). The genomes of two strains, which underwent the original 2 x 150 bp Illumina 
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sequencing and PacBio sequencing, were published with details on library preparation, 
sequencing, and assembly (see Chapter 7). 
The 15 TruSeq PCR-free libraries which were chosen for additional Illumina sequencing were 
PCR amplified with KAPA Hi-Fi for 5 cycles. The final libraries were assessed on a 
BioAnalyzer (Agilent) for size and a Qubit Fluorometer (Invitrogen) for mass. The concentration 
of each final library was determined through qPCR (Kapa Biosystems). The libraries were 
normalized and pooled. The pool of libraries was loaded on a MiSeq 600 cycle v3 flow cell 
generating 2 x 300 paired end sequence data targeting an additional 100x coverage per sample. 
Draft genomes were assembled using MEGAHIT as with the original 96 assemblies. 
Interestingly, the additional 2 x 300 bp sequencing did not seem to greatly improve the quality of 
the draft genomes, as evidenced by the contig counts and N50 lengths. This discrepancy may be 
partly due to the original 2 x 150 sequencing producing enough read data for approximately 200x 
fold coverage the additional while the 2 x 300 sequencing only resulted in roughly 50x fold 













Table 5. List of strains chosen for 2 x 300 bp Illumina sequencing and assembly results 
 

















AL04 2,036,885 782 11,301,112 164,142 391,201 821 11,458,582 193,646 
BAT24 1,729,231 357 9,486,057 256,527 404,482 383 9,494,737 277,984 
BE277 2,148,815 302 9,017,290 277,108 498,118 290 8,694,361 277,108 
BE282 2,489,907 306 8,598,617 370,259 581,536 305 7,892,733 357,090 
BE356 2,424,424 768 9,304,540 123,559 618,654 795 9,316,203 183,166 
BM10 2,414,060 693 8,907,934 206,289 567,420 701 8,913,205 206,289 
EM04 2,845,561 715 7,423,092 167,922 587,621 772 7,445,144 165,518 
ES09 1,974,693 384 8,004,884 350,916 683,659 359 7,998,661 415,023 
JA06 2,235,084 434 10,251,260 168,112 457,259 442 10,254,302 213,176 
JG07 1,948,056 403 8,697,082 291,113 525,690 428 8,705,345 291,113 
JV180 3,402,599 391 8,082,789 385,067 707,881 454 8,104,256 444,161 
JV186 1,870,266 397 7,236,288 223,038 892,132 471 7,262,953 245,626 
JV974 2,156,619 765 10,325,532 208,728 714,113 814 10,235,916 259,587 
JV995 2,280,918 662 8,125,896 156,601 490,565 650 8,122,922 158,799 
JV996 1,718,066 570 8,094,488 156,601 536,857 599 8,107,249 158,799 
 
As compared to the Illumina sequencing, PacBio sequencing allowed for the genomes to be 
assembled on much fewer genomes. In one case (BE327), a full genome was assembled. These 
high-quality assemblies allowed for fragmented biosynthetic gene clusters in the Illumina 
assemblies to be joined, providing a clearer view of the biosynthetic potentials of these strains. 
Preliminary analysis of the draft genomes revealed that one strain (BM11) was actually an E. coli 
contaminant. Additionally, 3 strains (BAT2, BE237, and BE304) contained a mixture of two 
strains. Finally, four strains (BE28, BE29, BE132, and BE350) proved to be re-isolates of JV180, 






Table 6. List of strains chosen for PacBio sequencing and assembly results 
 
Original (2 x 150) PacBio 










BE133 746 9,930,516 105,986 2,550,310,971 5 9,791,935 9,306,862 
BE277 302 9,017,290 277,108 3,702,241,109 2 8,644,767 8,641,032 
BE308 423 9,261,303 215,089 3,751,302,636 6 9,210,507 7,647,761 
BE319 263 8,558,901 331,196 3,239,280,775 4 8,575,992 4,785,636 
BE327 246 8,500,088 404,390 5,692,994,945 1 8,476,695 8,476,695 
BE356 768 9,304,540 123,559 2,779,481,931 3 6,616,652 6,569,312 
CS06 361 8,682,499 238,624 4,814,006,921 4 8,567,140 7,192,574 
JV180 391 8,082,789 385,067 2,597,107,056 5 8,006,517 7,244,875 
JV184 470 9,471,885 206,890 4,738,490,877 2 9,405,146 8,599,015 
JV974 765 10,325,532 208,728 6,375,991,040 4 10,211,859 9,614,926 
 
Although many of the sequenced strains originated from the same few soil samples, preliminary 
analysis of the 88 remaining draft genomes reveals a large diversity of Streptomyces, with 16S 
sequences ranging from 94.7% - 100% identity (Figure 13). Furthermore, two strains, JA07 and 
BM12, belong to the actinomycete genera Nocardia and Kribella, respectively. A tBLASTn 
search with the FtdB amino acid sequence of JV180 as the query revealed that 42 strains had 





Figure 13. The genome-sequenced strains represent a diverse collection of Streptomyces. The 
16S sequence of S. coelicolor strain A(3) was used as the query of a BLASTn search to extract 
the 16S sequences from the 88 genome-sequenced strains (indicated in blue). Sequences which 
did not have close matches in my in-house 16S sequence list were used as queries in BLASTn 
searches against the nr database in GenBank to identify their closest relatives. Where possible, 
the sequences of type strains were used for the phylogeny. Sequences were aligned with 
MUSCLE, degapped, and used to build a neighbor-joining tree with the Kimura80 nucleotide 
substitution model in CLC Main Workbench. A root was set above the node containing several 
non-Streptomyces actinomycetes. Branches which supported by less than 25% of 500 bootstrap 
simulations were collapsed. 
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The PTM BGCs showed remarkable diversity in gene content (Figure 14 and 15). Of the 42 
PTM BGCs, 23 of them have the same ftdABCDEF gene arrangement as the frontalamide BGC 
of Streptomyces. sp. strain SPB78. Based on bioinformatic searches in other published genome 
sequences, this type of PTM BGC appears to be the most commonly found. In addition, 11 of the 
isolates have clifednamide-type PTM BGCs and 3 strains had ftdG-containing BGCs. I also 
noticed that 3 strains had ftdE-less PTM BGCs. Based on the established role of FtdE, these 
strains should produce alteramide-like PTMs with 5-5 carbon ring systems. Interestingly, these 
strains appear to have a novel CYP450 enzyme, which is more like CftA and IkaD than FtdF, 
based on amino acid sequence alignments. These novel CYP450 enzymes may produce PTMs 
with novel modifications. Additionally, two other strains, BM10 and CS02 have PTM BGCs 










Figure 14. The genome-sequenced strains encode diverse FtdB enzymes, reflecting diverse PTM 
BGCs. The FtdB amino acid sequence of Streptomyces sp. strain JV180 was used as the query of 
a BLASTx search to extract the FtdB sequences from the 88 genome-sequenced strains 
(indicated in blue). Sequences were aligned with ClustalOmega against an in-house collection of 
FtdB sequences, degapped, and used to build a neighbor-joining tree with the Jukes-Cantor 
substitution model in CLC Main Workbench. A root was set above the node containing FtdB 
sequences from Gram-negative proteobacterial strains. Branches which supported by less than 
25% of 500 bootstrap simulations were collapsed. FtdB sequences belonging to strains that have 




A more detailed and comprehensive phylogenetic analysis of all available PTM BGCs is being 
conducted by Blodgett lab members Anna Day, an undergraduate student, and Chris Harper, a 
PMB student. In summary, in this chapter I have detailed bioinformatic and experimental work 
undertaken to study diversity in PTM BGC gene content and how they cause PTM structural 
differences. Bioinformatic analyses of our data and other publicly available bacterial genomes 
reveals a large diversity in the gene contents of PTM BGCs. Further characterization of the 
products of these clusters should reveal diverse PTMs, which may have novel or improved 
antibiotic or cytotoxic properties. Furthermore, deducing the functions of PTM tailoring enzymes 
will open the door for combinatorial biosynthesis of even more PTM chemical structures through 
synthetic biology. Finally, comparative metabolomic and genomic analyses of these strains could 
reveal novel mechanisms that cause differences in the regulation of strong and weakly expressed 










PTMs demonstrate remarkable chemical and functional diversity despite the genetic simplicity of 
their biosynthetic gene clusters. These chemical modifications can result in major changes in the 
binding targets and affinities of these molecules, which may also translate to increased efficacy 
or reduced side effects for antibiotics and other drugs. Structural changes in natural products are 
often the result of changes in the enzymes encoded for by biosynthetic gene clusters, or off-target 
effects by other enzymes encoded in the host strains.  
By collecting the sequences of PTM BGCs, I was discovered a large diversity of PTM BGCs. I 
predicted several correlations between the predicted enzymes and previously isolated PTM 
molecules without cognate BGCs. This resulted in the discovery of the clifednamide BGC and 
the novel PTM-tailoring cytochrome P450, CftA (see Chapter 6). I also predicted and tested the 
functions of FtdF and FtdG. I also predicted that an unusual type of PTM BGC found in sea 
sponge-associated bacteria may be responsible for producing the cylindramide-type PTMs. 
Finally, I was also involved in the sequencing of numerous Actinomycete isolates obtained by 
the Blodgett lab as well as WUSTL undergraduate students in the BIOL3493 class. The genomes 
of these bacteria and others deposited on GenBank reveal an even greater diversity of PTM 
BGCs than described in this chapter. 
As whole-genome sequencing technologies continue to improve and become more accessible, it 
is reasonable to predict that even more types of PTM BGCs may be discovered. Studying these 
PTM BGCs should result in the discovery of novel PTM molecules, which may have improved 
inhibitory activity, or novel targets. Even if certain PTM BGCs may not be readily expressed, the 
wide distribution of PTM BGCs makes it likely that another strain could be isolated that actively 
expresses the same BGC. The distribution of PTM BGCs is likely related to its genetic 
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simplicity, which also makes simplifies engineering approaches that seek to activate expression 
by regulatory manipulation, if such a route is chosen. In summary, PTMs have numerous 
potential applications, and study of PTM biosynthesis offers potential for numerous useful 
discoveries. As the functions of more PTM biosynthetic enzymes are further characterized, novel 
PTMs could be produced through combinatorial BGCs with biosynthetic genes originating from 
different PTM BGCs.    
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Chapter 4: Draft Genome Sequence of 
Streptomyces sp. strain JV178, a Producer of 
Clifednamide-Type Polycyclic Tetramate 
Macrolactams 
This chapter was previously published in the journal Genome Announcements as: 
Qi Y, D’Alessandro JM, Blodgett JAV. 2018. Draft genome sequence of Streptomyces sp. strain 
JV178, a Producer of Clifednamide-Type Polycyclic Tetramate Macrolactams. Genome 
Announc. 6:e01401-17. https://doi.org/10.1128/genomeA.01401-17. 
4.1 Personal contributions 
I performed bioinformatic analyses to hypothesize that Streptomyces sp. strain JV178 likely had 
a novel polycyclic tetramate macrolactam (PTM) biosynthetic gene cluster (BGC). In particular, 
I hypothesized that the JV178 PTM BGC may be similar to that of Streptomyces torulosus strain 
NRRL B-3889, based on sequence homology to the fragment of the JV178 PTM BGC that had 
been PCR-amplified and sequenced by Dr. Joshua Blodgett. I provided the phenol-chloroform 
DNA extract protocol that was used by John D’Alessandro, a former technician in the Blodgett 
lab, to extract genomic DNA. The genomic DNA of strain JV178 was submitted for Illumina 
sequencing by the McDonnell Genome Institute (WUSTL), along with actinophage genome 
samples from the BIOL 191 undergraduate Phage Hunters course, by Dr. Chris Shaffer, an 
instructor for the course. I performed the quality control, adaptor trimming, de novo assembly, 





Here, we report the draft genome sequence of Streptomyces sp. JV178, a strain originating from 
Connecticut (USA) garden soil. This strain produces the polycyclic tetramate macrolactam 
compounds clifednamides A and B. The draft genome contains 10.65 Mb, 9,045 predicted 
protein coding sequences, and several natural product biosynthetic loci. 
4.3 Genome Announcement 
Members of the Streptomyces genus of Gram-positive filamentous bacteria produce diverse 
secondary metabolites, including two-thirds of clinical antibiotics (1). Streptomyces genomes 
have been shown to contain a rich repertoire of small-molecule-encoding biosynthetic loci (2). A 
high proportion of sequenced Streptomyces strains encode the biosynthesis of polycyclic 
tetramate macrolactams (PTMs) (3). Streptomyces sp. strain JV178 was isolated from a 
Connecticut (USA) garden soil sample during a screen to discover new PTM compounds (4). We 
have sequenced its genome to further understand clifednamide-type PTM biogenesis.  
Strain JV178 was grown in Trypticase soy broth supplemented with 0.6% glycine at 28°C. 
Genomic DNA was extracted by phenol-chloroform extraction as described elsewhere (5). 
Sequencing was performed on a MiSeq platform (2 × 301-bp reads [Illumina, Inc., San Diego, 
CA, USA]) on a paired-end library prepared using a high-throughput library preparation kit 
(Kapa Biosystems). Adapter sequences and low-quality reads (quality score 0.05) were removed 
using CLC Genomics Workbench (CLC Bio-Qiagen, Aarhus, Denmark). The trimmed reads 
totaled 3,064 Mb, corresponding to approximately 287-fold coverage. De novo genome assembly 
was performed in CLC Genomics Workbench, and resulting contigs having less than 200 bp or 3 
average coverage were discarded. The resulting draft genome contains 10,650,097 bp in 759 
contigs (N50, 540,451 bp), with a G+C content of 71.0%. Gene prediction and annotation by the 
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Rapid Annotations using Subsystems Technology version 2.0 pipeline (6, 7) predicted 9,045 
protein coding sequences and 126 RNA genes.  
Automated secondary metabolism analysis using antiSMASH version 4.0 (8) and PRISM version 
3.0 (9) predicted 39 biosynthetic gene clusters. Six of these matched known clusters for 
concanamycin (10), coronafacic acid (11), marineosins (12), melanin, ectoine, and anticapsin 
(13). Using this sequence, the clifednamide biosynthetic cluster was also found (14), along with 
clusters predicted to encode five terpenes, three polyketides, three non-ribosomal peptides, eight 
hybrid polyketide/non-ribosomal peptides, four siderophores, five lantipeptides, a single lasso 
peptide, and three bacteriocins. Multi-locus sequence alignment using atpD, gyrB, recA, rpoB, 
and trpB concatenates (15) identified the closest sequenced relative of strain JV178 as 
Streptomyces torulosus strain NRRL B-3889, consistent with prior 16s rRNA gene analysis (3). 
These results place this strain in the S. scabiei clade (16), which contains several plant-associated 
Streptomyces species, including the potato pathogen S. scabiei 87.22 (17). While we failed to 
detect homologs of known pathogenicity loci, such as txtAB (18), eight genes were predicted to 
encode the plant-growth hormone auxin. The absence of recognizable pathogenicity loci and the 
predicted ability to produce the plant modulators concanamycin (10), coronafacic acid (11), and 
auxin suggest a plant-associated but nonpathogenic lifestyle. These observations suggest 
potential roles for the clifednamides, whose targets are still unknown. 
4.3.1 Accession number(s) 
The draft genome sequence of Streptomyces sp. strain JV178 was deposited in 
DDBJ/ENA/GenBank under the accession number PEKU00000000. The version described in 




The genome of Streptomyces sp. strain JV178 was sequenced with the help of Chris Shaffer and 
the McDonnell Genome Institute at Washington University in St. Louis. We also thank Michael 
Guzman (WUSTL) for assistance and advice with the assembly. This study received no specific 
grant from any funding agency in the public, commercial, or not-for-profit sector. 
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Chapter 5: Native and Engineered 
Clifednamide Biosynthesis in Multiple 
Streptomyces spp. 
This chapter was previously published in the journal ACS Synthetic Biology as: 
Qi Y., Ding E., and Blodgett J., Native and Engineered Clifednamide Biosynthesis in Multiple 
Streptomyces spp., ACS Synthetic Biology 7, 357-362 (2017). DOI: 10.1021/acssynbio.7b00349 
5.1 Personal contributions 
I identified putative clifednamide-type PTM BGCs in the genomes of several Streptomyces 
strains previously deposited on GenBank. I obtained four genome-sequenced strains with 
putative clifednamide-type PTM BGCs and one genome-sequenced strain with an ikarugamycin-
type PTM BGC from the Agricultural Research Service culture collection (NRRL – Northern 
Regional Research Laboratory). In addition, an undergraduate student in Dr. Joshua Blodgett’s 
BIOL3493 class isolated another clifednamide-producing strain, KL33. I characterized these 
strains for PTM production and genetic tractability and generated a ΔcftA mutant of 
Streptomyces sp. strain NRRL F-6131. Edward Ding, a former undergraduate student in the 
Blodgett lab, cloned the cftA expression plasmids and conjugated the strains into the 
ikarugamycin producer Streptomyces sp. strain NRRL F-2890. I characterized the PTM 
production from these strains and identified clifednamide C as a novel congener through MS/MS 






Polycyclic tetramate macrolactam (PTM) natural products are produced by actinomycetes and 
other bacteria. PTMs are often bioactive, and the simplicity of their biosynthetic clusters make 
them attractive for bioengineering. Clifednamide-type PTMs from Streptomyces sp. strain JV178 
contain a distinctive ketone group, suggesting the existence of a novel PTM oxidizing enzyme. 
Here, we report the new cytochrome P450 enzyme (CftA) is required for clifednamide 
production. Genome mining was used to identify several new clifednamide producers, some 
having improved clifednamide yields. Using a parallel synthetic biology approach, CftA 
isozymes were used to engineer the ikarugamycin pathway of Streptomyces sp. strain NRRL F-
2890 to yield clifednamides. Further, we observed that strong CftA expression leads to the 
production of a new PTM, clifednamide C. We demonstrate the utility of both genome mining 
and synthetic biology to rapidly increase clifednamide production. 
5.3 Letter 
Actinomycete bacteria are widely studied for their ability to produce diverse bioactive secondary 
metabolites. Already the source of nearly two-thirds of clinical antibiotics,1 actinomycete 
genome sequencing has revealed a wealth of previously unrecognized biosynthetic gene 
clusters.2−4 With many of these clusters apparently encoding drug-like molecules, these 
organisms remain as promising sources of much-needed future antibiotics and other 
therapeutics.5,6  
An unusually high proportion of sequenced actinomycete genomes contain polycyclic tetramate 
macrolactam (PTM) biosynthetic clusters.7 PTMs are of therapeutic interest, with family 
members having documented activity against bacteria, protozoa, fungi, plants, and cancer cell 
lines.8−11 In addition to their bioactivity, the relative simplicity and commonality of PTM 
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biosynthetic loci has made them attractive targets for genomics-based discovery and engineering 
via synthetic biology approaches.12−14 Despite containing only 3−6 genes, these small clusters 
encode diverse structures15 (Figure 1).  
 
 
Figure 1. Representative PTM biosynthetic clusters and their products. (A) the Streptomyces sp. 
strain JV178 clifednamide cluster (A: R = H, B: R = OH); (B) the Streptomyces sp. strain ZJ306 
ikarugamycin cluster; (C) The Lysobacter enzymogenes C3 HSAF cluster; (D) the Streptomyces 
sp. strain SPB78 frontalamide cluster (A: R = OH, B: R = H). Orange ORFs encode for sterol 
desaturases, red for iterative polyketide synthase nonribosomal peptide synthase fusion proteins, 
green for FAD-dependent oxidoreductases, blue for zincdependent alcohol dehydrogenases, and 
yellow for cytochrome P450s. ORFs in black are not conserved between PTM biosynthetic 
clusters 
 
The clifednamides are a family of PTMs discovered from Streptomyces sp. strain JV178, an 
environmental isolate from Connecticut garden soil.16 The clifednamides have therapeutic 
potential due to their structural similarity with ikarugamycin, which is active against a wide 
range of organisms.8,10,11 The clifednamides are distinguished from ikarugamycin by a ketone 
group on carbon 29 (Figure 1A). However, efforts to extensively profile clifednamide 
bioactivities have been limited by low yields from strain JV178 (Table 1).  
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Table 1. PTM Titers from Strains in This Study a,b 
a N.D.: Not detected. b Trace*: A credible MS/MS signal is found at the expected retention time, 
but the corresponding UV peak area was below the threshold for reliable quantification (>83 
nM). 
 
To understand clifednamide biosynthesis toward engineering its production, strain JV178 was 
genome-sequenced (see Methods). Due to the structural similarity of ikarugamycin and 
clifednamides, we expected strain JV178 would encode an ikarugamycin-like PTM cluster. 
Using BLAST, we identified a 5-gene PTM locus that likely encodes the clifednamides. 
Homology analysis of these genes allowed us to propose a plausible clifednamide biosynthetic 
pathway (Figure S1).  
Strain Ikarugamycin Clifednamide A Clifednamide B Clifednamide C 
S. sp. strain JV178 Trace*  0.94 μM 1.87 μM N.D.  
S. purpeofuscus Trace* Trace  0.10 μM N.D. 
S. sp. strain NRRL F-6131 Trace*  Trace*  Trace*  N.D. 
S. sp. strain F-6131 rpsL 
(K43N) 
Trace*  Trace*  Trace*  N.D. 
S. torulosus  N.D. 0.30 μM 0.91 μM N.D. 
S. neyagawaensis  N.D. 19.53 μM 6.46 μM 7.20 μM 
S. sp. strain KL33 N.D. 3.23 μM N.D. 0.55 μM 
S. sp. strain NRRL F-2890 28.2 ± 5.27 μM N.D. N.D. N.D. 
S. sp. strain F-2890 
PermE*pDA1652-cftAJV178 
1.10 ± 0.68 μM 13.7 ± 1.04 μM N.D. 2.62 ± 0.70 μM 
S. sp. strain F-2890 
PermE*pHM11a-cftAJV178 
N.D. 19.8 ± 4.86 μM N.D. 16.6 ± 0.01 μM 
S. sp. strain F-2890 
PermE*pDA1652-cftApurpeofuscus 
12.7 ± 2.08 μM 15.8 ± 2.79 μM N.D. Trace* 
S. sp. strain F-2890 
PermE*pHM11a-cftApurpeofuscus 
3.20 ± 0.34 μM 13.5 ± 3.02 μM N.D. 0.87 ± 0.06 μM 
S. sp. strain F-2890 
PermE*pDA1652-cftAF-6131 
12.9 ± 0.96 μM 18.0 ± 1.13 μM N.D. Trace* 
S. sp. strain F-2890 
PermE*pHM11a-cftAF-6131 
1.95 ± 0.47 μM 15.2 ± 1.58 μM N.D. 3.96 ± 0.80 μM 
S. sp. strain F-2890 
PermE*pDA1652-cftAtorulosus 
3.03 ± 0.14 μM 17.8 ± 4.37 μM N.D. 1.03 ± 0.15 μM 
S. sp. strain F-2890 
PermE*pHM11a-cftAtorulosus 
0.99 ± 1.14 μM 17.4 ± 1.73 μM N.D. 4.27 ± 2.31 μM 
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Three of the genes, ikaA, ikaB and ikaC, recapitulate the ikarugamycin cluster.12 As such, 
clifednamide biosynthesis likely begins with IkaA, an iterative polyketide synthase/ 
nonribosomal peptide synthase fusion protein. Biochemical studies of its ortholog in HSAF 
biosynthesis17 indicate the protein initiates PTM biosynthesis by ligating two polyketide chains, 
built from six malonyl-CoA precursor units each, to the nonproteinogenic amino acid L-ornithine 
(Figure S1).18 The resulting tetramate-polyene product is reductively cyclized by IkaB and IkaC 
to produce the 5−6−5 carbon ring system shared by ikarugamycin and clifednamides.19 A ftdA 
homologue was also found in the cluster. A PTM hydroxylase common to a number of PTM 
pathways,7,20,21 ftdA is likely responsible for the C25 hydroxyl group of clifednamide B. The 
remaining open reading frame is encoded between ikaA and ikaB (Figure 1A). Predicted to 
encode a novel cytochrome P450, we reasoned its cognate enzyme (designated CftA, for 
clifednamide tailoring A) may install the C29 ketone of the clifednamides. No additional PTM 
genes were detected in the genome of strain JV178, further suggesting the cftA-containing cluster 
encodes the clifednamides. 
Strain JV178 was poorly transformed with plasmids having a pSG5 origin of replication, 
confounding gene deletion analyses in this strain. Toward experimentally verifying our 
clifednamide biosynthetic model, we thus used a genome mining approach to identify additional 
producers. Several actinomycetes having publicly available genome sequences were found to 
harbor PTM clusters syntenic with the strain JV178 locus (Figure S2).  
Four such strains were obtained from the USDA NRRL strain collection. Each strain was grown 
on a panel of solid media and extracted with ethyl acetate for LC−MS/MS analysis. 
Clifednamide production was determined by comparison with extracts containing clifednamides 
A and B from strain JV178. All four strains appear to produce both compounds based on product 
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retention times, UV absorbance spectra, and mass fragmentation patterns (Figure 2). Notably, 
Streptomyces neyagawaensis strain NRRL B-3092 produced approximately 26 μM of 
clifednamides A and B combined, about 10-fold greater than Streptomyces sp. strain JV178 
(Figure 2E, Table 1). The other three strains, Streptomyces purpeofuscus strain NRRL B-1817, 
Streptomyces sp. strain NRRL F-6131, and Streptomyces torulosus strain NRRL B-3889 
produced considerably lower amounts (Figure 2B−D, Table 1). Interestingly, a local PTM-
producing soil isolate (Streptomyces sp. strain KL33, Supporting Information) also produced 
significant clifednamide A titers, but no clifednamide B was detected (Figure 2F).  
 
 
Figure 2. LC-MS/MS chromatograms of clifednamide production by (A) Streptomyces sp. strain 
JV178, (B) Streptomyces purpeofuscus strain NRRL B-1817, (C) Streptomyces sp. strain NRRL 
F-6131, (D) Streptomyces torulosus strain NRRL B-3889, (E) Streptomyces neyagawaensis strain 
NRRL B-3092, and (F) Streptomyces sp. strain KL33. The retention times for clifednamides A and 
B (cfA and cfB) are indicated by grey bars.  
 
Of the newly obtained clifednamide producers, Streptomyces sp. strain NRRL F-6131 proved to 
be the most amenable to intergeneric conjugation. This strain was thus used to interrogate 
clifednamide biosynthesis. A rpsL(K43N) mutant was isolated for streptomycin 
counterselection.22 As noted for other Streptomyces metabolites, this lesion also increased PTM 
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production23 (Figure 3A,B). Markerless cftA deletion resulted in the loss of clifednamide 
production. However, the strain produced increased amounts of a previously minor compound 
(m/z 479) (Figure 3C). This peak was confirmed to be ikarugamycin by comparison with an 
authentic standard, and its apparent accumulation is consistent with it being a clifednamide 
biosynthetic precursor. An additional peak of interest (m/z 495) was detected in the ΔcftA 
mutant. This was tentatively identified as butremycin, a known C25-hydroxyl derivative of 
ikarugamycin (Figure S1).24 The experimental mass matches the compound and its UV profile is 
consistent with other PTMs. MS/MS analysis revealed a daughter ion with a m/z of 154, 
consistent with C25-hydroxylated PTMs such as clifednamide B. Because butremycin is 





Figure 3. Deletion of cftA in Streptomyces sp. strain NRRL F-6131. LC-MS/MS chromatograms 
of extracts from (A) the wild-type strain, (B) the rpsL (K43N) mutant, and (C) the rpsL ΔcftA 
double mutant. The peaks for ikarugamycin (ika), butremycin (but), clifednamide A (cfA), and 




Our biosynthetic model suggested an ikarugamycin-producing microbe could be engineered to 
produce clifednamide via cftA expression. BLAST searches using sequences from the 
characterized ika cluster of Streptomyces sp. strain ZJ30619 identified Streptomyces sp. strain 
NRRL F-2890 (hereafter referred to as strain F-2890) as a candidate ikarugamycin producer. 
Characterization of the strain revealed it produced up to 28 μM (13.6 mg/L) of ikarugamycin 
(Figure 4A), rivaling S. neyagawaensis clifednamide production. A genetic system was 
established in strain F-2890 to further verify our biosynthetic model and systematically evaluate 
the activities of a panel of CftA isozymes. To do this, four cftA orthologs were cloned under two 
versions of the strong constitutive PermE* promoter. While the original ermE promoter in 
Saccharopolyspora erythraea begins transcription at the start codon,25 a short 5′- UTR 
containing a ribosome binding site is often added to PermE* expression plasmids. The two 
PermE* promoters used in this study contain different 5′-UTR sequences (see Supporting 
Information), and our plasmids harboring pHM11a26-derived PermE* drive higher xylE reporter 
expression than identical constructs having pDA165227-derived PermE* instead (Figure S3).28  
The resulting panel of PermE*-cftA constructs was chromosomally integrated in strain F-2890 at 
the ΦC31 attB site29 following intergeneric conjugation. As expected, the resulting strains all 
produced clifednamide A, which was confirmed by HRMS (C29H36N2O5 [M + H]+ m/z 
493.2696 found, calculated 493.2696; Figures 4, S4, S6, and Table 1). Interestingly, CftA 
homologues from different strains produced varying amounts of clifednamide A, with the strain 
JV178 homologue producing the most (20 μM). No clifednamide B or butremycin was observed 
in any of these strains due to ftdA being absent in the host. In general, constructs driven by the 
stronger pHM11a-derived PermE* promoter converted more ikarugamycin precursor to 






Figure 4. Production of PTMs in Streptomyces sp. strain NRRL F-2890 expressing CftA from 
Streptomyces sp. strain JV178. (A) Wild-type strain F-2890, (B) strain F-2890 
attBΦC31::PermE*pDA1652-cftAJV178, and (C) strain F-2890 attBΦC31::PermE*pHM11a-cftAJV178. 




Additionally, all four pHM11a constructs and two pDA1652 constructs resulted in a new product 
(m/z 509) having a characteristic PTM UV profile (Figures 4, S4, and S5). MS/MS 
fragmentation produced a daughter ion with m/z of 139, a diagnostic daughter ion shared among 
PTM molecules lacking C25 hydroxylation such as clifednamide A, ikarugamycin, and 
capsimycin30 (Figures S7 and S8). Furthermore, metabolic labeling with 2 H7-L-ornithine 
resulted in a correspondingly heavier mass (m/z 516) and daughter ion (m/z 146; Figure S7B,D). 
These results parallel those following 2 H7-L-ornithine labeling of clifednamide A (Figure 
S7A,C). With multiple lines of data together establishing this new mass as a PTM family 
molecule, this molecule was named clifednamide C. HRMS molecular formula determination 
(C29H36N2O6, m/z 509.2645 found for [M + H]+ , calculated 509.2646, Figure S6) suggests 
clifednamide C is a hydroxylation or epoxidation product of clifednamide A. In comparing 
MS/MS fragmentation patterns of clifednamide C against ikarugamycin, clifednamide A, and 
literature values for capsimycin, all four molecules gave expected m/z 139.1 and 181.1 daughter 
ions that likely map to the ornithine-tetramate regions conserved among the molecules. In 
contrast, few other fragments match between the compounds, confirming each PTM has unique 
5-6-5 carbocycle oxidation patterns. Due to fragmentation complexity (Figure S8), further 
analyses are required to completely solve the clifednamide C structure. While we first identified 
clifednamide C following heterologous CftA expression, we also detected it in S. neyagawaensis 
extracts, confirming its production in native clifednamide producers.  
The tandem oxidation of ikarugamycin by CftA to produce both clifednamides A and C is 
analogous to the activity of the recently characterized IkaD.30 A cytochrome P450 associated 
with some ikarugamycin biosynthetic clusters, IkaD primarily installs an epoxide across carbons 
7 and 8. However, it can also hydroxylate C29, the same position targeted for keto insertion by 
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CftA (Figure S1). We noted that strain F-2890, the ikarugamycin-producing host strain, also 
contains an IkaD homologue. However, ikarugamycin was the major observed PTM product in 
the F-2890 parent strain, indicating IkaD activity is minimal in this strain. 
The putative CftA orthologs identified in this study share at least 80% amino acid sequence 
identity, but have less than 57% amino acid sequence identity with IkaD and presumed IkaD 
orthologs. Thus, under the cytochrome P450 naming convention,31 CftA and IkaD are members 
of distinct subfamilies within the CYP107 clade. Aside from IkaD and CftA, additional PTM-
associated P450 enzymes also fall within the CYP107 group (Figure S9, S10). Beyond CYP107 
family P450s, our data also indicates the existence of three other distinct CYP families (<40% 
identity with CYP107) associated with PTM loci. The largest group is comprised of FtdF 
homologues (as found in the frontalamide cluster), but no role has yet been established for these 
enzymes. Together, our analyses suggest further investigations into PTM-associated CYPs will 
continue to reveal enzymes with varied PTM scaffold specificity, oxidative activities and 
regioselectivity. 
In conclusion, we used a combination of comparative genomics, genetics, and genome mining to 
reveal the novel cytochrome P450 CftA is responsible for clifednamide production. We engaged 
in a synthetic biology approach to engineer clifednamide production by utilizing cftA orthologs 
sourced from newly identified clifednamide producing strains. Increased availability of 
clifednamides will enable increased throughput in bioactivity assays, with the eventual goal of 
identifying the molecular targets of PTMs. In addition to increased clifednamide production over 
Streptomyces sp. strain JV178, we noted substantial differences from cftA homologues. As such, 
this work demonstrates the value of leveraging bioinformatically identified panels of isozymes in 
a plug-and-play fashion to rapidly identify efficient biocatalysts. Further, we show CftA belongs 
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to an expanding family of PTM cytochrome P450 enzymes with the apparent capability to carry 
out multiple oxidation events. These enzymes may be useful to engineer diversity-oriented 




5.4.1 Strains, Plasmids, Primers, Enzymes, Chemicals and General Methods.  
Strains, plasmids, and primers are described in Tables S1−S3. Several strains were obtained from 
the Agricultural Research Service Culture Collection (NRRL). All primers were purchased from 
Integrated DNA Technologies. All restriction enzymes and Taq polymerase were purchased from 
New England BioLabs. T4 ligase was purchased from New England BioLabs and ThermoFisher. 
KOD Hot Start DNA Polymerase (EMD Millipore) in FailSafe PCR 2X PreMix (Epicentre) was 
used to amplify DNA sequences for cloning from Streptomyces genomic DNA. Taq polymerase 
was used for colony PCR. Ikarugamycin (>99%) was purchased from Santa Cruz Biotechnology. 
L-Ornithine2,3,3,4,4,5,5-d7 HCl (>98% atom D) was purchased from CDN Isotopes. All other 
chemicals were obtained from Sigma-Aldrich or Fisher Scientific. Streptomyces genomic DNA 
was prepared for PCR by grinding a colony in 100 μL DMSO as described by Van Dessel et al.32 
Standard protocols for manipulating E. coli were based on those of Sambrook et al.33 
Streptomycetes were routinely propagated on ISP2 agar34 and Trypticase Soy Broth (Difco) at 28 
°C. Glass beads were added to liquid cultures to disrupt mycelial clumps.  
5.4.2 Genome Sequencing of JV178.  
Genomic DNA was extracted from TSB-grown mycelia as previously described.35 An Illumina 
301-bp paired-end sequencing library was prepared using a High-Throughput Library 
Preparation Kit (Kapa Biosystems) and was sequenced on an Illumina MiSeq platform (Illumina, 
Inc., San Diego, CA, USA) by the Washington University in St Louis McDonnell Genome 
Institute. Sequencing reads were trimmed and de novo assembled using CLC Genomics 
Workbench (CLC Bio-Qiagen, Aarhus, Denmark). An annotated sequence for the Streptomyces 
sp. strain JV178 clifednamide cluster was deposited to GenBank (accession no. MF89327).  
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5.4.3 Streptomycete Conjugations. 
Streptomyces sp. strain NRRL F-6131 spores were collected from ISP4 agar,34 while 
Streptomyces sp. strain NRRL F-2890 spores were collected from ISP2 agar. Spores were 
harvested using TX Buffer.36 Conjugations were performed using JV36 as the general E. coli 
donor as previously described.7 Exconjugants were selected with 50 μg/mL colistin and 25 or 50 
μg/mL apramycin. Successful conjugations were verified by colony PCR. 
5.4.4 cftA Markerless Gene Disruption. 
The cftA coding sequence of Streptomyces sp. strain NRRL F-6131 was replaced with a 
truncated gene containing the first nine codons and the last ten codons of the wild-type coding 
sequence with homologous recombination as previously described.37 Streptomycin-resistant 
(StrR) mutants were isolated on ISP2 + Str25 agar. The rpsL genes were amplified and 
sequenced. Strain JV739 bearing the rpsL (K43N) mutation was chosen for subsequent 
experiments as the mutation did not interfere in clifednamide production. The 990 bp upstream 
flanking region of cftA was amplified using primers YQ273 and YQ274 (introduced a XbaI site 
and homology to pUC19). The 1079 bp downstream flanking region of cftA was amplified using 
primers YQ275 (introduced homology to the upstream flanking region) and YQ276 (introduced a 
HindIII site and homology to pUC19). The 2668 bp fragment of pUC19 was amplified 
withprimers YQ268 and YQ269. PCR amplicons were assembled using the NEBuilder HiFi 
Assembly kit (New England BioLabs). The resulting pUC19-ΔcftA was digested with XbaI and 
HindIII and the 1956 bp fragment was ligated into pJVD52.1 digested with XbaI/HindIII. The 
resulting pJVD52.1-ΔcftA was introduced into strain JV739 by intergeneric conjugation, and 
apramycin-resistant (AprR) exconjugants were selected. Exconjugants were grown in TSB 
nonselectively at 37 °C and double-recombinants were selected for on ISP2 + Str100. The ΔcftA 
mutants were confirmed by PCR with primers YQ277−280.  
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5.4.5 cftA Heterologous Expression.  
The cftA homologues were amplified using primers ED9−16 (introduced NdeI and XbaI sites). 
The PCR products were digested with NdeI and XbaI and ligated into pJMD2 or pJMD3 to 
generate plasmids pED1−8. After confirming the inserts by Sanger sequencing (Genewiz) with 
primers PermE*-fw and PXS6, the constructs were introduced into Streptomyces sp. strain 
NRRL F-2890 by intergeneric conjugation. Integration at the ΦC31 attB site was confirmed with 
primers R2NJ, F3NJ, Int 7NJ, and Int 8NJ.  
5.4.6 PTM Detection by HPLC−MS/MS.  
Strains were cultivated in 15 mL of TSB liquid medium in 125 mL Erlenmeyer flasks shaken in 
1-in. orbitals at 250 rpm at 28 °C. Six mm glass beads were added to disrupt mycelial clumps. 
After 2 days of growth, 200 μL of cultures were plated on HT,38 ISP4, ATCC172, or JBFM1 
(adapted from Medium 2:39 2% D-fructose; 5% D(+)Mannose; 0.167% Na-L-aspartate; 0.06% L-
arginine HCl; 0.05% L-histidine HCl; 0.2% K2HPO4; 0.2% KH2PO4; 0.5% NaCl; 0.006% 
ZnSO4-7H2O; 0.0256% MgSO4-7H2O; 0.051% MgCl2-6H2O; 0.001% CoCl2-6H2O; 0.036% 
NaSO4; 2.13% MES free acid; 1.5% agar; 2% R2 Trace elements; 1.5% Agar; pH 6.0) and 
incubated at 28 °C. After 6 days, the agar was diced and immersed in ethyl acetate overnight. 
The ethyl acetate was evaporated at low pressure and the extract was suspended in 400 μL of 
HPLC-grade methanol and syringe filtered. Analysis was performed using a Phenomenex Luna 
C18 column (75 × 3 mm, 3 μm pore size) installed on an Agilent 1260 Infinity HPLC connected 
to an Agilent 6420 Triple-Quad mass spectrometer using the following method: T = 0, 5% B; T 
= 3, 40% B; T = 13, 60% B; T = 17, 100% B, T = 20, 100% B; A: water +0.1% formic acid, B: 
acetonitrile +0.1% formic acid; 0.9 mL/min. Ten μL of the methanol-dissolved extract was 
injected per run. The precursor ion scan mode was used to identify molecules that fragmented 
(collision energy, 30 V) into daughter ions with m/z of 139.2 or 154.2. The resulting data was 
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analyzed offline with Agilent MassHunter Qualitative Analysis software. We quantified PTM 
production in native and recombinant strains by integrating UV absorbance values at 320 nm, 
detected with an HPLC in-line diode array detector (DAD). Because the PTMs in this work have 
identical UV chromophores arising from their conserved ornithine-tetramate substructures 
(Figures 1, S5, S7, and S8), an ikarugamycin standard curve (R2 = 0.9947, 5−200 μM) was used 
to calculate both ikarugamycin and clifednamide production titers throughout this work. 
However, we acknowledge minor differences might exist in the molar extinction coefficients of 
these PTMs, leading to subtle differences between our reported and actual concentration values. 
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6.1 Personal contributions 
Streptomyces sp. strain JV180 was previously isolated by Dr. Blodgett. Cole Martini, a former 
WUSTL undergraduate student, isolated Streptomyces sp. strain SP18CM02 in Dr. Blodgett’s 
BIO3493 class. I extracted the genomic DNA for Streptomyces sp. strain JV180. Jennifer Greif, a 
former undergraduate student in the Blodgett lab, extracted the genomic DNA for Streptomyces 
sp. strain SP18CM02. Library preparation, sequencing, quality control, and genome assembly 
were performed by McDonnell Genome Institute (WUSTL) scientists Chad Tomlinson, 
Christopher Markovic, and Catrina Fronick. Dr. Blodgett, Dr. Keshav Nepal, a postdoc in the 








Here, we report the draft genome sequences of two related Streptomyces sp. strains, JV180 and 
SP18CM02. Despite their isolation from soils in Connecticut and Missouri (USA), respectively, 
they are strikingly similar in gene content. Both belong to the Streptomyces griseus clade and 
harbor several secondary metabolite biosynthetic gene clusters. 
6.3 Microbial Resource Announcement 
Streptomyces species produce many diverse secondary metabolites that are medicinally relevant 
(1). Recent advancements in genome sequencing have revealed Streptomyces as a reservoir of 
diverse biosynthetic gene clusters (BGCs). A high proportion of Streptomyces harbor BGCs 
encoding polycyclic tetramate macrolactams (PTMs), molecules of interest due to their structural 
complexity, atypical biosyntheses, and biomedical significance (2–4). Streptomyces sp. strain 
JV180 and Streptomyces sp. strain SP18CM02 are soil isolates found to carry PTM BGCs. The 
isolation of strain JV180 was previously reported (3), while strain SP18CM02 was recently 
isolated using identical methods from calcium carbonate-treated soil collected at Tyson Research 
Center in Eureka, MO, using low-tryptone-yeast extract (LTY) medium supplemented with 
nalidixic acid.  
Both strains were grown in Trypticase soy broth supplemented with 0.6% glycine at 28°C, and 
genomic DNA was extracted with the Qiagen DNeasy UltraClear microbial kit for Illumina 
sequencing or phenol-chloroform (5) for PacBio sequencing. For PacBio sequencing, genomic 
DNA was sheared to approximately 15 kb using Covaris g-TUBEs. The PacBio SMRTbell 
Express template prep kit 2.0, barcoded overhang adapter kit 8A, and barcoded overhang adapter 
kit 8B were used for library construction. Final library pools were assessed on an Agilent 2100 
Bioanalyzer using a DNA 12000 kit. DNA polymerase binding complex was processed using the 
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PacBio Sequel binding kit 3.0 and sequencing primer 4. The PacBio Sequel sequencing plate 3.0 
and a single-molecule real-time (SMRT) cell (1M v3 Tray) were used for the sequencing run. 
The resulting reads were evaluated based on mean read length, which was 27,869 bp. PacBio 
read error correction, adapter trimming, and assembly were done in Hierarchical Genome 
Assembly Process 4 (HGAP4). Default parameters were used with the exception of the advanced 
parameter, “aggressive mode.” The assembly was polished in Pilon 1.23 with Illumina reads, 
which were obtained as described below (6, 7).  
For Illumina sequencing, dual-indexed libraries were constructed with 2 mg of genomic DNA 
(gDNA) utilizing the TruSeq PCR-free library prep kit (Illumina) on the SciClone next-
generation sequencing (NGS) instrument (Perkin Elmer) targeting 550- bp inserts. Then, 50 ml 
of gDNA was fragmented on an LE200 Covaris instrument, and the library was evaluated on a 
LabChip GX system (Perkin Elmer). The library was sequenced on a NovaSeq 6000 (Illumina) 
S4 300 cycle flow cell for 2 × 150-bp paired-end reads, and NovaSeq Real Time Analysis 3.3.3 
software (Illumina) was used to ensure that $80% of resulting bases had a quality score of $Q30. 
FLEXBAR 3.4 (8) was used for adapter trimming, and MEGAHIT (9) was used for genome 
assembly with default parameters. Genomic features were annotated with Rapid Annotations 
using Subsystems Technology 2.0 (10) and antiSMASH (11) (Table 1).  
 





Strains JV180 and SP18CM02 share 100% identical 16S rRNA sequences, and their closest 
match in GenBank was Streptomyces californicus strain NRRL B-3320 (99.93%), a strain that 
has a similar genome size (8,023,053 bp) and belongs to the Streptomyces griseus clade (12). 
MUSCLE pairwise alignments (13) revealed that strains JV180 and SP18CM02 share 99.93, 
99.76, 99.29, 99.91, and 99.53% nucleotide identities for atpD, gyrB, recA, rpoB, and trpB, 
respectively. Strains JV180 and SP18CM02 possess 34 and 35 BGCs, respectively, and all strain 
JV180 BGCs are conserved in strain SP18CM02. 
6.3.1 Data availability 
The draft genome sequences of strains JV180 and SP18CM02 were deposited in 
DDBJ/ENA/GenBank under accession numbers JACGMP000000000 and JACGMQ000000000, 
respectively. The SRA accession numbers for strain JV180 are SRR12430886 and 
SRR12430887 for Illumina and PacBio sequencing, respectively, and that for strain SP18CM02 
is SRR12430885. The versions described in this paper are the first versions.  
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Chapter 7: Conclusions and Future 
Directions 
7.1 Abstract 
 Bacterial whole-genome sequencing and automated genome annotation is now commonplace. 
Advances in these technologies coupled with lower experiment costs have led to an explosion of 
Streptomyces genomes for analysis.  One major consequence from this is the realization that the 
genomes of Streptomyces and other closely related actinobacteria contain many more 
biosynthetic gene clusters (BGCs) for drug-like compounds than previously thought. However, 
the products of many of these BGCs are undetectable in laboratory cultures, which poses a major 
roadblock for genomics-based drug discovery. It is commonly hypothesized that such BGCs are 
transcriptionally downregulated, possibly due to a lack of chemical signals in standard growth 
media that are normally present in native growth environs. In my thesis work, I used comparative 
genomics and metabolomics to study polycyclic tetramate macrolactam (PTM) biosynthesis. The 
genetic simplicity and widespread conservation of PTM BGCs in Streptomyces strains enabled 
me to directly compare actively expressed and apparently silent PTM BGCs. Leveraging these 
features, I was able to examine how genetic variations resulted in differences in the expression of 
PTM BGCs as well as differences in the structures of PTMs produced by different BGCs. 
Herein, I briefly highlight some of my key findings and discuss potential future research 
questions that arise from them. 
7.2 Genetic variations in the regulation of PTM 
biosynthesis 
One of my major thesis goals was to address a long-standing question in Streptomyces genome-
mining: why are some BGCs highly expressed and why are the products of other BGCs 
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undetectable in laboratory cultures? Streptomyces genomes can encode upward of 30 BGCs for 
specialized metabolites (1). These are important because it is widely thought that they may 
encode for much needed novel antibiotics or other useful compounds. However, the apparent 
silence of many BGCs hinders the genome-mining of Streptomyces BGCs for new drugs (2).  
Focusing on a group of 11 closely related Streptomyces griseus clade strains carrying PTM 
BGCs, I demonstrated how PTM production could vary widely between individual strains, from 
being robustly expressed under most culturing conditions to being almost undetectable in other 
strains. By examining the regions upstream of the first open reading frame in the PTM BGC 
(PftdA), I found conserved patterns in promoter sequence variations that correlated with robust and 
weak PTM production. This suggested that weak PTM producers had downregulated PftdA 
promoters. When the PftdA regions of various strains were used to replace the native PftdA region 
of a robust PTM producer, PftdA regions of other robust PTM producers resulted in robust BGC 
expression and PTM production, while PftdA regions of weak PTM producers resulted in 
decreased BGC expression and PTM production. These results supported the long-held belief 
that silent BGCs are transcriptionally downregulated, by directly comparing the promoters of 
active and silent PTM BGCs. To my knowledge, this is the first comparative metabologenomics 
study to understand the effects of native promoter variation on BGC expression across different 
Streptomyces. This contrasts with a recent study that examined several strains from the marine 
actinomycete genus Salinispora, where the authors highlighted changes in cluster-situated 
regulators as possible causes of observed differences in BGC expression (3).  
Through detailed mapping of the PftdA region in strain JV180, a genetically tractable S. griseus 
PTM-producer, I found a dinucleotide ‘AG’ indel whose presence or absence strongly affected 
PftdA strength. I also mapped the transcript start site, −10 box, and −35 box of PftdA and showed 
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that AdpA likely directly regulates PftdA, which was also supported by EMSA experiments 
performed by Keshav Nepal, a postdoc in the Blodgett lab. I found that although there were some 
differences in the sequences of the −35 boxes and binding sites of the AdpA transcriptional 
regulator in the PftdA regions S. griseus clade strains, these SNPs had much weaker effects on PftdA 
strength than the ‘AG’ indel. The ‘AG’ indel’s apparent ability to tune PftdA strength strongly 
suggests an evolutionary divergence between PTM-expressing and PTM-silent S. griseus clade 
members.  
It is commonly thought that the products of BGCs that are highly expressed in across various 
conditions without any exogenous triggers are produced by Streptomyces strains to prevent other 
organisms from stealing nutrients released when they undergo lysis during morphological 
differentiation (4). In this model, most other BGCs are repressed and only expressed under 
specific conditions when they are needed. I interpret our results to suggest that different strains 
may have diverged BGC regulatory networks that lead to differences in which BGCs are 
preemptively expressed and which are downregulated in the absence of specific stimuli. This 
finding challenges the notion that all silent BGCs should be activated through synthetic 
regulatory manipulation or rewiring; learning to recognize weak promoters from genomic 
sequences will allow researchers to avoid poorer producers a priori and focus discovery efforts 
on strains that are likely to produce the desired molecules.  
In future experiments, the promoters of other PTM BGCs could be systematically interrogated 
using the approach I pioneered for S. griseus above in order to discover new signatures that 
differentiate strong and weak promoters. One group of PTM BGCs which could be examined are 
the clifednamide-type PTM BGCs. When I characterized several clifednamide-type PTM BGCs, 
I noticed dramatic differences in PTM production between these strains. While the strongest 
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producer, S. neyagawaensis, produced over 30 μM of clifednamide PTMs in total, weaker 
producers such as S. torulosus and S. sp. strain NRRL F-6131 produced less than 83 nM 
(minimum quantifiable threshold). Subsequent to this, during a large-scale genome sequencing 
project in the lab, I identified 11 additional isolates with clifednamide BGCs that could be 
studied. Preliminary characterization of these strains showed that one strain, BE34, produced 
little to no PTMs, while others produced varying amounts of PTMs. Eight of these BE strains 
appear to be especially closely related by 16S rDNA and iPKS-NRPS (IkaA) sequence 
homology, providing a similar study cohort as the S. griseus strains that I extensively 
characterized in my thesis. One area to be cautious of when examining transcriptional regulation 
of clifednamide-type PTM BGCs is the possibility that these BGCs contain two promoters, PftdA 
and PikaA. This appears to be likely given the larger intergenic space between ftdA and ikaA 
(approximately 250 nucleotides) and the fact that several strains have ftdA-less clifednamide 
BGCs. This would add additional complexity to the experiments needed to understand 
clifednamide regulation in comparison to the S. griseus clade strains, which only have a single 
PTM promoter, PftdA. 
Additionally, the PftdA regions of the S. griseus clade strains can be studied in further detail, as 
these promoters and UTRs have several interesting features yet to be characterized. First, it 
remains unclear how AdpA can bind downstream of the transcript start site in promoters like 
PftdA and PadsA without downregulating transcription. To fully understand this, it may be 
necessary to carry out in vitro transcription experiments. However, to my knowledge, such 
methodology has not been widely used in studying Streptomyces transcriptional regulation. This 
may be due to the fact that many Streptomyces promoters of interest control specialized 
metabolism and are therefore not transcribed using the housekeeping σ70. Aside from hrdB 
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encoding σ70, Streptomyces genomes encode for dozens of additional σ factors that enable 
exquisite regulatory control. As a result, the complex relationship between numerous σ factors 
and their target promoters is yet to be well-understood.  
Another feature of the PftdA regions of the S. griseus clade strains that bears further study is the 
highly conserved region containing the AG indel, which appears to be a key factor in controlling 
the strengths of these PftdA’s. It is possible that this region acts as a binding site for another 
transcription factor or is involved in the formation of mRNA secondary structures. Based on my 
RT-qPCR analysis of grh BGC mutants, PftdA could be controlled by multiple regulators, and a 
pull-down experiment to identify other proteins which bind the PftdA region could reveal other 
regulators of PftdA in addition to AdpA. Alternatively, mRNA folding of the PftdA UTR could be 
studied through more detailed in silico analysis and mutational studies. As UTR secondary 
structures can often control mRNA degradation and translation dynamics, the effects of UTR 
variations could be studied through transcriptomic and proteomic analyses as well as ribosomal 
occupancy in in vitro translation experiments. Through these experiments, it may be possible to 
discover novel regulators of PTM expression, such as a new transcription factor or riboswitch. 
The widespread presence of PTM BGCs in Streptomyces and other bacteria could mean that any 
mechanisms controlling PTM BGCs are also equally widespread, raising the potential impact of 
such research.  
Another related research goal is to demonstrate that these findings can be leveraged to activate a 
silent PTM BGC. Although I indirectly showed that restoring the ‘AG’ indel could increase the 
strength of the PftdA of IFO13350 and that PftdA_JV180 was stronger than PftdA_IFO13350 in both JV180 
and IFO13350 host strains, I was unable to activate PTM production in IFO13350 or any other S. 
griseus strain with a weak PTM BGC. Further experiments could attempt to develop genetic 
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tools for these strains or identify a genetically tractable S. griseus clade strain with a silent BGC 
to be engineered.  
With the growing body of research on the regulation of Streptomyces BGCs and the promoters 
controlling these BGCs, it may become possible to predict a priori whether a given BGC should 
be expressed or not. This would greatly streamline genome-mining efforts to discover novel drug 
candidates. Additionally, well-characterized BGC promoters with complex regulation could be 
used in place of constitutive promoters when regulatory rewiring is necessary, as constitutive 
expression of antibiotic BGCs during exponential growth could negatively impact cell growth 
rates, maximum cell density, and ultimately drug production titers.  
7.3 Metabolomic variations affecting PTM biosynthesis 
The crosstalk between the griseorhodin and PTM biosynthetic gene clusters was an unexpected 
finding. One original motivation for deleting the grh BGC was that PTM production could be 
increased by eliminating an unneeded pathway that competed for a shared precursor pool. 
Instead, I observed almost complete loss of PTM production in the ΔgrhR2-V mutant. These 
results contradicted a popular strategy for increasing production titers in Streptomyces (5) and 
also suggested that another PftdA transcriptional regulator existed.  
Further experiments showed that PTM production and BGC transcription were reduced by the 
deletion of certain grh BGC genes. However, this interaction did not actually involve the 
production of griseorhodin molecules, as evidenced by the fact that deletion of grhQSAB had no 
effect on PTM production and that a griseorhodin-enriched fraction and a griseorhodin analog, γ-
rubromycin, were unable to chemically complement the loss of PTM production in the ΔgrhR2-V 
mutant. Instead, genetic complementation studies pointed to grhGH, a two-gene operon encoding 
166 
 
for production of the shared precursor unit malonyl-CoA, as a key player. While regulatory 
crosstalk between BGCs has been previously documented, the most-well documented 
mechanisms of BGC crosstalk involved pleiotropic cluster situated regulators (CSRs) (6). Based 
on complementation studies, the grh CSRs, GrhR2 and GrhR3, do not appear to have any effect 
on PftdA, and there is no PTM CSR which could explain how griseorhodin production decreased 
in a ΔftdA-F mutant.  
Due to these results, I hypothesize that the PTM BGC could be regulated, either directly or 
indirectly, by a malonyl-CoA or long chain acyl-CoA dependent mechanism. While 
actinomycetes lack homologs of other well-characterized regulators of lipid metabolism such as 
FapR (7) and FadR (8), a novel global regulator of lipid metabolism, FasR, has been 
characterized in several actinomycetes, including Streptomyces coelicolor (9), Corynebacterium 
glutamicum (10), and Mycobacterium tuberculosis (11). Data from C. glutamicum suggests that 
FasR regulates its target promoters in a long chain acyl-CoA responsive manner, but this result 
has not been reproduced in Streptomyces yet, to my knowledge. The grh-PTM interaction 
presents an opportunity for the potential role of FasR in Streptomyces secondary metabolism to 
be investigated. Further genetic and transcriptomic analyses of grh BGC mutants, acetyl-CoA 
carboxylase mutants, and fasR mutants could be used to probe this relationship. 
Another significant finding was that S. griseus strain IFO13350 and other poor PTM producers 
in the S. griseus clade lack grh BGCs. This suggests that other factors besides differences in PfftdA 
sequences contribute to difference in PTM production. The interdependence of the PTM and 
griseorhodin BGCs on each other goes against the commonly held notion that BGCs compete for 
precursor units. Instead, it is likely that the malonyl-CoA produced by GrhGH help to support 
both PTM and griseorhodin production, as well as other polyketides encoded for by S. sp. strain 
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JV180. These findings also raise a caution towards the frequently used strain engineering 
strategy of eliminating unwanted BGCs in order to create a metabolic chassis strain. Rather than 
wholesale deletion of entire BGCs, which can contain pleiotropic CSRs and precursor 
biosynthetic genes, it may be better to selectively inactivate key biosynthetic genes in unwanted 
biosynthetic pathways.  
Interestingly, although S. griseus strain IFO13350 and other poor PTM producers in this clade 
lack grh BGCs, these strains have other polyketide BGCs which contain grhGH homologs. How 
these BGCs influence PTM biosynthesis could be explored by genetic, transcriptomic, and 
metabolomic studies. One challenge in this area is that I was unable to make gene knockouts in 
strain IFO13350 due to its strong DNA restriction system. We have recently sequenced the 
genomes of 3 environmental isolates, BE277, BE319, and BE327, which also belong to the S. 
griseus clade. Based on phylogenetic analyses, these strains clade with poor PTM producers in 
the S. griseus clade, and replacement of JV180 PftdA sequence with those of BE277, BE319, and 
BE327 confirmed that these strains have weak PftdA’s. However, unusually, BE319 and BE327 
were able to produce a similar amount of PTMs as JV180. One possible cause of this is the fact 
that these two strains possess two polyketide BGCs with grhGH homologs, which help boost 
their ability to produce PTMs. If these strains prove to be genetically tractable, this relationship 
should be further explored. 
7.4 Genetic variations in PTM biosynthetic genes 
Another type of genetic variations affecting PTM biosynthesis that I was interested in exploring 
was the genetic diversity in biosynthetic enzymes encoded within PTM BGCs. When I began 
working on my thesis project, only three PTM BGCs had been completely characterized, which 
were the HSAF BGC in Lysobacter enzymogenes C3 (12), the frontalamide BGC from 
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Streptomyces sp. SPB78 (13), and the ikarugamycin BGC of Streptomyces sp. Tü 6239 (14). In 
addition, a few frontalamide-type BGCs had been studied in promoter-rewiring experiments (15, 
16). At the time, it was poorly understood how these PTM BGCs could produce the diverse PTM 
structures that had been published over the previous few decades. These structural differences 
are important because they contribute to the ability of these PTM molecules to bind and inhibit 
different targets. Better knowledge of PTM biosynthetic enzymes could be used to create 
engineered PTM BGCs to produce novel chemicals using prior knowledge of PTM enzymes 
(17).  
As I began to collect BGC sequences for comparative studies of promoter sequence variation, I 
started to notice that PTM BGCs could contain a larger diversity of genes than previously 
reported. Through phylogenetic analyses, I realized that the fragment of the iPKS-NRPS that had 
been sequenced in the original clifednamide producer, Streptomyces sp. strain JV178 (18), had 
high homology to the iPKS-NRPS enzymes encoded for by one group of unusual PTM BGCs. 
Further studies into these BGCs resulted in the identification of the clifednamide-type PTM 
BGCs and the novel cytochrome P450 enzyme, CftA (19). These results gave me confidence that 
novel PTM biochemistry could be identified and studied through similar comparative genomics 
and metabolomics approaches. Currently, we are collaborating with the Wencewicz lab to 
elucidate the structure of clifednamide C, the novel clifednamide congener that I identified by 
LC-MS/MS, and to verify the ability of CftA to carry out two rounds of oxidation in vitro. 
Recently, another research group has identified and published the structures of seven novel 
clifednamide congeners obtained through promoter rewiring and heterologous expression of a 
clifednamide-type PTM BGC (20). 
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Based on similar genetic and metabolomic data, I have also proposed the functions for the 
commonly found cytochrome P450 enzyme, FtdF, and a Rieske 2Fe-2S domain protein, which I 
have named FtdG. These models are based on genetic and metabolomic evidence we have 
collected in laboratory experiments so far, but the function of FtdF needs to be verified by 
structural elucidation of PTMs produced by ftdF-null and ftdF-overexpressing strains as well as 
in vitro enzymatic assays with purified PTMs and FtdF enzymes. Recently, a similar model for 
FtdF activity was postulated by another group by structural elucidation of the PTMs produced by 
Streptomyces sp. strain SCSIO 40010, which has a similar ftdABCDEF BGC as JV180 (21). 
Similarly, the function of FtdG as a redox partner for FtdA needs to be verified in coupled in 
vitro assays. In addition, I have proposed that PTM BGCs found in sea-sponge associated 
bacteria, which contain an unusual thioesterase gene, could produce cylindramide-type PTMs 
that contain two less carbon atoms than typical PTMs. Many of the strains encoding these PTM 
BGCs are not actinomyces and also may not be easily obtainable. However, the thioesterase gene 
has a short coding sequence and a codon-optimized version could be synthesized for relatively 
low cost, allowing for the function of this enzyme to be studied by heterologous expression in 
PTM producing Streptomyces strains.  
Bioinformatic analyses of PTM BGCs suggests that further genetic diversity exists within more 
unusual PTM BGCs. The sequencing of 96 Blodgett lab strains and the bioinformatic analysis of 
their encoded PTM BGCs showed that it was possible to obtain strains with diverse PTM BGCs 
from just a few local soil samples, which could enable the study of novel PTM BGCs and their 
products. These studies could also help to connect PTM BGCs to previously published PTM 
molecules without cognate BGCs. However, one caveat to this is that some chemical 
modifications could be carried out by non-BGC enzymes. For example, while the frontalamide-
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type BGC (ftdABCDEF) is the most commonly found type of PTM BGC, the terminal olefin 
moiety found in the frontalamides has not been reported from any other sources. This suggests 
that the terminal olefin moiety could be the result of a non-PTM BGC enzyme encoded 
elsewhere in the genome of Streptomyces sp. strain SPB78. A more comprehensive analysis of 
PTM BGCs found in these draft genomes and other publicly available genome sequences is 
currently being carried out in the Blodgett lab by undergraduate students Anna Day, Maya 
Tsingos, and PMB student Chris Harper.  
Another potential research topic for PTMs is their ecological significance. The frequency of 
PTM BGCs being found in the genomes of Streptomyces and other bacteria from various sources 
clearly points to a selective advantage for the ability to produce these molecules. Based on 
phylogenetic analysis of all PTM BGCs, it seems that certain types of PTM BGCs are specific to 
strains found in specific niches. For example, clifednamide-type PTM BGCs tend to be found in 
plant-associated Streptomyces strains, and the putative cylindramide-type PTM BGCs tend to be 
found in sea sponge-associated Streptomyces strains. These specialized PTMs may be involved 
in host-microbe interactions in addition to having anti-bacterial or anti-fungal properties like 
other PTMs.  
7.4 Conclusions 
The goal of my thesis was to use comparative genomics and metabolomics to study polycyclic 
tetramate macrolactam biosynthesis to try to understand the long-standing question in the field of 
genome mining for antibiotic discovery: Why are many BGCs in Streptomyces genomes 
apparently silent? The high conservation of PTM BGCs provided a uniquely suitable system to 
study this question by comparing naturally occurring genetic variations and their effects on PTM 
expression. I was able to show that for S. griseus clade strains with PTM BGCs, mutations in the 
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promoter resulted in reduced PTM expression. This confirmed the commonly held belief that 
silent BGCs are transcriptionally downregulated. How the mutations I identified, such as the key 
‘AG’ indel, caused these differences in expression and how widespread such mechanisms are in 
silencing BGCs remains to be further explored.  
Another key finding from my thesis was that PTM production in Streptomyces sp. strain JV180 
is dependent on the presence of the griseorhodin BGC. It is also possible that differences in the 
BGCs encoded by S. griseus clade strains contributes to differences in PTM production, as grh 
BGCs were only found in the genomes of robust PTM producers. Further studies may reveal 
several interesting findings, such a potential malonyl-CoA responsive regulator or other forms of 
metabolic and regulatory crosstalk between antibiotics BGCs. These results were completely 
unexpected at the time I began my thesis work and showed that complex factors control 
antibiotic production.  
Recent technical advances have turned genomics and other ‘-omics’ tools into an accessible 
discovery suite that enables many researchers to study non-model organisms in a manner that 
would have been cost-prohibitive even a decade ago. As cellular processes are recognized to be 
increasingly complex and interdependent, such ‘-omics’ tools may often be needed for 
researchers to study biology with a more holistic view of what is occurring in a cell. When 
applied in comparative studies, these powerful tools can allow researchers to study how naturally 
occurring minor genetic variations cause phenotypic differences. In the future, I believe that 
similar comparative approaches can be applied to study the BGCs of PTMs and other pathways 
to reveal important regulatory mechanisms and discover potential new drugs.  
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Appendix I: Supplementary Information for 
Chapter 2: A comparative metabologenomic 
approach reveals new mechanistic insights 
into Streptomyces antibiotic crypticity 
Supplementary methods 
Marker-less gene deletion/promoter replacement  
All gene deletions and PftdA mutants were constructed using double homologous recombination as 
previously described (1). To avoid undesired recombination between the wild-type and the 
mutant PftdA sequences, an intermediate ΔPftdA::tsr mutant was constructed, and the steps will be 
described as an example for all mutants: 
Streptomycin-resistant (StrR) mutants of Streptomyces sp. strain JV180 were isolated on ISP2 + 
Str100 agar. The rpsL genes were amplified with primers (YQ4-Sg_rpsL_f and YQ5-Sg_rpsL_r) 
and sequenced. JV307 bearing the rpsL_K43R mutation was chosen for subsequent experiments 
as no phenotypic changes were observed, including PTM production. The upstream and 
downstream homology regions flanking PftdA were amplified from JV180 (primers YQ211-
180DPro-us-f and YQ212-180DPro-us-r; YQ213-180DPro-ds-f and YQ214-180DPro-ds-r). The 
tsr gene was amplified from pJVD53 (primers YQ215-tsr-f and YQ216-tsr-r). The vector pUC19 
was linearized by PCR-amplification (primers YQ268-pUC19-us and YQ269-pUC19-ds) and 
digested by DpnI. PCR products were assembled using the NEBuilder HiFi Assembly kit (NEB). 
Correct cloning was confirmed by restriction digest and Sanger sequencing. The resulting 
pUC19-ΔPftdA::tsr and were digested with XbaI and HindIII and ligated into pJVD52.1 using the 
same restriction sites. The resulting pJVD52.1-ΔPftdA::tsr was introduced into JV307 by 
conjugation, and apramycin-resistant (AprR) exconjugants were selected. Exconjugants were 
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grown in TSB non-selectively at 37˚C and recombinants were selected for on ISP2 + Apr50. AprR 
colonies were grown TSB non-selectively at 37˚C and double recombinants were selected for on 
ISP2 + Str100. The resulting ΔPftdA::tsr mutant was confirmed by colony PCR.  
Circular Rapid Amplification of cDNA Ends 
Streptomyces sp. strain JV180 was cultured on solid ATCC172 medium overlaid with a 
cellophane film. After six days, mycelia were harvested from three plates and pooled in 5 mL 
RNAlater with 4 mm diameter beads. The mycelia were homogenized by vortexing for about 1 
minute and allowed to settle for 5 minutes. The cell suspension was transferred to a clean tube 
and pelleted by centrifugation at 3,214 × g for 10 minutes. The supernatant was discarded the 
pellet was frozen at −20°C. The following day, approximately 100 mg of the frozen pellet was 
powdered by grinding with mortar and pestle in liquid nitrogen and resuspended in 450 µL of 
buffer RLT (QIAGEN). The suspension was lysed with a Fisherbrand model 120 sonic 
dismembrator at 30% amplitude with 4 cycles of 15 seconds of sonication followed by 30 second 
of resting. Total RNA was extracted with the QIAGEN RNeasy kit following the manufacturer’s 
protocol after this point and its integrity was verified by gel electrophoresis.  
The cRACE protocol was adapted from that of Bose and Newman (2). Genomic DNA was 
removed with Turbo DNase (Ambion). Superscript II Reverse Transcriptase (Invitrogen) was 
used to generate cDNA with random hexamers. Leftover RNA was removed with RNase H and 
cDNA was purified with Wizard SV Gel and PCR clean-up kit (Promega) and eluted in 
nuclease-free water. Adaptor ligation was performed in a buffer containing 1X RNA ligase 
buffer, 25% PEG 8000, 10 µg/mL BSA, 1 mM hexamine cobalt (III) chloride, 100 pmol 
WNp213, and 25 Units of T4 RNA (Ambion) ligase. The reaction was carried out at room 
temperature overnight and purified with the Wizard SV Gel and PCR clean-up kit. The eluate 
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was used for PCR amplification with Taq DNA polymerase (NEB) using Failsafe Premix G 
(Epicentre) with primers WNp210 and YQ186. PCR products were amplified in a second 
reaction using 1.5 µL of the first reaction as template with nested primers YQ188 and YQ185 as 
reverse primers. PCR products were cloned into pCR2.1-TOPO using the TOPO-TA cloning kit 
(Invitrogen) and the inserts were Sanger sequenced by Genewiz to map the transcript start site.  
Griseorhodin enrichment 
A griseorhodin-enriched fraction was obtained using a modified Kupchan scheme (3, 4) and 
solid phase extraction column. Strain JV180 was plated on approximately 1 L worth of 8340 agar 
plates. After 6 days, the agar plates were diced and collected in a large 2 L flask and the agar was 
submerged with acetonitrile overnight. The acetonitrile was collected and evaporated under low 
pressure and the agar was extracted with acetonitrile again. The dried extract was resuspended in 
9:1 (v/v) methanol/water. The solution was extracted with equal volume of petroleum ether 
followed by equal volume of ethyl acetate, which extracted the red pigment from the aqueous 
solution. The ethyl acetate was evaporated under low pressure and resuspended with 1:1 
methanol/water. A Bond Elut C18-OH (Agilent) solid phase extraction column was used to 
further purify the extract. The column was primed with water before the extract was loaded. The 
column was washed with water, and 1:3 acetonitrile /water. The red pigments were eluted by 1:1 
acetonitrile/water. This fraction was dried under low pressure and resuspended in 500 µL 1:1 
acetonitrile/water and filtered before LC-MS analysis.  
The griseorhodin-enriched fraction was analyzed using a Phenomenex Luna C18 column (75 x 3 
mm, 3 µm pore size) installed on an Agilent 1260 Infinity HPLC connected to an Agilent 6420 
Triple-Quad mass spectrometer. For each run, 10 µL sample was injected and the 
chromatography conditions were as follows: T = 0, 5% B; T = 2, 5% B; T = 16, 100% B, T = 20, 
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100% B; A: water + 0.1% formic acid, B: acetonitrile + 0.1% formic acid; 0.7 mL/min. The 
diode array detector was set to measure absorbance at 488 nm. The mass spectrometer was set to 
mass scan mode with m/z ranges 100 – 1000 for positive and negative ions and the fragmentor 




Supplementary Tables and Figures 
Table S1. List of strains used in this study 
Strain Relevant characteristics / Genotype Source  
Escherichia coli 
DH5α  cloning host, F– φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17 (rK–, 




plasmid expression host, F– ompT hsdSB (rB–, mB–) gal dcm (DE3) Novagen 
JV36 conjugal donor strain, dam-3 dcm-6 metB1 galK2 galT27 lacY1 tsx-78 supE44 thi-
1 mel-1 tonA31 ΔhsdRMS-mrr::FRT(rK- mK-) attHK::pJK202 (ΔoriR6K-
aadA::FRT bla::pir) (Tra+, AmpS) 
Blodgett 






model Streptomyces griseus strain, aka strain ISP-5235 NRRL 
Streptomyces 
sp. strain JV180 
environmental isolate, PTM producer Blodgett 
et al (6) 
JV251 Streptomyces californicus strain NRRL B-3320 NRRL 
JV252 Streptomyces floridae strain NRRL 2423 NRRL 
JV253 Streptomyces puniceus strain NRRL B-2895 NRRL 
JV254 Streptomyces griseus subsp. griseus strain NRRL F-5144 NRRL 
JV255 Streptomyces globisporus subsp. globisporus strain NRRL B-2709 NRRL 
JV256 Streptomyces albus subsp. albus strain NRRL B-2445 NRRL 
JV257 Streptomyces griseus subsp. griseus strain NRRL WC-3480 NRRL 




environmental isolate, PTM producer Qi et 
al(7) 
JV307 JV180 rpsL_K43R This 
study 
JV352 JV307 ΔftdA-F This 
study 
JV631 JV307 ΔPftdA::tsr This 
study 
JV1851 JV307 ΔPftdA::PermE*_pHM11a This 
study 
JV847 JV307 ΔPftdA::PftdA_IFO13350 This 
study 
JV1961 JV307 ΔPftdA::PftdA_SP18CM02 This 
study 




JV1178 JV307 ΔPftdA::PftdA_JV252 This 
study 
JV1673 JV307 ΔPftdA::PftdA_JV253 This 
study 
JV898 JV307 ΔPftdA::PftdA_JV254 This 
study 
JV1186 JV307 ΔPftdA::PftdA_JV255 This 
study 
JV1182 JV307 ΔPftdA::PftdA_JV256 This 
study 
JV1184 JV307 ΔPftdA::PftdA_JV257 This 
study 
JV1188 JV307 ΔPftdA::PftdA_JV258 This 
study 
JV503 JV180 attBΦC31::pJMD1-PftdA_IFO13350-xylE This 
study 
JV505 JV180 attBΦC31::pJMD1-PftdA_JV180-xylE This 
study 
JV527 JV180 attBΦC31::pJMD1-PermE*_pHM11a This 
study 
JV1871 JV180 attBΦC31::pJMD1-PftdA_JV180-ftdA-xylE This 
study 
JV1873 JV180 attBΦC31::pJMD1-PftdA_IFO13350-ftdA-xylE This 
study 
JV1743 IFO13350 attBΦC31::pJMD1-PftdA_IFO13350-xylE This 
study 
JV1745 IFO13350 attBΦC31::pJMD1-PftdA_JV180-xylE This 
study 
JV1747 IFO13350 attBΦC31::pJMD1-PermE*_pHM11a This 
study 
JV1875 IFO13350 attBΦC31::pJMD1-PftdA_JV180-ftdA-xylE This 
study 
JV1877 IFO13350 attBΦC31::pJMD1-PftdA_IFO13350-ftdA-xylE This 
study 
JV712 JV307 PftdAΔ−528_−207 This 
study 
JV716 JV307 PftdAΔ−528_−57 This 
study 
JV1933 JV307 PftdAΔ−528_−38 This 
study 
JV1836 JV307 PftdAΔ−528_−31 This 
study 
JV1986 JV307 PftdAΔ2_28 This 
study 




JV1675 JV307 PftdAΔ49_68 This 
study 
JV1655 JV307 PftdAΔ69_88 This 
study 
JV1680 JV307 PftdAΔ89_108 This 
study 
JV1688 JV307 PftdAΔ109_128 This 
study 
JV1697 JV307 PftdAΔ129_148 This 
study 
JV1693 JV307 PftdAΔ149_181 This 
study 
JV2084 JV307 PftdAΔ−528_−31:: −35boxJV254 This 
study 
JV2088 JV307 PftdAΔ−528_−31:: −35boxJV255 This 
study 
JV2090 JV307 PftdAΔ−528_−31:: −35boxJV256 This 
study 
JV2100 JV307 PftdAΔ−528_−31:: −35boxJV257 This 
study 
JV556 JV307 ΔadpA This 
study 
JV623 JV556 attBΦC31::pSET152-adpA_JV180 This 
study 
JV664 JV556 attBΦC31::pSET152-adpA_IFO13350 This 
study 
JV629 JV556 attBΦC31::pJMD3-adpA_JV180 This 
study 
JV618 JV556 attBΦC31::pJMD3-adpA_IFO13350 This 
study 
JV2111 JV1851 ΔadpA This 
study 
JV938 JV307 PftdAΔ29_48::IFO13350 This 
study 
JV1553 JV307 PftdA_35G/T This 
study 
JV1565 JV307 PftdA_37C/A This 
study 
JV1555 JV307 PftdA_40G/T This 
study 
JV1567 JV307 PftdA_42C/A This 
study 
JV894 JV307 PftdAΔAG This 
study 




JV1032 JV307 ΔPftdA::PftdA_IFO13350+AG This 
study 
JV564 JV307 ΔgrhR2-V This 
study 
JV1832 JV307 ΔgrhR1-E This 
study 
JV1898 JV307 ΔgrhFGH This 
study 
JV1698 JV307 ΔgrhGH This 
study 
JV1892 JV307 ΔgrhI-P This 
study 
JV1706 JV307 ΔgrhQSAB This 
study 
JV1854 JV1851 ΔgrhGH This 
study 
JV2108 JV1851 ΔgrhR2-V This 
study 
JV671 JV564 attBΦC31::pJMD2-grhR2 This 
study 
JV669 JV564 attBΦC31::pJMD2-grhR3 This 
study 
JV919 JV564 attBΦC31::pJMD2-grhF This 
study 
JV921 JV564 attBΦC31::pJMD2-grhG This 
study 
JV923 JV564 attBΦC31::pJMD2-grhH This 
study 
JV1070 JV564 attBΦC31::pJMD2-grhGH This 
study 
JV1054 JV564 attBΦC31::pJMD2-accBE_JV180 This 
study 
JV1060 JV564 attBΦC31::pJMD2-SGR1943-44 This 
study 
JV1066 JV564 attBΦC31::pJMD2-SGR3280-81 This 
study 
JV1018 JV180 attBΦC31::pJMD2-grhG This 
study 
JV978 JV254 attBΦC31::pJMD2-grhG This 
study 
JV982 JV258 attBΦC31::pJMD2-grhG This 
study 






Table S2. List of plasmids used in this study. 
plasmid description source 
pUC19 bla oripUC cloning vector NEB 
pCR2.1-
TOPO 
AmpR oripBR322 TOPO-TA cloning vector Invitrogen 
pET11a AmpR oripBR322 lacI T7 promoter protein expression vector Novagen 
pCM130 oripBR322 TetR xylE reporter gene vector Marx et al 
(8) 
pSET152 aac(3)IV oriT oripUC intΦC31 attPΦC31 self-integrating vector Bierman 
et al (9) 
pJMD2 AprR oriT oricolE1 intΦC31 attPΦC31 PermE* sequence from pDA1652 Ko et al 
(10) 
pJMD3 pJMD2 variant with PermE* sequence from pHM11a Ko et al 
(10) 
pJVD52.1 AprR oriT oripSG5(ts) reppUC rpsL+ shuttle vector Blodgett 
et al (5) 
pJVD53 TsrR AmpR oriT oripIJ101 oriR6K nitR protein expression vector Blodgett 
et al (5) 
pJMD1 ligation of PCR product of pSET152 (primers PXPX2 and PXPF2) digested with 
BamHI, SpeI and overlap extension PCR product of [pJVD53 (primers Fd-pSET and 
Fd-xylE) and pCM130 (primers xylE-pSET and xylE-fd)] amplified with primers 




ligation of pJVD52.1 and overlap extension PCR products of JV180 (primers YQ82-
180PTM_us_f and YQ91-180PTM_us_o_v2; YQ84-180PTM_ds_f and YQ85-




gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r; 






gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r; 
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and pJMD2 (primers YQ243-





gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r; 
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and IFO13350 (primers YQ249-





gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r; 
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV251 (primers YQ231-DPro-





gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r; 
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV252 (primers YQ231-DPro-







gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r; 
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV253 (primers YQ231-DPro-





gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r; 
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV254 (primers YQ252-DPro-





gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r; 
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV255 (primers YQ254-DPro-





gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r; 
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV256 (primers YQ256-DPro-





gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r; 
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV257 (primers YQ249-DPro-





gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r; 
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV258 (primers YQ256-DPro-




























































ligation of pJMD1 and overlap extension PCR product of [pJMD1 (primers YQ67-
XylE-fw and xylE-REV) and JV180 (primers YQ50-P180-overlap-r and YQ51-P180-





ligation of pJMD1 and overlap extension PCR product of [pJMD1 (primers YQ67-
XylE-fw and xylE-REV) and JV180 (primers YQ69-P13350-overlap-r and YQ70-






gibson assembly of PCR products of pJMD1 (primers YQ67-XylE-f and YQ177-






gibson assembly of PCR products of pJMD1 (primers YQ67-XylE-f and YQ177-





ligation of pUC19 and overlap extension PCR product of JV180 (primers YQ180-
DadpA-u-f-xbaI and YQ189-DadpA-us-r-2; YQ190-DadpA-d-f-o-3 and YQ169-




ligation of pJVD52.1 and pUC19-ΔadpA, both digested with XbaI and HindIII, for 





ligation of pSET152 and the PCR product of IFO13350 (primers YQ225-adpA-f-xbaI 




ligation of pSET152 and the PCR product of JV180 (primers YQ225-adpA-f-xbaI 





ligation of pJMD3 and the PCR product of IFO13350 (primers YQ119-AdpA_fw_n 




ligation of pJMD3 and the PCR product of JV180 (primers YQ119-AdpA_fw_n and 





gibson assembly of PCR product of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), PCR products of JV180 (primers YQ211-180DPro-us-f and YQ265-














ligation of pJVD52.1-PftdA-Δ-528_-307 and PCR product of JV180 (primers 





ligation of pJVD52.1-PftdA-Δ-528_-307 and PCR product of JV180 (primers 





gibson assembly of PCR product of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), PCR products of JV180 (primers YQ211-180DPro-us-f and YQ265-
Dpro-us-r-v2; YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and overlap 
extension PCR product of JV180 (primers YQ238-Dpro-DAG-r and YQ260-Dpro-





gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds) and JV180 (primers YQ211-180DPro-us-f and YQ390-180PTM-dAG-





gibson assembly of PCR product of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), PCR products of JV180 (primers YQ211-180DPro-us-f and YQ265-
Dpro-us-r-v2; YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and overlap 
extension PCR product of JV180 (primers YQ239-Dpro-DadpA-r and YQ260-Dpro-






gibson assembly of PCR product of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds), PCR products of JV180 (primers YQ211-180DPro-us-f and YQ265-
Dpro-us-r-v2; YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and overlap 
extension PCR product of JV180 (primers YQ240-Dpro-DadpA158-r and YQ260-





gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds) and pUC19-ΔPftdA::P13350 (primers YQ211-180DPro-us-f and YQ407-

































ligation of pUC19 and overlap extension PCR product of JV180 (primers YQ183-
Dgrh-us-r-3 and YQ191-Dgrh-us-f-x-4; YQ184-Dgrh-ds-f-o-2 and YQ163-Dgrh-ds-




ligation of pJVD52.1 and pUC19-ΔgrhR2-V, both digested with XbaI and HindIII This study 
pUC19-
ΔgrhGH 
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds) and JV180 (primers YQ466-grhGdel-u-f and YQ467-grhGdel-u-r; 




gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269-
pUC19-ds) and JV180 (primers YQ485-grhQdel-u-f and YQ486-grhQdel-u-r; 




ligation of pJVD52.1 and pUC19-ΔgrhGH, both digested with XbaI and HindIII This study 
pJVD52.1-
ΔgrhQSAB 
ligation of pJVD52.1 and pUC19-ΔgrhQSAB, both digested with XbaI and HindIII This study 
pJMD2-
grhR2 
ligation of pJMD2 and the PCR product of JV180 (primers YQ244-grhR2-f-n and 




ligation of pJMD2 and the PCR product of JV180 (primers YQ246-grhR3-f-n and 




ligation of pJMD2 and the PCR product of JV180 (primers YQ286-grhF-f-n and 




ligation of pJMD2 and the PCR product of JV180 (primers YQ288-grhG-f-n and 




ligation of pJMD2 and the PCR product of JV180 (primers YQ294-grhH-f-n and 




ligation of pJMD2 and the PCR product of JV180 (primers YQ288-grhG-f-n and 




ligation of pJMD2 and the PCR product of JV180 (primers YQ351-180accB-f and 





ligation of pJMD2 and the PCR product of IFO13350 (primers YQ355-158accB-f and 





ligation of pJMD2 and the PCR product of IFO13350 (primers YQ359-3281-f and 
YQ362-3280-r), both digested with NdeI and XbaI 
This study 
pKN001 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR products of 
JV180 (primers G35T-us-F and G35T-us-R; G35T-ds-F and G35T-ds-R) for 
construction of the PftdA-AdpAo::G35T point mutant 
This study 
pKN002 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers G40T-us-F and G40T-us-R; G40T-ds-F and G40T-ds-R) for 
construction of the PftdA-AdpAo::G40T point mutant 
This study 
pKN003 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers C37A-us-F and C37A-us-R; C37A-ds-F and C37A-ds-R) for 
construction of the PftdA-AdpAo::C37A point mutant 
This study 
pKN004 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers C42A-us-F and C42A-us-R; C42A-ds-F and C42A-ds-R) for 




pKN012 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers 69-88-us-F and 69-88-us-R; 69-88-ds-F and 69-88-ds-R) for 
construction of the PftdA∆(69_88) mutant 
This study 
pKN015 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers 49-68-us-F and 49-68-us-R; 49-68-ds-F and 49-68-ds-R) for 
construction of the PftdA∆(49_68) mutant 
This study 
pKN016 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers 89-108-us-F and 89-108-us-R; 89-108-ds-F and 89-108-ds-R) for 
construction of the PftdA∆(89_108) mutant 
This study 
pKN017 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers 129-148-us-F and 129-148-us-R; 129-148-ds-F and 129-148-ds-R) 
for construction of the PftdA∆(129_148) mutant 
This study 
pKN018 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers 109-128-us-F and 109-128-us-R; 109-128-ds-F and 109-128-ds-R) 
for construction of the PftdA∆(109_128) mutant 
This study 
pKN019 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers 149-181-us-F and 149-181-us-R; 149-181-ds-F and 149-181-ds-R) 
for construction of the PftdA∆(149_181) mutant 
This study 
pKN027 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers grhR1-grhE-us-F and grhR1-grhE-us-R; grhR1-grhE-ds-F and 
grhR1-grhE-ds-R) for construction of the ∆grhR1-E mutant 
This study 
pKN028 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers -528--31-us-F and -528--31-us-R; -528--31-ds-F and -528--31-ds-R) 
for construction of the PftdA∆(−528_−31) mutant 
This study 
pKN029 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers grhF-grhH-us-F and grhF-grhH-us-R; grhF-grhH-ds-F and grhF-
grhH-ds-R) for construction of the ∆grhFGH mutant 
This study 
pKN030 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers grhI-grhP-us-F and grhI-grhP-us-R; grhI-grhP-ds-F and grhI-grhP-ds-
R) for construction of the ∆grhI-P mutant 
This study 
pKN031 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of 
JV180 (primers -528--38-us-F and -528--38-us-R; -528--38-ds-F and -528--38-ds-R) 






gibson assembly of the PCR products of pUC19-JV180-ΔPftdA::tsr (primers BE277-
PftdA500 bp-F and BE277-PftdA500 bp-R1) and SP18CM02 (primers CM02-
PftdA500 bp-F and CM02-PftdA500 bp-R) 
This study 
pKN038 ligation of pJVD52.1 and pUC19-JV180-ΔPftdA::PCM02, both digested with HindIII 
and XbaI 
This study 
pKN040 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR products of 
JV180 (primers 2-28-us-F and 2-28-us-R; 2-28-ds-F and 2-28-ds-R) for construction 
of the PftdA∆(2-28) point mutant 
This study 
pKN047 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR products of 
JV180 (primers -35JV254-us-F and-35JV254-us-R; -35JV254-ds-F and-35JV254-ds-




pKN048 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR products of 
JV180 (primers -35JV255-us-F and-35JV255-us-R; -35JV255-ds-F and-35JV255-ds-
R) for insertion of -35 box from JV255 in JV1836 
This study 
pKN049 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR products of 
JV180 (primers -35JV256-us-F and-35JV256-us-R; -35JV256-ds-F and-35JV256-ds-
R) for insertion of -35 box from JV256 in JV1836 
This study 
pKN050 gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR products of 
JV180 (primers -35JV257-us-F and-35JV257-us-R; -35JV257-ds-F and-35JV257-ds-
R) for insertion of -35 box from JV257 in JV1836 
This study 
pKN052 ligation of pET11a and the PCR product of JV180 (primers pET11a-AdpA-F and 






Table S3. List of oligonucleotides used in this study. 
name Sequence (5’ to 3’) description 
PXPX2 AGATTACAACTAGTGATTACACGCTCACTGCCCGCT
TTCC 





















ATGTTGGCGTCGTGGTCCAGC PCR upstream homology 








TCACCAGTCGTGCACGGTCCC PCR downstream homology 






























































































PCR JV251-JV253 PftdA for 














































PCR JV256, JV258 PftdA for 























PCR IFO13350 and JV257 PftdA 




























PCR PftdA Δ29_48::13350 for 
PftdA editing plasmid 




Amplification of xylE 
YQ177-
pXylE-rv 








































PCR IFO13350 PftdA-ftdA for 
















GTCTCGTTAGCTCGCTGGATCCTA/3InvdT/ cRACE - adapter 
YQ179-
WNp210 























































































ACTAGTGACATATGAGCCAGGACTCCGCC clone adpA into pJMD3 
YQ120-
AdpA_rv1_x 
ACTAGTGATCTAGACTACGGGGCGCTCCGCTGTC clone adpA_JV180 into pJMD3 
YQ121-
AdpA_rv2_x 






















































































TACGGGCGTTTGTTCTCCAG verify JV180 grhG clone 
YQ351-
180accB-f 















CAGATGTTCATCACCGGCCC verify JV180 accBE clone 
YQ364-
13350accB-int 
CCAGAAGGGTGATGATCGGG verify SGR1943-44 clone 
YQ365-
13350grhG-int 
AGCGGAATGTTGAAGGCGTC verify SGR3280-3281 clone 
YQ372-
grihrdBF 
CACCAAGGGCTACAAGTTCT qPCR primers for hrdB, from 
































































AGACAGCTTTGAGAACCGCC verify JV180 ΔgrhQSAB 














clone PftdA from strain 



































































































AAAATACCGCATCAGGCGCCATTC Sequencing primers for 



























































































































































AdpAMT-R ATGCTTCCGGCTCGTATGTTG verify double cross-over for 
AdpA binding site mutants AdpAMT-R1 CAGGACAGGTCGGAGCCGTA 
AdpAMT35-F GTTCACTTCACGGCCGGAAT verify double cross-over for 
G35T mutant 




AdpAMT40-F GTTCACGTCACTGCCGGAAT verify double cross-over for 
G40T mutant 




CTCGACGGGGAACCGCGGGGT amplify AdpA binding site to 





































































































































































TTCGGATCAATGCGGCCGTGGCGTGAACCGATGCC IFO13350 PftdA AdpA binding 






GGCATCGGTTCACTTCACGGCCGGAATGATCCGAA JV180 PftdA AdpA binding site 






GGCATCGGTTCACGTAACGGCCGGAATGATCCGAA JV180 PftdA AdpA binding site 






GGCATCGGTTCACGTCACTGCCGGAATGATCCGAA JV180 PftdA AdpA binding site 






GGCATCGGTTCACGTCACGGACGGAATGATCCGAA JV180 PftdA AdpA binding site 








Table S4. % identity of 16S, concatenated MLST genes, and PTM enzyme amino acid 
sequences of the strains used in this study, relative to Streptomyces sp. strain JV180. 
Strain 16S MLST# FtdA FtdB FtdC FtdD FtdE FtdF 
Streptomyces sp. strain JV180 100 100 100 100 100 100 100 100 
S. sp. strain SP18CM02 100 99.91 99.36 99.4 100 99.83 100 98.96 
S. californicus strain NRRL B-3320 (JV251) 99.93 99.75 99.36 98.52 99.64 99.30 99.72 99.74 
S. floridae strain NRRL 2423 (JV252) 99.79 99.72 99.68 98.74 99.82 99.65 99.15 99.48 
S. puniceus strain NRRL B-2895 (JV253) 99.11 99.80 99.36 98.89 99.82 99.83 99.43 98.96 
S. griseus subsp. griseus strain NRRL F-5144 (JV254) 99.79 97.37 83.44 87.74 91.34 91.30 91.17 87.21 
S. globisporus subsp. globisporus strain NRRL B-2709 
(JV255) 99.59 97.49 81.21 87.11 87.95 92.00 89.74 86.68 
S. albus subsp. albus strain NRRL B-2445 (JV256) 99.59 97.19 81.37 88.64 93.04 92.32 91.74 87.21 
S. griseus subsp. griseus strain NRRL WC-3480 (JV257) 99.73 97.74 82.48 88.01 91.96 92.86 91.45 87.99 
S. baarnensis strain NRRL B-2842 (JV258) 99.59 97.14 81.37 88.55 93.04 92.32 91.74 87.21 
S. griseus subsp. griseus strain IFO13350 99.73 97.70 83.44 88.11 92.14 93.03 91.17 87.99 
# - MLST: concatenated partial sequences of atpD, gyrB, recA, rpoB, and trpB corresponding to 




Figure S1. Maximum likelihood phylogenetic tree of selected S. griseus clade strains. Strains 
used in this study are highlighted in red, and the strain JV180-like group is highlighted in green. 
atpD, gyrB, recA, rpoB, and trpB sequences of previously established S. griseus clade strains 
were taken from previous published lists (see refs (13, 14)). S. griseus clusters I-IX, as defined 
by Rong et al(13, 14) are represented in the tree. Sequences were aligned with MUSCLE and the 
alignments were concatenated. The maximum likelihood tree was built using the GTR+I+G 
model using CLC Main Workbench. Branches supported by less than 50% of 500 bootstrap 





Figure S2. Genetic and metabolomic identification of PTMs produced by 13C5-ornithine 
feeding. (A) LC-MS chromatograms of extracts from JV180 rpsL and ΔftdA-F mutants. The 
retention times of major PTM peaks were marked in gray. (B) Mass spectra of clifednamide A 
produced by the known clifednamide producer S. torulosus strain NRRL B-3889(11) on media 
supplemented with 50 mg/L of L-ornithine or 13C5-labeled L-ornithine. Mass spectra of selected 
PTM peaks produced by JV180 on media supplemented with 50 mg/L of L-ornithine or 13C5-





Figure S3. Tandem mass spectrometry-based identification and quantification of PTMs. 
(A) The structures of known clifednamides A and B, which differ by an FtdA-installed 
hydroxylation (shown in red). The product ion spectra of (B) clifednamide A and (C) 
clifednamide B produced by collision-induced dissociation at 20 V. Mass spectra were converted 
to centroids for visual clarity. S. torulosus strain NRRL B-3889 was grown on media 
supplemented with (top) L-ornithine or (bottom) 13C5-labeled L-ornithine. Inset: proposed 
structures of ornithine-derived fragments, with 13C5 atoms indicated by heavy dots, which would 




Figure S4. PTM production by S. griseus clade strains on various media: (A) ISP2 (Difco), 
(B) ISP4 (Difco), (C) ISP-S (see methods), and (D) YMS8 (0.4% yeast extract; 1% malt extract; 





Figure S5. PTM production by S. griseus clade strains on various media: (A) supplemented 
minimal medium (15), (B) minimal medium (15), (C) low tryptone-yeast extract (15), and (D) 





Figure S6. PTM production by S. griseus clade strains on various media: (A) YMS (15), (B) 
ATCC172, (C) Hickey-Tresner (17), and (D) SFM (15). Retention times for PTM peaks are 
highlighted in gray. A peak marked with an asterisk in the extract of JV255 from SFM had a 









Figure S7. Improved detection for PTMs via LC-MS/MS. Chromatograms of extracts of 
(Red) Streptomyces sp. strain JV180 and (blue) Streptomyces griseus subsp. griseus strain 
IFO13350 monitored using (A) UV absorbance at 280 nm, (B) MS scan mode in positive mode 
211 
 
for m/z from 100-1000, and (C) precursor ion scan mode for ions fragmenting into m/z 139 or 
154 daughter ions. Retention times for prominent PTM peaks are marked with dotted grey lines. 
 
Figure S8. ftdA-F are transcribed on one mRNA molecule. (A) Diagram of the PTM 
biosynthetic gene cluster, and PCR probes for intergenic regions. (B) PCR amplification of PTM 
intergenic regions using genomic DNA (positive control), RNA (negative control), and cDNA 





Figure S9. Nucleotide alignment of PTM promoters and 5’ UTRs belonging to S. griseus 
clade strains used in this study. Nucleotides in blue have >70% conservation, while nucleotides 
in red have <30% conservation. Many nucleotides in black (between 30-70% conservation) are 
still conserved within the JV180-like strain (green) and IFO13350-like strain groups (red). 





Figure S10. PftdA_JV180 drives stronger xylE transcription than PftdA_IFO13350. RT-qPCR was 
used to compare xylE transcript abundance from different PftdA-ftdA-xylE constructs in both 
JV180 and IFO13350 hosts. We used the PftdA-ftdA-xylE constructs in case proper expression 
required mRNA secondary structures forming from the 5’ UTR and the ftdA coding sequences. 
Relative transcription and statistical significance were calculated by Student’s T-test relative to 





Figure S11. Transcript start site mapping of the JV180 PftdA by cRACE. The sequencing 






Figure S12. Mutations in the −35 box cause slight decreases in PTM BGC expression. (A) A 
diagram of the PftdA region in −35 box mutants. Due to difficulties in cloning, IFO13350-type 
−35 boxes were introduced into the Δ−528_−31 mutant background. (B) Relative PTM 
production from −35 box mutants (n = 3). (C) Relative ftdB transcript abundance from −35 box 
mutants (n = 6). Statistical significance was calculated by Student’s T-test relative to the 




Figure S13. Predicted secondary structure of the JV180 PftdA UTR. The structure was 
predicted with mFold using the RNA folding form for the UTR sequence and the first 30 






Figure S14. Predicted secondary structure of the PftdA UTR from JV180-like PftdA’s. The 
structures were predicted with mFold using the RNA folding form for the UTR sequence and the 
first 30 nucleotides of ftdA for (A) SP18CM02, (B) JV251, (C) JV252, and (D) JV253. The 





Figure S15. Predicted secondary structure of the PftdA UTR from strains (A) IFO13350 and 
(B) JV257. The structures were predicted with mFold using the RNA folding form for the UTR 





Figure S16. Predicted secondary structure of the PftdA UTR from strains (A) JV254 and (B) 
JV255. The structures were predicted with mFold using the RNA folding form for the UTR 





Figure S17. Predicted secondary structure of the PftdA UTR from strains (A) JV256 and (B) 
JV258. The structures were predicted with mFold using the RNA folding form for the UTR 





Figure S18. adpA is required for morphological development and secondary metabolite 
expression. (top) Wild-type JV180 and (bottom) its ΔadpA mutant (JV556) were streaked on 
ISP2 agar and incubated for 2 days at 28 °C. The ΔadpA mutant is deficient in secondary 
metabolite production (red pigment) and morphological differentiation (white aerial mycelia), 





Figure S19. Additional complementation data for ΔadpA. Relative PTM production (A) on 
solid agar media (n = 3) and (B) in shake flasks (n = 4, except for JV180 rpsL where n = 3). The 
pSET152-adpA constructs were designed to express adpA under its native promoter and failed to 
express properly in flask cultures, whereas the pJMD3 vector uses the constitutive PermE*. We 
speculate the pSET152-adpA construct failed to express properly in flask cultures due to 
differences in culture conditions, which is in line with the previous report that AdpA only 
appeared to be a transcriptional activator for the PTM BGC in strain IFO13350 when grown on 
solid media(18). Additionally, the actual adpA promoter could contain more regulatory binding 
regions upstream which were not included in the construct. Statistical significance was 
calculated by Student’s T-test relative to the JV180 rpsL parent strain (*p < 0.05, **p < 0.01, 





Figure S20. Additional electrophoretic mobility shift assays with AdpA-PftdA. (A) 
Competition assay with unlabeled DNA probe. (B-D) assays with JV180 probes containing 
transversion mutations in nucleotides reported to directly interact with AdpA. The lane marked 





Figure S21. S. griseus clade strains contain different secondary metabolite BGCs. BGCs 
were identified using AntiSMASH (19). Each row represents a unique BGC. Green boxes 
indicate BGCs shared by all 11 strains. Yellow boxes indicate BGCs shared by two or more 





Figure S22. JV180-subclade strains produce a red pigment absent in other S. griseus clade 
strains. Strains JV180, IFO13350, SP18CM02, and JV251-JV258 were streaked on ISP2 and 





Figure S23. Identification of griseorhodin in JV180 culture extracts. (A) UV chromatogram 
of JV180 rpsL and ΔgrhR2-V mutant mutants. (Inset) absorbance spectrum of the putative 
griseorhodin A peak, which closely matches the absorbance characteristics reported 
previously(20). PTM peaks (marked with p) were also missing in the ΔgrhR2-V mutant. (B) The 
structure of griseorhodin A and the expected and observed m/z. (C) Image of JV180 rpsL (top) 
and the ΔgrhR2-V mutant (bottom) streaked on ISP2 agar and incubated for 2 days at 28°C. The 
ΔgrhR2-V mutant lacks griseorhodin pigmentation. (D) griseorhodin production observed from 





Figure S24. Sporulation is reduced in the ΔgrhR2-V mutant and partially complemented by 
ectopically expressing grhGH. Statistical significance was calculated by Student’s T-test 
relative to the JV180 rpsL parent strain or otherwise indicated (n = 3; *p < 0.05, **p < 0.01, 




Figure S25. Griseorhodin does not act as a signaling compound in Streptomyces sp. strain 
JV180. (A) UV chromatogram of the griseorhodin-enriched fraction. The m/z 509, 511, and 527 
peaks have the same masses as griseorhodin A (21), griseorhodin G (20), and griseorhodin C 
(22). (B) PTM production by JV180 and its ΔgrhR2-V mutant in flasks with added DMSO 
(negative control), the griseorhodin- enriched fraction, or γ-rubromycin (n = 3). (C) Disc 
diffusion assay of ΔgrhR2-V mutant with DMSO (negative control), the griseorhodin- enriched 
fraction, and γ-rubromycin. PTM production and sporulation were not restored by a chemical 
signaling mechanism. Instead, production and growth inhibition were observed. Statistical 
significance was calculated by Student’s T-test relative to the DMSO control (*p < 0.05, **p < 




Figure S26. Two acetyl-CoA carboxylase genes play a key role in the grh-PTM BGC 
interaction. (A) PTM production by the ΔgrhR2-V mutant (JV564) on solid media and 
complementation by various constructs. grhR2, grhR3, and grhF were not able to restore PTM 
production, while grhG and/or grhH were able to restore some PTM production. Additionally, 
accBE and their homologs from strain IFO13350 were also able to restore some PTM production 
(n = 3 for JV180 rpsL and JV564, n = 2 for complementation strains). (B) PTM production by 
the ΔgrhFGH and ΔgrhGH mutants on solid media barely differs (n = 3). Statistical significance 
was calculated by Student’s T-test relative to the JV180 rpsL parent strain (*p < 0.05, **p < 




Figure S27. Heterologous expression of grhG in IFO13350-like strains increases PTM 
production and transcription. (A) Relative PTM production by strains JV180, IFO13350, 
JV254, and JV258 heterologously expressing grhG on solid agar (for IFO13350, JV254, and 
JV258, n = 3; otherwise, n = 2). (B) Relative ftdB transcript abundance in strain IFO13350 
heterologously expressing grhG. Methods for culturing and extracting RNA were largely the 
same as for JV180-derived strains, except the samples were harvested after 2 days of culturing 
for RT-qPCR (n = 3). Statistical significance was calculated by Student’s T-test relative to the 
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Appendix II: Supplementary Information for 
Chapter 5: Native and Engineered 
Clifednamide Biosynthesis in Multiple 
Streptomyces spp. 
Supplementary methods 
XylE reporter comparison of PermE* promoters 
The two PermE* promoter variants used in this study were characterized using the xylE reporter 
gene1. The promoters were constructed by PCR amplifying PermE* from pIJ102572, 
concomitantly adding 5’-UTR sequences adapted from pHM11a or pDA1652. To construct the 
pHM11a promoter variant, primers YQ102 and YQ103 were used, with YQ103 encoding the 5’ 
UTR of PermE*pHM11a. Similarly, primers YQ106 and YQ107 were used to recreate 
PermE*pDA1652 (pDA1652 PermE* gratefully provided by Dylan Alexander, personal 
communication) in two successive PCR reactions. The resulting 5’UTR sequences of the two 
promoters were: PermE*pHM11a:  
5’-TAGGATCAGCTTACAGAACCACTCCACAGGAGGACCCATATG-3’  




(bold: promoter -10 region, underlined: Shine-Dalgarno sequence, italicized: NdeI restriction site 
containing the start codon).  
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Reporter cassettes to measure xylE expression from the variant PermE* promoters were created 
by overlap extension PCR. The 5’ end of xylE was amplified from pJMD1, a pSET152-derived 
integrating vector, using primers YQ67 and xylE-REV. After fusing the xylE fragment with the 
PermE* promoters by PCR, the amplicons and pJMD1 were digested with AscI and HpaI and 
ligated. The resulting plasmids were introduced into Streptomyces albus strain J1074 by 
intrageneric conjugation. 
XylE reporter activity was measured based on the method described by Luo et al3. Briefly, 5 mL 
of cell culture at different time points were collected and centrifuged at 3,214 × g for 10 min to 
remove the supernatant. The pellets were washed with 20 mM phosphate buffer, pH 7.5 and re-
pelleted. Two milliliters of sample buffer (100 mM phosphate buffer, pH 7.5; 20 mM Na-EDTA, 
pH 8.0; 10% v/v acetone) were added to resuspend the cell pellets followed by sonication on ice. 
0.1% Triton X-100 solution was added into the samples, which were then incubated on ice for 15 
min. Then, the samples were centrifuged for 5 min (15,000 × g, 4°C), and the supernatants were 
transferred to fresh tubes. In a 96-well plate, 180 μL assay buffer (10 mM phosphate buffer, pH 
7.5; 0.2 mM catechol) was added to 20 μL of clarified lysate, and accumulation of 2-
hydroxymuconic semialdehyde was monitored by absorbance at 375 nm  over 10 minutes. Total 
protein concentration was determined by the Bradford method. The slope of the linear portion of 
the absorbance curve was used to compare xylE expression between samples.  
Isolation and characterization of Streptomyces sp. strain KL33 
Streptomyces sp. strain KL33 was isolated as part of an actinomycete enrichment culture from 
soil samples collected at Tyson Valley Research Center in Eureka, Missouri using methods 
previously described4. During WUSTL undergraduate laboratory classwork, strain KL33 was 
identified as a potential PTM producing Streptomycete during PCR-based characterization of 
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environmental isolates. Specifically, strain KL33 was confirmed as a member of the 
Streptomyces genus after cloning and sequencing a fragment of the 16S ribosomal RNA gene 
using oligos S-C-Act-235-a-S-20 and S-C-Act-878-a-A-195. The resulting amplicon sequence 
was deposited to GenBank with accession number MG575211. The strain was assessed for 
potential PTM production after amplifying a conserved ikaA/ftdB gene fragment from its genome 
using degenerate primers YQ158 and YQ159 (designed using CODEHOP6). Being PTM-locus 
positive, strain KL33 was found to produce substantial clifednamide A by LC/MS (see main 
text). The DNA sequence of its ikaA amplicon was most similar to that of Streptomyces sp. strain 
FxanaA7 (Figure S4). Notably, the clifednamide cluster of strain FxanaA7 lacks a ftdA homolog, 
likely making the strain incapable of clifednamide B production. We only observed clifednamide 





Supplementary Tables and Figures 
Table S1 Strains used in this study 
Strain  Relevant characteristics Reference or 
source 
Escherichia coli 
NEB10 DH10B derivative, cloning host NEB 
JV36 dam-3 dcm-6 metB1 galK2 galT27 lacY1 tsx-78 supE44 
thi-1 mel-1 tonA31 ΔhsdRMS-mrr::Frt(rK- mK-) 




Streptomyces sp. strain 
JV178 





Wild-type clifednamide producer NRRL 
Streptomyces sp. strain 
NRRL F-6131 
Wild-type , clifednamide producer NRRL 
JV739 rpsL (K43N) This study 
JV837 rpsL (K43N) ΔcftA This study 
Streptomyces torulosus 
(NRRL B-3889) 
Wild-type, clifednamide producer NRRL 
Streptomyces sp. strain 
NRRL F-2890  
Wild-type, ikarugamycin producer NRRL 
JV770 attBΦC31::pED1 This study 
JV772 attBΦC31::pED2 This study 
JV774 attBΦC31::pED3 This study 
JV776 attBΦC31::pED4 This study 
JV778 attBΦC31::pED5 This study 
 JV780 attBΦC31::pED6 This study 
 JV782 attBΦC31::pED7 This study 




Wild-type, clifednamide producer This study 
Streptomyces sp. strain 
KL33 
Environmental isolate (Streptomyces ossamyceticus)a, 
clifednamide producer 
This study 
Streptomyces albus Strain J1074 Jon Clardy  
JV944 attBΦC31::pJMD1-PermE*pHM11a This study 
JV947 attBΦC31:: pJMD1-PermE*pDA1652 This study 




Table S2 Plasmids used in this study 
Plasmid Description Reference or 
Source 
pUC19 bla reppUC cloning vector NEB 
pJVD52.1 aac(3)IV oriT reppSG5(ts) reppUC rpsL+ shuttle vector Blodgett et al7 
pSET152 aac(3)IV oriT attP-intΦC31 reppUC self-integrating 
vector 
Bierman et al8 
pIJ10257 hyg oriT attP-intΦBT1 vector containing PermE* Hong et al2 
pJMD1 pSET152 derivative containing promoter-less xylE  Unpublished 
pJMD2 pSET152 derivative containing PermE*pDA1652 
promoter 
Unpublished 
pJMD3 pSET152 derivative containing PermE*pHM11a 
promoter 
Unpublished 
pUC19-ΔcftA pUC19 derivative with insertion of 2 kb fragment for 
deletion of cftA gene, constructed by Gibson 
Assembly 
This study 
pJVD52.1-ΔcftA pJVD52.1 derivative with insertion of 2 kb XbaI-
HindIII fragment for deletion of cftA gene 
This study 
pED1 pJMD2 derivative with insertion of 1.2 kb NdeI-XbaI 
PCR fragment containing cftA from JV178 
This study 
pED2 pJMD3 derivative with insertion of 1.2 kb NdeI-XbaI 
PCR fragment containing cftA from JV178 
This study 
pED3 pJMD2 derivative with insertion of 1.2 kb NdeI-XbaI 
PCR fragment containing cftA from S. purpeofuscus 
This study 
pED4 pJMD3 derivative with insertion of 1.2 kb NdeI-XbaI 
PCR fragment containing cftA from S. purpeofuscus 
This study 
pED5 pJMD2 derivative with insertion of 1.2 kb NdeI-XbaI 
PCR fragment containing cftA from S. sp. F-6131 
This study 
pED6 pJMD3 derivative with insertion of 1.2 kb NdeI-XbaI 
PCR fragment containing cftA from S. sp. F-6131 
This study 
pED7 pJMD2 derivative with insertion of 1.2 kb NdeI-XbaI 
PCR fragment containing cftA from S. torulosus 
This study 
pED8 pJMD3 derivative with insertion of 1.2 kb NdeI-XbaI 
PCR fragment containing cftA from S. torulosus 
This study 
pJMD1-PermE*pHM11a pJMD1 derivative with insertion of PermE*pHM11a This study 





Table S3. PCR primers used in this study. Restriction enzyme sites are underlined. 
Primers Description Sequence (5’ - 3’) 
YQ268 Construction of cftA deletion 
cassette 
TCTAGAGGATCCCCGGGTAC 
YQ269 Construction of cftA deletion 
cassette 
AAGCTTGGCGTAATCATGGTC 




YQ274 Construction of cftA deletion 
cassette 
GGTCAGCGGCGGGTGCTGCC 








YQ277 Confirmation of cftA deletion ACCTGCCGACCTTCATGATC 
YQ278 Confirmation of cftA deletion GAGTTCATCGCCCACAACG 
YQ279 Confirmation of cftA deletion CGGAGAAGTACGTGGCGAAC 
YQ280 Confirmation of cftA deletion CGAAGATCCTGGTGCGGTAC 








ED11 Amplification of 
Streptomyces sp. strain F-
6131 cftA 
ACTAGTGACATATGCTCCGGCAGCACCCGCC 
ED12 Amplification of 
Streptomyces sp. strain F-
6131 cftA 
ACTAGTGATCTAGATCACCAGACGATCGGGAGCG 
ED13 Amplification of 
Streptomyces torulosus cftA 
ACTAGTGACATATGCCGGATCAACACCCCCC 
ED14 Amplification of 
Streptomyces torulosus cftA 
ACTAGTGATCTAGATCACCAGGCGACCGGGAGTG 
ED15 Amplification of 





ED16 Amplification of 
Streptomyces sp. strain 
JV178 cftA 
ACTAGTGATCTAGATCACCAGGCGACCGGGAGTG 
PermE*-fw Confirmation of cloning TTGACGGCTGGCGAGAGG 
PXS6 Confirmation of cloning GGCCGATTCATTAATGCAGC 
R2NJ Confirmation of conjugation TCGTGGCCGTCCAGCYCNCCNGCDAT 
F3NJ Confirmation of conjugation GACCCGTTCATCATGATGGAYCARATGGG 
Int 7NJ Confirmation of conjugation CTCTTCGTTCGTCTGGAAGG 
Int 8NJ Confirmation of conjugation CTTGTCTTCGTTGGCGCTAC 
YQ67 Amplification of xylE ATGAACAAAGGTGTAATGCG 
xylE-REV Amplification of xylE CAGTGAGCTGTTAACCAGGTGAGCACGGTCATGAA
TCG 
YQ102 Amplification of PermE* GGCGCGCCAGCCCGACCCGAGCACGC 















Amplification of 16S 





Amplification of 16S 
ribosomal RNA gene 
fragment 
CCGTACTCCCCAGGCGGGG 
YQ158 Degenerate PCR screen for 
ikaA 
CCTGTCCATCGACTGGGGNCCNTGGGC 








Figure S1. Biosynthesis and subsequent tailoring of ikarugamycin by enzymes discussed in this 





Figure S2. Clifednamide biosynthetic clusters identified in this study. Streptomyces sp. strain 
FxanaA7 represents the closest match to the partially sequenced clifednamide biosynthetic 






Figure S3. PermE*-driven xylE reporter expression in Streptomyces albus strain J1074. Assays 





Figure S4. Production of PTMs in Streptomyces sp. strain NRRL F-2890 expressing CftA 
isozymes. (A) strain F-2890 attBΦC31::PermE*pDA1652-cftApurpeofuscus, (B) strain F-2890 
attBΦC31::PermE*pHM11a-cftApurpeofuscus, (C) strain F-2890 attBΦC31::PermE*pDA1652-cftAF-6131, 
(D) strain F-2890 attBΦC31::PermE*pHM11a-cftAF-6131, (E) strain F-2890 
attBΦC31::PermE*pDA1652-cftAtorulosus, and (F) strain F-2890 attBΦC31::PermE*pHM11a-cftAtorulosus. 







Figure S5. Overlaid UV spectra of PTM compounds produced by Streptomyces sp. NRRL F-
2890 or Streptomyces sp. NRRL F-2890 attBΦC31::PermE*pHM11a-cftAJV178 after two days of 
growth. Spectra corresponding to ikarugamycin (green, elution time 15.863 min), clifednamide 





Figure S6. High-resolution mass spectroscopy analysis of clifednamides. An extract from 
Streptomyces sp. strain NRRL F-2890 attBΦC31::PermE*pHM11a-cftAJV178 was analyzed via 
HRMS (Q-Exactive, Thermo-Fisher Scientific). The 493.2696 ion corresponds to clifednamide 
A [C29H36N2O5, calculated (M + H)
+ 493.2696]. The 509.2645 ion corresponds to clifednamide 








Figure S7. 2H7 L-ornithine labeling of clifednamide base mass and daughter ions. Streptomyces 
sp. strain F-2890 attBΦC31::PermE*pHM11a-cftAJV178 was grown on solid ATCC172 medium 
supplemented with 50 mg/L 2H7-L-ornithine. PTMs lacking C25 hydroxylation will fragment 
(CID = 30V) with a diagnostic daughter ion of m/z 139.2 (or +7 = 146.2) containing the 
ornithine-tetramate region of the molecules9. Analyses of labeled clifednamide A spectra (RT = 
7.20 min) show clear labeling of the base mass (Panel A, m/z 493.2 base, 500.2 labeled) and the 
diagnostic daughter ions (Panel C, m/z 139.2 base and 146.2 labeled). Similar labeling and 
fragmentation patterns were seen for clifednamide C (RT = 4.98 min, Panel B, m/z 509.2 base, 





Figure S8. Fragmentation analysis of PTMs. (A) Ikarugamycin, (B) clifednamide A, (C) and 
clifednamide C were fragmented by collision-induced dissociation (20 V) with an Agilent 6420 
Triple Quadrupole Mass Spectrometer. (D) Fragmentation of capsimycin as proposed by Yu et al 
(2017)9. Diagnostic 139.09 and 181.10 daughter ions (highlighted) mapping to the ornithine-
containing substructure of capsimycin were found in the ikarugamycin, clifednamide A and 
clifednamide C spectra. Because all four PTMs are likely identical in the ornithine-tetramate 
chromophore region (see Fig. S5), this was expected. However, the remaining fragments in each 
spectra, presumably incorporating the differentially oxidized 5,6,5 carbocyclic structures unique 
to each compound, have different mass profiles. These data support the identification of 
clifednamide C as a chemically distinct PTM. Due to the complex dehydration patterns seen 
during fragmentation, precisely mapping the oxidation event that differentiates clifednamide C 






Figure S9. Phylogenetic analysis of PTM cluster associated P450s. The maximum likelihood tree 
was built using the JTT substitution model. The Bacillus megaterium BM3 enzyme was used to 
root the tree. Protein sequences were aligned using ClustalOmega and manually degapped. 
Bootstrap values are expressed as percentages of 500 replicates at branch points. Scale bar shows 
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Appendix III: Miscellaneous projects 
Engineering of IFO13350-type PftdA’s 
Background 
Through earlier experiments, I found conserved differences between the PTM BGC promoters of 
JV180-like robust PTM-producing strains and the other S. griseus clade poor PTM-producing 
strains. Replacement of the PftdA in JV180 with PftdA’s from JV180-like strains largely maintained 
similar levels of PTM production and BGC transcription, while replacement with PftdA’s from 
IFO13350 and the other S. griseus clade poor-PTM producing strains caused strong reductions in 
PTM production and BGC transcription in JV180. Part of this appeared to stem from a conserved 
two-nucleotide indel located slightly downstream of the transcript start site of PftdA, which is 
present in JV180-like PftdA’s but absent in IFO13350-like PftdA’s. 
Engineering of the JV258 PftdA 
I aimed to replace the PftdA of IFO13350 or other S. griseus clade poor-PTM producing strains 
with the PftdA of JV180, or to insert the missing AG dinucleotide into their native PftdA’s. I 
hypothesized that this would result in increased PTM production and BGC transcription. To test 
if these strains were genetically tractable, I plated strains IFO13350, JV254-258 on ISP-S media 
for sporulation. Dense spores were collected from the plates for IFO13350, JV254, and JV258. I 
attempted to conjugate these strains with an E. coli conjugal donor strain harboring pJVD52.1. 
Apramycin-resistant colonies were obtained from conjugation plates of JV254 and JV258. 
Therefore, I designed promoter-replacement/editing constructs to replace the PftdA’s of JV254 and 
JV258 with PftdA_JV180 or PermE* (Table 1). I also designed additional constructs to insert the AG 




Table 1. List of plasmids and JV254 and JV258 mutants 
Plasmid Strain Genotype 
pUC19-254PftdA+AG JV254 S. griseus NRRL F-5144 wild-type 
pUC19-254ΔPftdA::P180 JV1001 JV254 rpsL(K88R) 
pJVD52.1-254PftdA+AG JV1002 JV254 rpsL(K88E) 
pJVD52.1-254ΔPftdA::P180 JV1003 JV254 rpsL(K88E) 
pUC19-258PftdA+AG JV258 S. baarnensis NRRL B-2842 wild-type 
pUC19-258ΔPftdA::P180 JV1106 JV258 rpsL(K43M) 
pUC19-258ΔPftdA::PermE*_pHM11a JV1107 JV258 rpsL(K88E) 
pJVD52.1-258PftdA+AG JV1194 JV1106 PftdA+AG colony a 
pJVD52.1-258ΔPftdA::P180 JV1195 JV1106 PftdA+AG colony b 
pJVD52.1-258ΔPftdA::PermE*_pHM11a JV1196 JV1107 PftdA+AG colony a 
 JV1197 JV1107 PftdA+AG colony b 
JV1198 JV1106 ΔPftdA::P180 colony a 
JV1199 JV1106 ΔPftdA::P180 colony b 
JV1551 JV1106 ΔPftdA::PermE*_pHM11a colony a 
JV1552 JV1106 ΔPftdA::PermE*_pHM11a colony b 
 
I plated spores of JV254 and JV258 on ISP2 with 100 mg/L streptomycin to select for 
spontaneous rpsL mutations to use as a counterselection marker. I obtained three rpsL mutants 
for JV254, and two rpsL mutants for JV258. These mutants were assessed for growth and PTM 
production phenotype changes. Of the JV254 rpsL mutants, JV1001 (K88R), showed reduced 
sporulation and loss of PTM production; JV1002 (K88E) had similar growth phenotypes as wild-
type JV254 and slightly lower PTM production; and JV1003 (K88N) had similar growth 
phenotypes as wild-type JV254 and slightly higher PTM production (Figure 1). Due to reduced 
sensitivity of the LC-MS/MS instrument (possibly due to the long timespan since the last system 
maintenance and tuning), no PTMs could be detected from JV258 or its rpsL mutants JV1106 
(K43M) and JV1107 (K88E). Even in previous experiments where PTMs were detected, JV258 





Figure 1. PTM production by JV254 and JV258 rpsL mutants.  
 
The promoter editing/replacement constructs were conjugated into JV1002, JV1106, and 
JV1107. After going through the recombination process, no successful promoter mutants were 
obtained for JV1002, as all colonies had wild-type promoters. I was able to recover 
PftdA_JV258+AG mutants for both JV1106 and JV1107. Additionally, I recovered a 
ΔPftdA::PftdA_JV180 mutant in the JV1107 background. However, when these strains were grown on 
8340 agar and analyzed for PTM production, no increase in PTM production was observed 
(Figure 2). As JV258 belongs to a different phylogenetic subclade from JV180 and IFO13350, I 
could not be certain if there were other deficiencies causing the lack of PTM production. One 
possible source of concern is that the rpsL mutations in JV1106 and JV1107 may have been 

























Figure 2. PftdA replacement and insertion of AG did not increase PTM production in JV258.  
 
In further attempts to elicit increased PTM production from JV258, I conjugated the 
PftdA_JV258+AG and ΔPftdA::PftdA_JV180 mutants with integrative plasmids expressing grhG in hopes 
of eliciting increased PTM expression. I also attempted to increase the ornithine precursor supply 
by adding exogenous ornithine to the growth media. However, no increase in PTM production 
was achieved.  
 
Table 2. List of JV258 strains expressing grhG, accB, or adpA  
Strain Genotype Strain Genotype 
JV874 NEB10 + pJMD2-grhG JV891 JV156 + pJMD2-grhG 
JV1023 NEB10 + pJMD2-accBJV180 JV1034 JV36 + pJMD2-accBJV180 





















JV1029 NEB10 + pJMD2-SGR3281 (grhGIFO13350) JV1040 JV36 + pJMD2-SGR3281 
JV436 DH5a + pJMD3-adpAJV180 JV439 JV156 + pJMD3-adpAJV180  
JV437 DH5a + pJMD3-adpAIFO13350 JV440 JV156 + pJMD3-adpAIFO13350 
JV605 NEB10 + pSET152-adpAJV180 JV606 JV156 + pSET152-adpAJV180 
JV639 NEB10 + pSET152-adpAIFO13350 JV640 JV156 + pSET152-adpAIFO13350 
JV1245 JV1106 + pJMD2-grhG colony a JV1280 JV1198 + pJMD2-accBJV180 colony b 
JV1246 JV1106 + pJMD2-grhG colony b JV1281 JV1198 + pJMD2-SGR1944 colony a 
JV1247 JV1106 + pJMD2-accBJV180 colony a JV1282 JV1198 + pJMD2-SGR1944 colony b 
JV1248 JV1106 + pJMD2-accBJV180 colony b JV1283 JV1198 + pJMD2-SGR3281 colony a 
JV1249 JV1106 + pJMD2-SGR1944 colony a JV1284 JV1198 + pJMD2-SGR3281 colony b 
JV1250 JV1106 + pJMD2-SGR1944 colony b JV1350 JV1106 + pJMD3-adpAJV180 colony a 
JV1251 JV1106 + pJMD2-SGR3281 colony a JV1351 JV1106 + pJMD3-adpAJV180 colony b 
JV1252 JV1106 + pJMD2-SGR3281 colony b JV1352 JV1106 + pJMD3-adpAIFO13350 colony a 
JV1253 JV1107 + pJMD2-grhG colony a JV1353 JV1106 + pJMD3-adpAIFO13350 colony b 
JV1254 JV1107 + pJMD2-grhG colony b JV1354 JV1106 + pSET152-adpAJV180 colony a 
JV1255 JV1107 + pJMD2-accBJV180 colony a JV1355 JV1106 + pSET152-adpAJV180 colony b 
JV1256 JV1107 + pJMD2-accBJV180 colony b JV1356 JV1107 + pJMD3-adpAJV180 colony a 
JV1257 JV1107 + pJMD2-SGR1944 colony a JV1357 JV1107 + pJMD3-adpAJV180 colony b 
JV1258 JV1107 + pJMD2-SGR1944 colony b JV1358 JV1107 + pJMD3-adpAIFO13350 colony a 
JV1259 JV1107 + pJMD2-SGR3281 colony a JV1359 JV1107 + pJMD3-adpAIFO13350 colony b 
JV1260 JV1107 + pJMD2-SGR3281 colony b JV1360 JV1107 + pSET152-adpAJV180 colony a 
JV1261 JV1194 + pJMD2-grhG colony a JV1361 JV1107 + pSET152-adpAJV180 colony b 
JV1262 JV1194 + pJMD2-grhG colony b JV1362 JV1194 + pJMD3-adpAJV180 colony a 
JV1263 JV1194 + pJMD2-accBJV180 colony a JV1363 JV1194 + pJMD3-adpAJV180 colony b 
JV1264 JV1194 + pJMD2-accBJV180 colony b JV1364 JV1194 + pJMD3-adpA_158 colony a 
JV1265 JV1194 + pJMD2-SGR1944 colony a JV1365 JV1194 + pJMD3-adpA_158 colony b 
JV1266 JV1194 + pJMD2-SGR1944 colony b JV1366 JV1194 + pSET152-adpAJV180 colony a 
JV1267 JV1194 + pJMD2-SGR3281 colony a JV1367 JV1194 + pSET152-adpAJV180 colony b 
JV1268 JV1194 + pJMD2-SGR3281 colony b JV1368 JV1196 + pJMD3-adpAJV180 colony a 
JV1269 JV1196 + pJMD2-grhG colony a JV1369 JV1196 + pJMD3-adpAJV180 colony b 
JV1270 JV1196 + pJMD2-grhG colony b JV1370 JV1196 + pJMD3-adpAIFO13350 colony a 
JV1271 JV1196 + pJMD2-accBJV180 colony a JV1371 JV1196 + pJMD3-adpAIFO13350 colony b 
JV1272 JV1196 + pJMD2-accBJV180 colony b JV1372 JV1196 + pSET152-adpAJV180 colony a 
JV1273 JV1196 + pJMD2-SGR1944 colony a JV1373 JV1196 + pSET152-adpAJV180 colony b 
JV1274 JV1196 + pJMD2-SGR1944 colony b JV1374 JV1198 + pJMD3-adpAJV180 colony a 
JV1275 JV1196 + pJMD2-SGR3281 colony a JV1375 JV1198 + pJMD3-adpAJV180 colony b 
JV1276 JV1196 + pJMD2-SGR3281 colony b JV1376 JV1198 + pJMD3-adpAIFO13350 colony a 
JV1277 JV1198 + pJMD2-grhG colony a JV1377 JV1198 + pJMD3-adpAIFO13350 colony b 
JV1278 JV1198 + pJMD2-grhG colony b JV1378 JV1198 + pSET152-adpAJV180 colony a 





Figure 3. Overexpression of grhG/accB did not increase PTM production in JV258 PftdA mutants.  
 
 























































































Similarly, I attempted to elicit increased PTM production by overexpressing adpA in JV258 and 
its mutants. In some cases, increased sporulation was observed, but no increase in PTM 
production was observed (data not shown). I also attempted to construct ΔPftdA::PermE* mutants in 
JV1106 and JV1107, as this strategy has been successfully used to activate numerous BGCs. I 
successfully constructed ΔPftdA::PermE* mutants in the JV1106 background strain, but the mutants 
do not appear to have been characterized. To further characterize the mutants, the JV1106 rpsL 
mutant and its derivatives were cultured in liquid ATCC-MOPS media and relative ftdB 
transcript abundance was analyzed by qRT-PCR. Likely due to the culturing conditions, no PTM 
production was detected. qRT-PCR analysis revealed no increase in transcript abundance from 
the PftdA_JV258+AG and ΔPftdA::PftdA_JV180 mutants over the parent strains. However, increased ftdB 
transcript abundance was observed when adpA was ectopically overexpressed in both JV1106 






Figure 5. Ectopic expression of adpA is sufficient to increase ftdB transcript abundance in JV258 
 
Attempts to engineer the IFO13350 PftdA 
Further experiments were conducted to attempt to engineer the PftdA of strain IFO13350. The 
Ohnishi group, which characterized the AdpA regulon, had demonstrated their ability to edit the 
genome of this strain. According to the methods published in these studies, a suicide vector was 
often used to facilitate the recombination between the genome and the desired editing template 
(1, 2). In the Blodgett lab, we typically use pJVD52.1, a self-replicating plasmid with a 





























Therefore, I cloned the promoter editing construct into a suicide pOJ260 vector. However, no 
apramycin resistant colonies were obtained after conjugation. 
A few studies had demonstrated a way to bypass the highly active DNA restriction system in 
strain IFO13350 by in vitro methylation of the plasmids before protoplast transformation (3). A 
protoplast transformation protocol was adapted from several sources (3–6). Although I was 
eventually unsuccessful in obtaining transformants, the protocol I used is detailed here for future 
reference. 
Protoplast preparation 
In a 125 mL flask with 6 mm beads, 25 mL of trypticase soy broth (TSB) supplemented with 5 
mM MgCl2 and 1% glycine was inoculated with 100 μL of S. griseus IFO13350 spore 
suspension. The flask was shaken at 250 rpm in a 28°C incubator for approximately 6 hours. 
After the spores were confirmed to have begun germinating by phase-contrast microscopy, 
autoclaved 50% PEG8000 solution was added to a final concentration of 5%. After 
approximately 24 hours, the culture was pelleted by centrifugation at 1,000 x g for 10 minutes. 
The pellet was washed twice gently with 15 mL of 10.3% sucrose (if needed, the sucrose-washed 
pellet was saved in the −20°C freezer). The pellet was resuspended in 4 mL of 1 mg/mL 
lysozyme solution in P-buffer [mix 103 g sucrose, 0.25 g K2SO4, 2.02 g MgCl2-6H2O, 2 mL R2 
trace elements, and water to 800 mL and autoclave as 80 mL aliquots; add 1 mL KH2PO4 (0.5%), 
10 mL CaCl2-2H2O (3.68%), and TES buffer (5.73%, pH 7.2) before use]. The suspension was 
incubated at 30°C for approximately 30 minutes and monitored by microscopy for protoplast 
formation. The solution was then mixed by pipetting up and down with a 5 mL serological pipet 
for three times and incubated at 30°C. After 15 minutes, 5 mL of P-buffer was added and mixed 
as before. The protoplasts were filtered through a plug of sterilized glass wool in a syringe. The 
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protoplasts were gently sedimented by centrifugation at 1,000 x g for 7 minutes. The supernatant 
was poured out and the protoplasts were gently resuspended 1 mL of additional P-buffer and 
saved as 200 μL aliquots in the −20°C freezer.  
As the hemocytometer was damaged, serial dilutions of the protoplast stock was plated on S. 
griseus protoplast regeneration medium [SpMR; 10.3% sucrose; 1% MgCl2-6H2O; 0.5% 
glucose; 0.5% Difco yeast extract; 2% TES-NaOH (1 M, pH 7.6); 0.2% R2 trace element 
solution; 2.2% Bacto agar; and 0.2% CaCl2 (5 M, autoclaved separately)]. A lawn formed on all 
plates, and as the highest dilution factor used was 105, I determined that the protoplast stock 
contained at least 1 x 109 cfu/mL.  
Protoplast transformation 
Plasmids were transformed into JV36, a methylation-deficient E. coli donor strain. Overnight 
cultures of JV36 transformants were used for plasmid purification with a Qiagen miniprep kit. 
The purified plasmid was treated with HpaII methyltransferase (NEB) in the following reaction 
mixture: 10 μL CutSmart buffer, 2.5 μL S-adenosylmethionine (SAM, 1.6 mM), 1 μL HpaII MT, 
up to 500 ng of plasmid DNA, and water up to 50 μL. The reaction was incubated at 37°C for 1 
hour.  
After thawing, the protoplasts were sedimented by centrifuging at 700 x g for 7 minutes at room 
temperature. The supernatant was poured off and the remaining protoplasts were resuspended in 
the remaining (approx. 50 μL) P-buffer by tapping the tube. The protoplasts were heat shocked at 
42°C for 10 minutes. For each transformation, 5 μL of the methylated plasmid (10 – 60 ng DNA) 
was added, followed immediately by 200 μL of T-buffer [mix sterile 25 mL sucrose (10.3%), 75 
mL water, 0.2 mL R2 trace element solution, and 1 mL K2SO4 (2.5%); aliquot 7 mL and add 150 
μL CaCl2 (5 M), 375 μL Tris-maleic acid buffer (1 M Tris base, adjusted to pH 8 with maleic 
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acid), and 5 mL PEG1000 (50% w/v)] and mixed by pipetting four times. Next, 1.3 mL of P-
buffer was added and 150-200 μL aliquots of the transformation mixture were spread on SpMR 
plates. After overnight incubation, the transformation plates were overlaid with soft SpMR (30% 
agar content) containing 30 mg/L apramycin. No apramycin resistant colonies were recovered 
from any of the attempted transformation experiments. 
Heterologous expression of the JV180 polycyclic tetramate 
macrolactam biosynthetic gene cluster 
Background 
We explored our lab’s ability to clone the biosynthetic gene cluster (BGC) for polycyclic 
tetramate macrolactams (PTMs) into a large, single-copy shuttle vector. This was motivated by 
the fact that genetic manipulation of the BGC and its promoter by homologous recombination 
could be carried out more rapidly in an E. coli cloning host. Due to the number of times that cells 
need to be restreaked to select for recombinants and the difference in growth rate between E. coli 
and Streptomyces, this could potentially save a large amount of time. The resulting plasmid could 
then be reintroduced into Streptomyces and integrated into the chromosome using the highly 
efficient and site-specific ΦC31 integrase. Another motivation for cloning the PTM BGC into a 
shuttle vector was to explore the use of other Streptomyces strains as potential heterologous hosts 
for increased PTM production. Increased PTM production and the absence of other secondary 
metabolites in engineered host strains could streamline purification of sufficient quantity of 
PTMs produced by our strains of interest for structural elucidation.  
Results and discussion 
The pJK050 fosmid vector was provided by the Metcalf lab at University of Illinois – Urbana 
Champaign (7). A fosmid library was prepared from a sample of Streptomyces sp. strain JV180 
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genomic DNA, which I had purified for genome-sequencing. Briefly, the genomic DNA sample 
was partially digested with Sau3AI and ligated with BamHI-digested pJK050. A fosmid 
containing the entire JV180 PTM BGC, fosmid 17A10, was obtained by PCR screening. This 
fosmid was also saved under the name pJMD10. Subsequently, features required to turn the 
fosmid into an E. coli – Streptomyces shuttle vector by λ recombination between the λ attB site 
derived from pJK050 and the λ attP site of pAE4, which contains a conditionally high-copy 
origin of replication (oriR6K), Apramycin resistance marker (aprR), ΦC31 integrase (int) and 
attP sequence, and origin of conjugal transfer (oriT). The resulting plasmid, pJMD11, was 
conjugated into a panel of strains (Table 3). Aside from purification of the JV180 genomic DNA, 
the steps described above were performed by John D’Alessandro, a former technician in the 
Blodgett lab. 
 
Table 3. pJMD11 host strains and exconjugants 
Host strain Description Strain # for exconjugants 
JV352 JV180 ΔftdA-F JV877-878 
JV2 S. avermitilis ATCC31267 JV879-880 
JV51 S. lividans 66 JV881-882 
JV16 S. coelicolor M145 JV883-884 
JV28 S. viridochromogenes DSM 40736 JV885-886 
 
None of the host strains contained PTM BGCs on their chromosomes. I grew each exconjugant, 
parent strain, and wild-type JV180 in 3 mL TSB in a 24-well deep well plate with one 4 mm 
glass bead added to disrupt mycelial clumping. The deep-well plate was shaken at 300 rpm for 2 
days at 28°C. 200 μL were then plated on agar plates of three different media formulations: ISP2, 
ATCC172, and 8340. The plates were incubated for 6 days at 28°C and extracted with ethyl 
263 
 
acetate overnight. The ethyl acetate was then removed under by vacuum in a speedvac and the 
dried extracts were resuspended in 500 μL of methanol for LC-MS/MS analysis using the 
standard precursor ion scan method. However, no PTM production was observed outside of 
JV180, the positive control (Figure 6). 
 
 
Figure 6. No PTM production was observed from pJMD11 exconjugants. LC-MS/MS 
chromatograms of extracts from strains grown on ATCC172.  
 
To verify that the entire PTM BGC was integrated at the ΦC31 attB site, primers were designed 
to PCR overlapping 1~2 kilobase fragments of the PTM BGC (Table 4). When this was done, no 
bands were obtained from JV877-878 (Figure 7). Additionally, the conjugal donor strain was 
tested by colony PCR and no bands were observed, suggesting that either the plasmid was 























JV180 JV352 S. viridochromogenes





Table 4. Primer pairs to verify PTM BGC integration and expected product sizes  
Primer 
pair 
Fw primer sequence Rv primer sequence 
Product 
size (bp) 
1 TGCGTGCGCCTCCGCGCTC GAAGCCGTCGATGTATCCGC 1619 
2 ACGGAACAAGGTGGCGATC CTTGACCGAGCCGACGTAG 1036 
3 CGGCGACCTCCAGTACATG ATGGCGACGCTGTGGTAAG 1317 
4 AGTTCGCCAAGTTCCTCACC TGAGGAGGGTCTGGAAGCAG 1140 
5 TTCCAGACCCTCCTCACCC GTCCTCGTCGGTGATGTCG 1362 
6 GGCCACGTTCGACATCACC TCAGCTGCTTGAGGAACCANADNGC 996 
7 CGAACTCCACACCGACGAG AGGGTTATGTCGAACTGCCC 1158 
8 TCCAGGCGATGTTCATCCTC CCGTTCGCAGTGGTCCATC 1148 
9 GACCTCCTCTTCGACACCAC CGTTGAAGGTGAGGCTGGG 1168 
10 CATCGAACTCCTCCACCACC AAGTACCTCTTCCCGTTGCG 1675 
11 TGCTCCCGTACCTCTTCAAC CAGATCTGGTGCATCTCGTTG 1272 
12 AGTACCTCTGCCGTGAACTC GATGAGGTGGGTCGTGCAG 1192 
13 ACTACCGCAAGCTCTACACC ACCACCTCCATGATCGAGTC 999 
14 GGAACTGATCAAGAAGCACGG CTGGTTGAACATGAGGTCGG 1593 
15 AGATCACCTTCGACCACACC GTGGGCGAGGTGTTCAACAC 1833 
 
 




To increase the stability of the plasmid in E. coli and reduce the likelihood of unwanted 
recombination, I used λ RED recombination (8) to delete an approximately 12.5 kilobase 
sequence from pJMD11. This region contained additional JV180 chromosomal DNA sequence 
downstream of the PTM BGC and was unneeded for PTM production. This would reduce the 
size of the plasmid from 45,907 base pairs for pJMD11 to 34,111 base pairs, a decrease of over 
25%. The resulting plasmid was named pJMD12 (Figure 8).  
 
 
Figure 8. Plasmid map of pJMD12 
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Table 5. pJMD12 host strains and exconjugants 
Host strain Description Strain # for exconjugants 
JV352 JV180 ΔftdA-F  
JV51 S. lividans 66  
JV16 S. coelicolor M145 JV939-940 
JV975 S. coelicolor M1152 JV992-993 
JV28 S. viridochromogenes DSM 40736  
JV110 S. roseosporus NRRL 15998  
JV158 S. griseus IFO13350  
 
pJMD12 was conjugated into a panel of host strains to test for heterologous PTM production 
(Table 5). Successful integration at the ΦC31 attB site was confirmed for all strains except for 
JV158 (S. griseus IFO13350). Additional PCR verification for the introduction of PTM BGC 
genes revealed that while the pJMD12 vector was successfully inserted into the attB sites, the 
PTM BGC was only stably integrated in JV16 (S. coelicolor M145) exconjugants, JV939 & 
JV940 (Figure 9). Some false positive bands appeared in the PCR screen for JV110 (S. 
roseosporus NRRL 15998) exconjugants as this strain has a silent PTM BGC. However, most 
specific primers did not produce PCR bands, suggesting that the PTM BGC was also lost from 
these exconjugants. At this point, I also discovered that John D’Alessandro had not verified 
integration at the ΦC31 attB site for the earlier pJMD11 conjugations, so it could not be 
determined if the strains failed to produce PTMs due to loss of PTM BGC genes from 





Figure 9. PCR verification of PTM genes in pJMD12 exconjugants. Primer pairs are the same as 
those listed in Table 4. Two colonies were tested for JV352 (negative control) and exconjugants 
of S. viridochromogenes (S.v.), S. coelicolor (S.c.), S. lividans (S.l.), and S. roseosporus (S.r.). 
 
The S. coelicolor strains containing the full pJMD12 were grown on various agar plates and 
extracted with ethyl acetate for PTM analysis by LC-MS/MS. I observed several peaks which 
matched the retention times and mass transitions of PTMs produced by JV180 (Figure 10). We 
also obtained S. coelicolor strain M1152 from the Bibb laboratory at the John Innes Centre (UK) 
to test as a host for PTM production. S. coelicolor strain M1152 was engineered to be a host for 
heterologous BGC expression through the deletion of the act, red, cpk, and cda BGCs and 
introduction of the rpoB[C1298T] mutation (9). pJDM12 was also successfully integrated into 
this strain. PTM production was observed from both S. coelicolor strains containing pJMD12 
when grown on ISP2 agar, but interestingly, lower PTM production was observed from the 




Figure 10. Heterologous PTM production in S. coelicolor. LC-MS/MS chromatograms of 
extracts of JV180 grown on ATCC172, and S. coelicolor derivatives grown on ISP2.  
 
Two hypotheses for this discrepancy are the loss of the cpk BGC in M1152 and the presence of 
the rpoB[C1298T] mutation. The cpk BGC encodes cpkKL, which are homologs of the acetyl-
CoA carboxylase genes from the grh BGC, grhGH. As we have reported, the deletion of grhGH 
in Streptomyces sp. strain JV180 reduces PTM transcription and production, and this may be due 
to reduced malonyl-CoA availability. It has also been reported that introduction of the 
rpoB[C1298T] mutation impaired growth and differentiation. This may have also affected the 
strain’s ability to produce PTMs and optimization of culture conditions could have alleviated this 
issue. Unfortunately, we were unable to obtain additional strains such as M1146 (no rpoB 























JV180 M145 M145 + pJMD12 M1152 + pJMD12
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the ΦBT1 attB site. However, the exconjugants had poor growth and this line of inquiry was 
discontinued. 
The influence of the PTM BGC on griseorhodin biosynthesis 
Background 
As described in chapter 2, polycyclic tetramate macrolactam (PTM) biosynthesis in Streptomyces 
sp. strain JV180 was found to be dependent on the griseorhodin biosynthetic gene cluster (BGC). 
PTM production and BGC transcription were severely reduced when the grh BGC was deleted 
(ΔgrhR2-V). Further genetic analyses showed that grhGH, encoding for malonyl-CoA 
production, may play a key role in this interaction. 
Results and discussion 
In a converse experiment, I noticed that the extracts of some JV180 mutants with reduced PTM 
production due to manipulation of the PTM BGC and its promoter appeared to contain less red 
pigment (griseorhodins). To test if this was a real trend or an experimental artifact, I attempted to 
quantify relative griseorhodin production from some JV180 mutants (Table 6).  
 
Table 6. Strains used to compare griseorhodin production 
Strain Genotype Notes 
JV307 JV180 rpsL (K43R) Parent strain 
JV352 JV307 ΔftdA-F PTM BGC KO 
JV564 JV307 ΔgrhR2-V Control, no griseorhodin production 
JV1698 JV307 ΔgrhGH Control, reduced griseorhodin production 
 
The strains were streaked from −80°C glycerol stocks onto ISP2 agar. After incubating for 2 
days at 28°C, an agar plug from each plate was used to inoculate 3 mL of TSB in a 24-deep well 
plate with one 4 mm bead added to disrupt clumping. The seed cultures were shaken at 300 rpm 
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in a 28°C shaker. After 2 days, 200 μL of the seed cultures were spread on 8340 agar plates in 
triplicate. After 6 days, griseorhodins were extracted using a protocol adapted from those 
described by (10, 11). The top layer of agar with the adherent cells were scraped off with a 
spatula and collected in 50 mL centrifuge tubes. Approximately 10 mL acidified MilliQ water 
(pH adjusted to approximately 3.5 with HCl) and sonicated for approximately 20 minutes. The 
tubes were centrifuged at 3,214 x g for 5 minutes and the water, which remained colorless, was 
decanted and neutralized. Approximately 20 mL of ethyl acetate was added, and the tubes were 
vortexed vigorously. The tubes were centrifuged at 3,214 x g for 5 minutes and the ethyl acetate 
was decanted into glass scintillation vials to be dried under low pressure. The agar/cell pellet was 
extracted again with approximately 20 mL of acetonitrile + 0.1% formic acid. The tubes were 
vortexed vigorously and centrifuged at 3,214 x g for 5 minutes, and the acetonitrile was decanted 
into glass scintillation vials to be dried under low pressure. Compared to ethyl acetate, 
acetonitrile appeared to extract griseorhodins more efficiently, and the red pigmentation 
appeared to be absent in the agar/cell pellet afterward. The residual water/acetonitrile were 
extracted with ethyl acetate and the ethyl acetate fractions were collected and dried under low 
pressure. The dried extracts were resuspended in 1 mL of acetonitrile and filtered before LC-MS 
analysis. 
Griseorhodin production was analyzed using a Phenomenex Luna C18 column (75 x 3 mm, 3 µm 
pore size) installed on an Agilent 1260 Infinity HPLC connected to an Agilent 6420 Triple-Quad 
mass spectrometer. For each run, 10 µL sample was injected and the chromatography conditions 
were as follows: T = 0, 5% B; T = 2, 5% B; T = 16, 100% B, T = 20, 100% B; where solvent A 
was water + 0.1% formic acid and solvent B was acetonitrile + 0.1% formic acid. The flow rate 
was 0.7 mL/min. The diode array detector was set to measure absorbance at 488 nm. The mass 
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spectrometer was set to mass scan mode with m/z ranges 100 – 1000 for positive and negative 
ions and the fragmentor voltage was set to = 70 V. The main griseorhodin peak, which had a 
positive m/z of 509 corresponding to griseorhodin A, eluted at approximately 10 minutes. The 
absorbance chromatogram at 488 nm was integrated and the area of the griseorhodin peak was 
used to compare relative griseorhodin production (Figure 11). As expected, griseorhodins were 
absent in the ΔgrhR2-V mutant and reduced in the ΔgrhGH mutant. Interestingly, griseorhodin 
production was also reduced in the ΔftdA-F mutant. This result runs counter to the popular 
strategy of deleting competing BGCs can be used to increase antibiotic production. In the future, 
this connection could be further explored by qPCR analysis of grh BGC genes in the ΔftdA-F 
mutant. Similarly, PftdA mutants exhibiting reduced PTM transcription could also be tested for 
griseorhodin production.  
 
 






































The malonyl-CoA metabolism of Streptomyces sp. strain 
JV180 
Background 
Through genetic studies of the griseorhodin biosynthetic gene cluster’s effects on polycyclic 
tetramate macrolactam (PTM) production, I found that the genes grhGH played an important role 
in this interaction. These genes encode the β and ε subunits of acetyl-CoA carboxylase (ACC), 
which converts acetyl-CoA to malonyl-CoA. Malonyl-CoA is a common precursor for PTM, 
griseorhodin, and fatty acid biosynthesis. Plants and bacteria encode multi-subunit ACC 
enzymes. The α subunit contains the biotin carboxylase domain and the biotin carboxyl carrier 
protein domain, responsible for carboxylating an attached biotin molecule. The β subunit 
contains the carboxyltransferase domain, which transfers the carboxyl group to acetyl-CoA to 
form malonyl-CoA. Finally, the ε subunit appears to be a unique subunit found in actinomycetes, 
and increases the turnover rate of the ACC complex despite not having any catalytic function of 
its own (12). Actinomycetes encode multiple copies of ACC genes with distinct roles. Some 
ACC genes are essential housekeeping genes which drive fatty acid biosynthesis, while other 
non-essential copies are found in BGCs for secondary metabolites (13, 14). 
Based on our data, we hypothesized that the PTM biosynthetic gene cluster (BGC) responded 
transcriptionally to malonyl-CoA availability in the cell. This may involve direct malonyl-CoA 
sensing, which occurs in B. subtilis (15), or indirect sensing via free fatty acids, which occurs in 
E. coli (16). In actinomycetes, regulation of fatty acid metabolism is less well-understood due to 
the number of biosynthetic genes (17), but seems to be partially controlled by FasR, a TetR-type 
transcriptional regulator (18, 19). In vitro experiments with the FasR of Mycobacterium 
tuberculosis indicates that this protein’s ability to bind its target promoters is controlled by long-
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chain acyl-CoA’s (20). To better understand how the PTM BGC of Streptomyces sp. JV180 
might respond to malonyl-CoA metabolism, I set out to develop a LC-MS/MS protocol to 
quantify intracellular malonyl-CoA concentrations. Additionally, due to the number of ACC 
genes and the possibility of genetic redundancy, I also attempted to characterize the transcription 
of ACC genes in JV180. 
Malonyl-CoA extraction and quantification 
After comparing the protocols described by several papers, I developed a protocol for Malonyl-
CoA extraction and quantification for Streptomyces sp. strain JV180. The extraction protocol 
was largely adapted from that described by (21), while the LC-MS/MS protocol was adapted 
from that described by (22).  
For malonyl-CoA quantification, strains were cultured in flask cultures. Strains were streaked 
from −80°C glycerol stocks onto ISP2 agar plates and incubated at 28°C for 2 days. An agar plug 
was used to inoculate 3 mL of TSB in a 24-well deep well plate with one 4 mm glass bead added 
to disrupt mycelial clumps. The seed cultures were shaken at 300 rpm in a 28°C incubator for 2 
days. In a 125 mL flask with 6 mm glass beads, 20 mL of ATCC-MOPS was inoculated with 200 
μL of the seed culture. The flasks were shaken at 250 rpm in a 28°C incubator. 
Before harvesting the cultures, 2 mL of 15% trichloroacetic acid (TCA w/v) was aliquoted into a 
15 mL tube and chilled on ice. A 2:1 mixture of AR200:DC200 silicone oils was added as a layer 
over the TCA. From each flask, 3 mL of the Streptomyces culture was sampled and added slowly 
to the silicone oil layer as to not disturb the oil layer. The samples were centrifuged at 3,214 x g 
for 10 minutes at 4°C. Immediately afterwards, approximately 2 mL of the TCA layer was 
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withdrawn with a Pasteur pipet into microcentrifuge tubes. The samples were centrifuged at 
10,000 x g for 5 minutes to separate residual silicone oil. 
A 3 mL OASIS HLB reverse-phase Solid Phase Extraction (SPE) column (Waters catalog # 
WAT094226) was loaded on a vacuum manifold and conditioned with 3 mL of methanol 
followed by 3 mL of 0.15% TCA. The cell extract was loaded onto the column and washed with 
2 mL of 0.15% TCA followed by 2 mL n-heptane. The malonyl-CoA enriched fraction was 
eluted twice with 0.5 mL of a methanol-ammonium hydroxide (99:1 v/v) solution into a glass 
test tube. The solvent was evaporated by vacuum in a speedvac and the dried material was 
resuspended in 100 μL of LC-MS grade water and syringe filtered before analysis. 
Malonyl-CoA was analyzed using a Waters Atlantis T3 column (100 x 2.1 mm, 3 μm pore size) 
installed on an Agilent 1260 Infinity HPLC connected to an Agilent 6420 Triple-Quad mass 
spectrometer. For each run, 10 μL of the sample was injected and the chromatography conditions 
were as follows: T = 0 min, 0% B; T = 3 min, 0% B; T = 7 min, 100% B; T = 9 min, 100% B; T 
= 11 min, 0% B; T = 13 min, 0% B; where solvent A was water + 50 mM ammonium acetate 
(pH 6.9) and solvent B was acetonitrile. The flow rate was 0.25 ml/min. The mass spectrometer 
was set to single reaction monitoring mode for the malonyl-CoA mass transition: precursor ion 
m/z = 854.1, product ion m/z = 347, fragmentor = 10 V, collision energy = 35 V, and polarity = 
positive. The resulting data was analyzed offline with Agilent MassHunter Quantitative Analysis 
software. Malonyl-CoA was quantified using a standard curve of 50 ng/mL – 50 μg/mL.  
I attempted to use this protocol to quantify intracellular malonyl-CoA concentrations in JV180- 
and IFO13350 strains bearing deletions in the grh cluster or overexpressing grhG. Strains were 
grown in triplicate sampled for malonyl-CoA quantification after 2 and 4 days of growth (Figure 
275 
 
12). The malonyl-CoA measurements showed large variance, especially for samples collected 
after 2 days of growth. The variance was much smaller for samples collected after 4 days of 
growth. This may reflect the fact that the metabolisms of the replicates were better synchronized 
after 4 days of growth, when all of the cultures should have entered stationary phase. Even so, 
the only sample which showed statistically significant difference at 4 days was the ΔgrhR2-V 
mutant compared to the JV180 rpsL parent strain. 
 
 
Figure 12. First attempt to quantify malonyl-CoA. 
 
I repeated the experiment with a different set of strains overexpressing grhG (Figure 13). 































were not consistent with the previous data set. While there did seem to be some differences 
between the wild-type strains, the overexpression of grhG oddly did not seem to increase 
malonyl-CoA significantly. This could be due to biological mechanisms working to maintain 
fatty acid homeostasis or flaws in the protocol. In the future, reproducibility and variance could 
be further improved by extracting a larger sample volume. Additionally, I observed issues with 
the chromatography conditions, which created split peaks in LC-MS analysis. 
 
 






























Transcriptomic analysis of ACC genes in Streptomyces sp. strain JV180 
In a related experiment, I worked with Kevin Blake, a rotating graduate student, to characterize 
the transcription of ACC genes in Streptomyces sp. strain JV180. This strain possesses four 
genes encoding for the β subunit of ACC, including grhG. Wild-type JV180 was inoculated into 
16 flasks of ATCC-MOPS and harvested every 2 days for PTM, RNA, and protein extraction 
(Figures 14 and 15). PTM and protein extraction and quantification were performed by Kevin, 
and RNA extraction, quantification, and RT-qPCR was done by myself. 
 
 
























Figure 15. JV180 PTM production is completed by 4 days of growth in flasks. 
 
The PTM and protein over time graphs show that while maximum biomass is reached within 2 
days of growth, PTM production continues to take place for another 2 days. This suggests that 
the flask cultures finish exponential growth and transition into stationary phase around 36 hours 
under the conditions tested. Homologs of SCO5535 (accB) and SCO2776 (accD1) were 
identified in the JV180 draft genome using BLASTn and aligned with their homologs in S. 
griseus IFO13350 and S. coelicolor A(3) to assign predicted functions (Figure 16). Primers for 
RT-qPCR were designed using the IDT PrimerQuest tool. Additionally, primers were designed 
for the most likely homolog of the housekeeping accA gene, encoding for the ACC α subunit, 





























Figure 16. Identification of ACC β-subunits in Streptomyces sp. strain JV180. Amino acid 
sequences were aligned with ClustalOmega, degapped, and used to construct a neighbor-joining 
tree using the Jukes-Cantor substitution model. The B. subtilis YqjD (AccB) protein sequence 
was used as an outgroup and 500 bootstrap simulations were performed. 
 
RT-qPCR analysis of the expression patterns of these genes over time revealed several 
interesting trends (Figure 17).  First, the transcription of the PTM BGC decreased from day 2 to 
day 8. However, PTM quantification clearly showed that most PTMs were produced between 
day 2 and day 4. This lag between transcription, translation (not measured here), and metabolite 
production has been previously observed (23, 24). Interestingly, accB transcript abundance 
increased over time, while grhG transcript abundance stayed at similar levels. This appears to be 
the opposite of what might be expected, as accB should encode the essential, housekeeping ACC 
β-subunit, while the expression of the grh BGC should show a peak like ftdA. Indeed, the 
transcript abundance of accA stayed similar over time, as one would expect from a housekeeping 
gene. Transcript abundance of accD1 and accD2 increased dramatically over time, but the 
functions of these enzymes are unclear so far (17). Further RT-qPCR experiments in JV180 
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mutants could explore for potential redundancy and the regulation of ACC genes by global 
regulators like adpA. Additionally, absolute quantification of transcripts by RT-qPCR or 
RNAseq could determine the relative transcript abundance of different ACC genes, which would 
lead to a better understanding of their roles.  
 
 
Figure 17. Transcription patterns for ACC genes in Streptomyces sp. strain JV180. The accD2 
sample collected at day 8 was omitted due to contaminated cDNA. 
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Piperazate (Piz) is a nonproteinogenic amino acid noted for its unusual N−N bond motif. Piz is a 
proline mimic that imparts conformational rigidity to peptides. Consequently, piperazyl 
molecules are often bioactive and desirable for therapeutic exploration. The in vitro 
characterization of Kutzneria enzymes KtzI and KtzT recently led to a biosynthetic pathway for 
Piz. However, Piz anabolism in vivo has remained completely uncharacterized. Herein, we 
describe the systematic interrogation of actinobacterial Piz metabolism using a combination of 
bioinformatics, genetics, and select biochemistry. Following studies in Streptomyces flaveolus, 
Streptomyces lividans, and several environmental Streptomyces isolates, our data suggest that 
KtzI-type enzymes are conditionally dispensable for Piz production. We also demonstrate the 
feasibility of Piz monomer production using engineered actinobacteria for the first time. Finally, 
we show that some actinobacteria employ fused KtzI−KtzT chimeric enzymes to produce Piz. 
Our findings have implications for future piperazyl drug discovery, pathway engineering, and 
fine chemical bioproduction.  
 




New drugs for treating antibiotic-resistant infections are urgently needed.1 Piperazate (Piz) is a 
nonproteinogenic amino acid and a largely overlooked pharmacophore. Since Piz was originally 
discovered as a building block of the antibacterial monamycins in 1971,2 several piperazyl 
antibiotics from filamentous actinomycete bacteria have been discovered. These include the 
matlystatins (peptide deformylase inhibitors),3,4 the luzopeptins (antitumor agents),5 the 
kutznerides (antifungals),6 and the sanglifehrins (antivirals and immunosuppressants)7,8 (Figure 
1A). Piz imparts intramolecular rigidity and prolyl mimicry9 to parent molecules, making it 
particularly desirable in the context of peptidyl turn analogues and other peptidomimetics.10,11  
 
 
Figure 1. Piz natural products and biosynthesis. (A) Piperazic acid (Piz, red) is incorporated into 
structurally diverse peptidyl natural products. (B) Current biosynthetic pathway for Piz 
production based on the characterization of Kutzneria sp. strain 744 KtzI and KtzT. 
 
Until recently, the biosynthesis of Piz and its N−N bond remained enigmatic. Following the 
biochemical characterization of two Kutzneria sp. strain 744 enzymes, KtzI12 and KtzT,13 a 
two-step pathway converting L-ornithine (L-Orn) to L-Piz (Figure 1B) was revealed. 
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Specifically, KtzI first converts L-Orn to its N-hydroxyl derivative N5 -OH-L-Orn, which is then 
cyclized to L-Piz by the hemoenzyme KtzT. An important advance in N−N bond biocatalysis, 
this model also suggested a new path for genomics-guided piperazyl molecule discovery.  
However, much remains unknown about Piz biosynthesis. Importantly, its production has never 
been investigated in vivo. This limits the bioengineering potential of this important drug building 
block. In addition, a family of proteins annotated as PaiB-type regulators13 share significant 
homology with KtzT, but the functional relationship of PaiB proteins and KtzT-type enzymes, 
and how this impacts Piz production, remained unclear. Understanding these relationships is the 
key to revealing the extent of Piz metabolism in nature and creating refined genome-mining 
methods to discover new piperazyl molecules. To further understand Piz biosynthesis, we 
utilized a combination of bioinformatics, genetics, and biochemistry to investigate production in 
several Streptomyces species. 
Several lines of evidence suggest in vivo Piz production is more nuanced than initially expected. 
Contrary to the KtzI− KtzT model, we found that the KtzI ortholog SfaB is dispensable during 
sanglifehrin production in Streptomyces flaveolus and that expressing the strain’s KtzT ortholog, 
SfaC, is sufficient for Piz monomer production in Streptomyces lividans. These observations 
strongly suggest piperazyl molecule biosyntheses likely benefit from N5 -OH-L-Orn production 
encoded outside of their cognate genomic loci, a trend supported by heterologous Piz production 
tests in several environmental Streptomyces stains. Following extensive phylogenetic analysis of 
KtzT/SfaC enzymes, we also discovered certain actinomycetes carry out Piz biosynthesis by 
chimeric enzymes featuring fused KtzI- and KtzT-type domains. Two chimeras were tested, 
revealing one from Micromonospora tulbaghiae with significant activity. Finally, our 
bioinformatic efforts also revealed specific residue patterns that differentiate PaiB- and KtzT-
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family proteins, and these patterns were experimentally validated using SfaC point mutants. 
Together, our data expand upon the current biosynthetic model and reveal new opportunities for 
piperazate pathway recognition and bioengineering. 
RESULTS AND DISCUSSION  
Analysis of Piz Metabolism during Sanglifehrin Production.  
The current Piz biosynthetic model is based on enzymes sourced from the kuzneride biosynthetic 
locus of Kutzneria sp. strain 744. However, this strain is challenging to transform, leading us to 
initiate our Piz metabolic studies in S. flaveolus DSM 9954. The characterized producer of the 
sanglifehrins, a family of therapeutically interesting piperazyl antivirals, S. flaveolus is readily 
transformed via intergeneric conjugation.14  
The sanglifehrin biosynthetic locus was sequenced previously,14 and the cluster encodes 
homologues of ktzI and ktzT (sfaB and sfaC, respectively). On the basis of the KtzI/KtzTbased 
Piz pathway, we predicted deleting either gene should abrogate sanglifehrin production via Piz 
precursor loss. S. flaveolus is known to produce >20 sanglifehrin congeners,14 with 
therapeutically relevant sanglifehrin A (m/z 1090.7) being among the most highly produced.15 
Liquid chromatography and tandem mass spectrometry (LC−MS/MS) detected sanglifehrin A 
production in both wild-type (JV270) and rpsL (JV571) strain extracts (Figure 2A and Figure 
S1). In contrast, our unmarked ΔsfaC (JV575) deletion mutant was deficient for sanglifehrin A 
production in addition to several other peaks that likely correspond to other sangifehrin-family 
compounds. Suggesting sfaC is indeed involved in Piz production, we found that either feeding 
exogenous L-Piz (0.25 mM) or ectopic sfaC expression (JV577) restored sanglifehrin production 
in the mutant background. Together, these findings are consistent with the current Piz 
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Figure 2. Genetic analysis of pzbB in Piz production in vivo. (A) LC− MS/MS detection of 
sanglifehrins (SRM, m/z 1090.7 → 294.1) produced by S. flaveolus rpsLK43R (JV571), S. 
flaveolus rpsLK43R ΔsfaC (JV575), S. flaveolus rpsLK43R ΔsfaC + sfaC (JV577), and S. 
flaveolus rpsLK43R ΔsfaB (JV574). The gray bar highlights the retention time for an authentic 
standard of sanglifehrin A. (B) Piz detection in transgenic S. lividans by LC−MS (m/z 131.1): (I) 
wild type (WT), (II) WT with sfaB (JV593), (III) WT with sfaC (JV594), (IV) WT with sfaB and 
sfaC (JV596), and (V) 50 μM L-Piz standard. The gray bar indicates the position of authentic 
Piz. (C) LC−MS/MS quantification of L-Piz production in sfaC-transformed Streptomyces 
species. Strains JV1403−JV1413 are environmental isolates; JV1405 (starred) produces similar 
quantities of Piz in the absence of sfaC (see the text). Error bars indicate standard deviations 
between biological triplicates. JV594 and JV596 are S. lividans transformants in panel B. 
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In contrast with sfaC, our sfaB (JV574) deletion mutant retains sanglifehrin production (Figure 
2A). This was unexpected because sfaB is a ktzI homologue and thus should be required for the 
Piz intermediate N5 -OH-L-Orn. On the basis of this observation, we surmised the S. flaveolus 
genome must encode additional functionally redundant N-hydroxylases. Lacking a sequenced 
genome to verify this, we designed degenerate polymerase chain reaction (PCR) primers to 
detect such genes using several published Orn N-OHase sequences (see the Supporting 
Information). This revealed the presence of at least one additional flavin-dependent N-OHase 
encoded within the genome of the S. flaveolus ΔsfaB strain.  
Heterologous L-Piz Production in Multiple Streptomyces Species.  
To further investigate Piz anabolism via SfaB/ SfaC, we carried out heterologous expression 
experiments in S. lividans strain 66. This commonly used heterologous host lacks apparent 
ktzT/sfaC homologues in its genome and is not known to produce piperazyl compounds. S. 
lividans was transformed with integrative plasmids expressing either sfaB (pYH014), sfaC 
(pYH015), or a combination of both plasmids. The resulting Piz production was monitored by 
LC−MS. As expected, wild-type S. lividans and the sfaB transgenic strain (JV593) lacked 
detectable Piz. In contrast, S. lividans expressing both sfaB and sfaC (JV596) or sfaC alone 
(JV594) produced Piz (Figure 2B). The finding that S. lividans can produce Piz via sfaC in the 
absence of sfaB echoed our S. flaveolus observations. While N5 -OH-L-Orn metabolism in S. 
lividans is poorly documented, the strain’s genome16 harbors multiple ktzI/sfaB homologues 
that may support its production (e.g., EFD65609.1 and EFD71462.1, the latter encoded within a 
predicted hydroxamate-type siderophore biosynthetic locus).  
The experiments described above revealed for the first time that Piz, a desirable drug building 
block, can be produced by engineered actinobacteria. They further suggested that N5 -OHL-Orn 
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metabolism, which remains poorly explored in the literature, may be fairly active within most 
Streptomycetes. To further understand this, we assayed several environmental Streptomyces 
isolates for the ability to produce Piz following transformation with pYH015, a sfaC expression 
plasmid (Table S1). Of 22 obtained transformants, 12 produced plasmiddependent Piz (Figure 
2C). A single strain, SP18CS05, also produced Piz in the absence of the plasmid. Further 
investigation by degenerate PCR with primers designed to amplify sfaC/ktzT homologues 
confirmed that this organism harbors a native copy. Thus, our summed observations reveal N5 -
OH-L-Orn metabolism is indeed a fairly common and potentially exploitable feature of many 
Streptomyces.  
Bioinformatic Analysis of KtzT/SfaC-Type Enzymes and PaiB Homologues.  
Prior to the biochemical characterization of KtzT, KtzT/SfaC homologues encoded within 
sequenced piperazyl molecule biosynthetic loci were often misannotated as PaiB-family 
transcriptional regulators.13 PaiB- and KtzT/SfaC-type proteins show significant amino acid 
similarity and likely share similar protein structures13 (Figure S8). Following KtzT’s recent 
functional assignment as a hemoenzyme, whether these protein families have identical or distinct 
catalytic functions remained unclear. Indeed, the recent revelation that Geobacillus 
stearothermophilus PaiB also binds heme indicates PaiB-family proteins could also function 
outside of transcriptional control.13  
To begin addressing if PaiB and KtzT/SfaC proteins are functionally distinct or are in fact 
identical, we first assembled a collection of high-confidence SfaC/KtzT ortholog sequences. This 
was done by screening genomes for co-localized ktzI/sfaB and ktzT/sfaC homologues and then 
scanning nearby gene neighborhoods for nonribosomal peptide synthase (NRPS) genes having 
Piz adenylation domains (see Methods; for an NRPS review, see ref 17). Because most resulting 
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hits lacked functional locus names, we annotated putative KtzI/SfaB and KtzT/SfaC orthologs as 
PzbA’s and PzbB’s (for piperazate biosynthesis A and B), respectively. This effort revealed >80 
predicted Piz biosynthetic loci (Table S4). To date, all known natural piperazyl molecules are 
produced by filamentous actinomycetes. Perhaps unsurprisingly, the vast majority of the 
identified putative piperazyl loci were discovered within actinobacterial genomes. However, our 
PzbA/B co-localization and PzbB sequence analyses suggest Piz metabolism likely extends to 
the proteobacteria, as well, identifying certain Collimonas fungivorans and Photorhabdus 
luminescens isolates as candidate piperazyl molecule producers (Table S4 and Figure 3). 
 
Figure 3. Maximum-likelihood phylogeny of PzbB homologues. PzbB enzymes (blue) are 
closely related to PaiB proteins (green) that are found in multiple bacterial phyla and some fungi. 
This analysis reveals a clade of PzbAB fusion enzymes (orange) whose PzbB domains are 
sequence-distinct from stand-alone PzbB’s. Nodes a−e correspond to PzbB’s tested in vivo in 
Figures 2 and 4 (from S. flaveolus, Actinoalloteichus cyanogriseus, Lentzea flaviverrucosa, and 
Kutzneria sp. 744 and Streptomyces himastatinicus, respectively). Nodes f and g correspond to 
PzbAB fusion proteins investigated herein from M. tulbaghiae and Amycolatopsis alba, 
respectively. All PzbAB’s and all except for two PzbB’s are sourced from actinobacteria. Node h 
corresponds to a putative stand-alone PzbB protein from the proteobacterium Photorhabdus; 
another proteobacterial PzbB from C. fungivorans is part of the actinobacterial PzbB tree 
(unmarked). A single stand-alone PzbB from actinobacterium Mycobacterium xenopi 




To identify and analyze PaiB-type proteins, we assembled a representative set of homologues 
mined from public databases (see methods) that were not associated with pzbA and/or NRPS 
genes. Whereas the vast majority of candidate pzbB genes were found in actinobacteria (all 
except 2; Figure 3), we found putative paiB genes to be more broadly distributed among a 
diversity of microorganisms, including firmicutes, proteobacteria, and some fungi. Notably, a 
maximum-likelihood phylogeny clearly separates the manually curated PzbB sequences from the 
other PaiB-type homologues, indicating PzbB’s are distinct and suggest the potential for 
different biological roles between the two protein clades (Figure 3).  
Sequence Diversity among PzbB Proteins.  
After determining that PaiB and PzbB proteins are clearly sequence-distinct, we further noted 
significant sequence variation within the PzbB group itself. For example, SfaC is 89.6% identical 
to PzbB from Streptomyces sp. strain PBH53 but only 33.6% identical to PzbB from 
Actinoalloteichus cyanogriseus. With PzbB’s ranging in length from only 200 to 252 amino 
acids, this raised the question of whether all members of the PzbB clade are indeed capable of 
Piz catalysis.  
To test if sequence diversity within the PzbB group affects Piz catalysis, we expressed a panel of 
diverse PzbB homologues (Figure 3) cloned from several actinomycetes (Lentzea flaviverrucosa, 
Streptomyces himastatinicus, Kutzneria sp. strain 744, and A. cyanogriseus) in S. flaveolus and 
S. lividans. Although all are weakly conserved with SfaC (33.6−40.8% amino acid identity), we 
found each tested PzbB is functional in Piz biogenesis in both heterologous hosts (Figure 4A,B). 
In contrast, PaiB cloned from Bacillus subtilis strain 168 (24.5% amino acid identity with SfaC) 
failed to rescue the ΔsfaC mutation (not shown). Along with the phylogenetic analysis presented 
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above, these data further support the PzbB group as a functionally conservative clade and further 
suggest PaiB proteins are functionally distinct (analyzed further below).  
 
 
Figure 4. Piz production by PzbB orthologs. (A) LC−MS/MS quantification of sanglifehrin A 
production in S. flaveolus rpsLK43R (JV571), rpsLK43R ΔsfaC (JV575), and ΔsfaC 
complemented with sequence-diverse pzbB’s: sfaC (JV577), ktzT (JV578), hmtC (JV579), 
pzbBA. cyanogriseus (JV585), and pzbBL. flaviverrucosa (JV586). JV575 was also 
complemented with PzbAB chimeras of Am. alba and M. tulbaghiae (JV580 and JV582, 
respectively) as well as the pzbB domains cloned from the same genes (JV581 and JV583, 
respectively). Error bars indicate standard deviations among biological triplicates. (B) LC−MS 
chromatograms for Piz production in (I) S. lividans with sfaB (JV593) expressing (II) hmtCS. 
himistatinicus (JV598), (III) pzbBA. cyanogriseus (JV599), (IV) pzbBL. flaviverrucosa (JV600), 
and (V) ktzT (JV597). (C) PzbAB fusion proteins have an N-terminal PzbA (ornithine 
hydroxylase) domain and a C-terminal PzbB domain. Conserved residues are indicated by black 
bars. Residues conserved in only PzbAB sequences are indicated by red bars. 
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Discovery and Characterization of Chimeric pzbAB Genes and Enzymes.  
Our data-mining efforts also led to the discovery of a subgroup of piperazyl molecule 
biosynthetic loci that harbor apparent PzbAB chimeric proteins. These enzymes are characterized 
by a linkerless amino-terminal PzbA domain fused to a carboxyl PzbB terminus (Figure 4C and 
Figure S8). PzbB domains extracted from these chimeras form a distinct clade within the PzbB 
tree and have greater sequence similarity with PaiB’s than their stand-alone counterparts (Figure 
3). By comparing the sequences of 83 stand-alone PzbA and PzbB pairs against 11 available 
chimeric PzbAB’s, we found that the fusion proteins are distinguished by unique position-
specific amino acid utilization patterns compared to stand-alone homologues (Figure 4C).  
To test if these chimeras catalyze Piz production, we expressed pzbAB genes cloned from Am. 
alba and M. tulbaghiae in S. flaveolus ΔsfaC. Both chimeras restored sanglifehrin, but to a lesser 
extent than stand-alone PzbB’s tested in Figure 4A. The Am. alba chimera barely complemented 
the mutant, while the M. tulbaghiae gene restored ∼75% of wild-type (WT) activity (Figure 4A). 
To test if both PzbA and PzbB of the fused proteins domains are functional (as the chimeric 
PzbB domains might have sourced N5 -OH-L-Orn from background S. flaveolus metabolism), 
we expressed truncations of both pzbAB chimeras in S. flaveolus ΔsfaC. The truncated gene 
encompassing the M. tulbaghiae PzbB domain (amino acids 453−672) also rescued sanglifehrin 
production, retaining ∼40% of the activity of the full-length pzbAB gene. Similar to the full-
length pzbAB from Am. alba, the cloned pzbB (amino acids 456−661) domain showed little 
activity. Why the chimeras of Am. alba and M. tulbaghiae show such distinct activity differences 
in our heterologous assay remains unclear. Despite this, our data importantly demonstrate that 
PzbAB from M. tulbaghiae is catalytically competent and its PzbB domain supports Piz 
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catalysis. Other newly identified PzbAB proteins documented in this work (Figure 3 and Table 
S8) may be similarly active.  
 
 
Figure 5. In vitro PzbB and coupled PzbA/B assays. (A) LC−MS chromatograms for (I) the 50 
μM L-Piz standard and in vitro end point products of (II) SfaC and (III) PzbABM. tulbaghiae 
using L-N5 - hydroxyornithine as the substrate. (B) LC−MS chromatograms of in vitro reaction 
end points of (I) coupled SfaB/SfaC and (II) PzbABM. tulbaghiae using L-ornithine as the 
substrate. (C and D) Logo plots of residues surrounding the conserved KLSQ motifs of PzbB and 
PaiB proteins, respectively. The numbers below the first and last amino acids correspond to their 
respective positions in S. flaveolus SfaC and B. subtilis 168 PaiB, respectively. 
 
Following the in vivo assays described above, we employed in vitro assays to confirm that 
purified PzbAB from M. tulbaghiae catalyzes Piz catalysis from both N5 -OH-L-Orn and L-Orn 
(Figure 5A,B). For these experiments, we employed SfaC or SfaB/SfaC coupled reactions as 
controls. SfaB, SfaC, and PzbAB were purified by Ni2+-affinity chromatography after 
expression in Escherichia coli (Supporting Methods and Figures S2, S6, and S7). From prior 
KtzT observations, we expected both SfaC and PzbAB should be hemoproteins. We confirmed 
this by direct prosthetic group analysis (Figures S2 and S7) and catalytic rate calculations 
(below). Once heme B binding was established for both proteins, the transformation of synthetic 
N5 -OH-L-Orn to L-Piz from heme B-replete SfaC and M. tulbaghiae PzbAB was monitored by 
LC−MS/MS, HRMS, and 1 H NMR (Figure 5a and Figures S3−S5). We confirmed both proteins 
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produced L-Piz under these conditions. While this activity was expected from SfaC (a KtzT 
ortholog), these assays conclusively demonstrate exogenous N5 -OH-L-Orn can enter the PzbB 
active site of the intact M. tulbaghiae PzbAB chimera.  
Building on these results and prior coupled KtzI−KtzT studies,13 we predicted a single-pot 
reaction containing either SfaB and SfaC or PzbAB should generate L-Piz from L-Orn in the 
presence of O2, NADPH, FAD, and b-heme. For the SfaB− SfaC coupled assay, purified SfaB 
was first tested for activity as described for KtzI. NADPH consumption in the presence of LOrn, 
FAD, and O2 indicated a kcat of ∼7.7 min−1 (Figure S6), comparable to that of KtzI (kcat = 7.0 
min−1 ). Subsequent assays testing SfaB and SfaC or M. tulbaghaiae PzbAB revealed production 
of Piz from L-Orn (Figure 5B), confirming the activity of both M. tulbaghiae enzyme domains. 
Taken together, our in vivo and in vitro experiments reveal M. tulbaghiae PzbAB as a versatile 
catalyst capable of transforming both L-Orn and N5 -OH-L-Orn to L-Piz. This work also 
highlights PzbAB proteins for future substrate channeling, domain−domain interaction, and 
evolutionary covariation investigations.  
Identifying Hallmark PzbB Sequence Signatures.  
Finally, following our in vivo and in vitro explorations of several pzbB and pzbAB genes, we 
initiated combined bioinformatic and mutational studies to differentiate piperazate-linked pzbB 
genes from apparent paiB’s. To do this, 85 PzbB and 51 PaiB protein sequences were aligned, 
revealing a highly conserved sequence motif shared in both protein groups [KLSQ, 
corresponding to SfaC residues 183−186 (Figure S8 and Figure 5C,D)]. Scrutinizing the amino 
acid differences surrounding this common motif revealed two residue position identity 
differences between PzbB’s and PaiB’s. At position 181, PzbB’s typically have methionine while 
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PaiB’s have lysine. At position 187, PzbB homologues have aspartate or glutamate while PaiB 
homologues typically have asparagine.  
We then tested the effects of substituting PaiB-type residues at these positions into SfaC. Thus, 
SfaC M181K and E187N mutant proteins were purified and assayed for Piz production. 
Assuming Michaelis−Menten kinetics, WT heme-replete SfaC progress curves indicate an 
apparent Km of 360 μM (Figure S9). In assays supplemented with the N5 -OH-L-Orn substrate 
at ∼10Km, the WT SfaC (+hemin) kcat was found to be 8000 ± 500 min−1 (without hemin, 88 ± 
2 min−1 ). In contrast, the SfaC M181K (with hemin, 99 ± 8 min−1 ; without hemin, 0.41 ± 0.01 
min−1 ) and E187N (with hemin, 110 ± 10 min−1 ; without hemin, 0.89 ± 0.02 min−1 ) mutants 
had turnover numbers multiple orders of magnitude lower than that of the WT.  
Both mutant proteins were purified with absorbance maxima at 411 nm, suggesting decreased 
activity is independent of heme loss. Attempts to directly measure mutant Km values were 
hindered by visible precipitation caused by elevated N5 - OH-L-Orn levels. Despite this, the 
observed reduction in the level of L-Piz catalysis by the mutant enzymes clearly demonstrates a 
negative correlation with PaiB position-specific residues. On the basis of these observations and 
our phylogenetic analyses presented above, our work contributes further evidence that PaiB 
proteins likely function outside of piperazate metabolism. These findings are potentially 
important for accurate recognition of piperazyl molecule biosynthetic loci during genome mining 
efforts and future mechanistic inquiries. 
METHODS  
Reagents, Media, and Enzymes.  
All chemicals and medium components were purchased from Sigma-Aldrich, Fisher Scientific, 
or Santa Cruz Biotechnology unless otherwise noted. N5 -OH-LOrnithine hydrochloride (>90%) 
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was synthesized by and purchased from AKos Consulting & Solutions GmbH. L-Piperazic acid 
dihydrochloride (>95%) was synthesized by and purchased from WuXi AppTec. DL-Piz 
racemate was purchased from BOC Sciences. Restriction endonucleases, T4 DNA ligase, and 
Taq polymerase were purchased from New England BioLabs. DNA purification kits were 
purchased from Qiagen. KOD Hot Start DNA Polymerase (EMD Millipore) and FailSafe PCR 
2X PreMixes (Epicenter) were used for PCR from Streptomyces genomic DNA. 
Oligonucleotides (Table S2) were purchased from Integrated DNA Technologies (IDT).  
Instrumentation.  
Unless otherwise specified, LC−MS/MS analysis was performed on an Agilent 1260 Infinity 
HPLC instrument connected to an Agilent 6420 triple-quadrupole mass spectrometer with an 
electrospray ionization (ESI) source. The resulting data were analyzed offline with Agilent 
MassHunter software. Ultraviolet spectroscopy was performed using a Shimadzu UV-1800 
spectrophotometer.  
Bacterial Growth and Actinomycete Isolations.  
All strains used in this work are listed in Table S1, and plasmids are listed in Table S3. 
Actinomycetes were routinely propagated on ISP2 (Difco) agar plates or in Trypticase Soy Broth 
(TSB, Difco) at 28 °C. E. coli strains were grown on standard Luria-Bertani (LB) plates or in 
equivalent liquid media. Sterile glass beads (6 mm) were added to actinomycete liquid cultures 
to disrupt mycelial clumps. PCR templates for verifying transgenic or mutant actinomycetes 
were prepared by grinding cells in 100 μL of dimethyl sulfoxide, similar to the method of Van 
Dessel et al.18 Several Streptomyces strains were isolated using standard enrichment methods19 
from soils collected at the Tyson Valley Research Center in Eureka, MO. Isolates were 
confirmed as Streptomyces by 16S rDNA amplicon sequencing as described elsewhere20 
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(Tables S1 and S6). Prior to conjugation with pYH015, each isolate was screened for native 
pzbB’s. This was done using degenerate primers designed using BLOCKMAKER21 and 
CODEHOP22 software (Table S2).  
Actinomycete Conjugations.  
Streptomyces conjugations were performed essentially as described previously.23 S. flaveolus 
and S. lividans were grown on ISP2 agar (Difco) and ISP-S agar (Difco malt extract, 1.5%; 
Difco soluble starch, 0.5%; Difco yeast extract, 0.5%; CaCO3, 0.3%; Bacto agar, 2%; pH 
7.2−7.5), respectively, for sporulation. Spores were harvested using TX Buffer.24 E. coli strain 
JV36 was used as the conjugal donor. Exconjugants were selected with 50 μg/mL apramycin. 
After conjugation, JV36 was selected against with either 15 μg/mL polymyxin B or 30 μg/mL 
colistin. For plasmids using ΦC31 integration, multiplex PCR was used to verify correct attB 
insertion as previously described.23  
S. flaveolus Gene Deletions.  
Genes of interest were removed by double homologous recombination essentially as previously 
described using pJVD52.1.25 Streptomycin-resistant (StrR) mutants necessary for 
counterselection26 were isolated on ISP2 agar with 100 μg/mL streptomycin. S. flaveolus 
rpsL(K43R) was chosen for further sanglifehrin analysis because its production parallels that of 
the wild type. Deletion constructs were transformed into S. flaveolus rpsL(K43R), and 
exconjugants were selected via apramycin resistance. Double recombinants were identified via 
counterselection after growth for 3 days at 37 °C in TSB. Gene deletions were confirmed by 
PCR.  
S. flaveolus Sanglifehrin Detection.  
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S. flaveolus spores were used to inoculate 15 mL of TSB in a 125 mL Erlenmeyer flask at 28 °C 
with vigorous shaking. Glass beads were added to disrupt mycelial clumps. After overnight 
growth, the culture was spread for confluence to sanglifehrin production medium14 with 2% 
agar and incubated at 28 °C for 3 days. The agar with adherent cells was subsequently diced and 
immersed in ethyl acetate overnight. The resulting extract was evaporated at low pressure and 
resuspended in 500 μL of HPLCgrade methanol. Analysis was performed using a Phenomenex 
Luna C18 column (75 mm × 3 mm, 3 μm) using the following method: T = 0, 10% B; T = 5, 
10% B; T = 25, 100% B; T = 27, 100% B; T = 29, 10% B; T = 30, 10% B; A, water and 0.1% 
formic acid; B, acetonitrile and 0.1% formic acid; rate, 0.6 mL/min. Authentic sanglifehrin A 
was used to develop the m/z 1090.7 → 294.2 mass transition (fragmentor energy of 135 V and 
collision energy of 40 V) for single-reaction monitoring using MassHunter Optimizer (Agilent). 
For quantification, a standard curve was created using concentrations ranging from 100 ng/mL to 
1 mg/mL.  
Heterologous Piz Production.  
Streptomyces strains expressing SfaC were plated on YEME27-NSG [yeast extract-malt extract-
no sucrose or glycine; Difco yeast extract, 0.3%; Difco Bacto-peptone, 0.5%; Difco malt extract, 
0.3%; dextrose, 1.0%; Bacto agar, 2%; after autoclaving, MgCl2 (2.5 M), 0.2%] supplemented 
with 50 mg/L LOrn and incubated at 28 °C for 3 days. The agar was subsequently diced and 
immersed in methanol overnight. The methanol fraction was evaporated to dryness and 
resuspended in 500 μL of LC−MSgrade water and 500 μL of 6% sulfosalicylic acid. Samples 
were clarified by centrifugation (21000g for 5 min) and 0.2 μm filtration prior to LC−MS/MS.  
Detection of Piz via LC−MS and Quantification via LC−MS/ MS.  
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Analysis was performed using an Imtakt Intrada Amino Acid column (50 mm × 3 mm, 3 μm) 
using the following method: T = 0, 86% B; T = 3, 86% B; T = 10, 0% B; T = 11, 0% B; T = 12, 
86% B; T = 14, 86% B; A, water and 100 mM ammonium formate; B, MeCN and 0.1% formic 
acid; rate, 0.6 mL/min; 35 °C column. The flow was routed to waste between T = 7.6 and T = 7.9 
to avoid buffer salts. LPiz was detected at T = 5.8 (m/z 131.1 [M + H]+ ). For Piz quantification, 
an SRM transition (m/z 131.1 → 56.3; source voltage, 86 V; collision energy, 37 V) was 
monitored, and a standard curve (second-order polynomial; R2 = 0.9996) was generated between 
0.1 and 100 μM L-Piz-2HCl standard.  
PzbB/PaiB Sequence Mining and Phylogeny.  
Potential PzbB orthologs were identified in the JGI database using BLASTp with SfaC as the 
query. The following criteria were used to identify potential PzbB orthologs: the presence of a 
PzbA homologue and/or an NRPS having predicted Piz adenylation domain signatures within 
∼15 kb. Hits having low identity scores (0.01) were excluded, and likely Piz loading modules 
were identified by PRISM28 or AntiSmash.29 Identities of PzbB’s used to create the PzbB 
phylogeny in Figure 3 are listed in Table S4. BLASTp 2.6.0+ was used to calculate e values, 
coverages, and protein identities. PaiB homologues were found via InterPro, using the term 
“Transcriptional regulator PAI 2-type”. PaiB from Geobacillus stearothermophilus30 (Protein 
Data Bank entry 2OL5, chain A) was selected as a structural archetype for PaiB/PzbB 
ESPRIPT31 alignment. Efforts were taken to sample PaiB sequences from diverse 
microorganisms. To create a phylogeny of PzbB and PaiB proteins, the amino acid sequences of 
85 putative PzbB’s, 51 PaiB’s, and the C-terminal domains of 10 putative PzbAB chimeras were 
aligned with ClustalOmega. Highly similar PzbB sequences from overrepresented species were 
omitted, and the alignment was manually degapped. A maximum-likelihood phylogeny was 
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estimated using the WAG substitution model with 500 bootstrap simulations. Low-confidence 
branches (<50% of bootstrap replicates) were collapsed in CLC Main Workbench version 8.1. 
Sequence logos were generated from alignments at https://weblogo.berkeley.edu.  
Purification of SfaB, SfaC, and PzbAB.  
First, 5 mL cultures of E. coli Rosetta 2(DE3) carrying expression plasmid pYH004, pYH048, or 
pYH089 were grown overnight and used to inoculate 1 L of LB containing ampicillin (100 
μg/mL) and chloramphenicol (12 μg/ mL), in 2.8 L baffled flasks. After being shaken at 30 °C to 
mid log phase, cultures were cold shocked in an ice−water bath and induced with isopropyl β-D-
1-thiogalactopyranoside (final concentration of 100 μM). After being returned to an 18 °C shaker 
overnight, induced cells were pelleted, decanted, and suspended in 50 mL of lysis buffer [50 mM 
Tris-HCl, 500 mM NaCl, and 25 mM imidazole (pH 8.0)]. The resulting suspension was passed 
through an Avestin high-pressure homogenizer (16000 psi), and the lysate was cleared via 
centrifugation at 13000g for 30 min. For SfaC-His, ammonium sulfate (final concentration of 
40%) precipitation was additionally required to enrich the soluble fraction prior to affinity 
purification. Cleared lysates were incubated with lysis buffer-equilibrated Ni-NTA resin for 30 
min at 4 °C. After being loaded onto a gravity column, the resin was washed three times with 
five column volumes of wash buffer [50 mM HEPES, 500 mM NaCl, and 50 mM imidazole (pH 
8.0)]. For His6-SfaB, the column turned noticeably yellow. For SfaC-His6, the column turned 
noticeably brownish-red. Bound proteins were eluted with 5 mL of elution buffer [50 mM 
HEPES, 500 mM NaCl, and 500 mM imidazole (pH 8.0)]. After sodium dodecyl sulfate− 
polyacrylamide gel electrophoresis (SDS−PAGE) analysis, the elution fraction was concentrated 
[Pierce Concentrators, 9K molecular weight cutoff (MWCO), 7 mL] to ∼0.5 mL and 
subsequently desalted into 50 mM HEPES (pH 8.0) using Zeba Spin Desalting Columns (7K 
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MWCO, 2 mL). Protein concentrations were measured via the Bradford assay with a bovine 
serum albumin standard curve. Enzyme fractions estimated to be >90% pure following 
SDS−PAGE were immediately assayed or were frozen on dry ice and stored at −80 °C. See the 
Supporting Information for enzyme cofactor characterization and SfaB assay details.  
SfaC Kinetic Assay.  
A 1 mM hemin stock solution was prepared in 20 mM NaOH. Kinetic assays were set up with 
the following conditions: SfaC-His6 (0.05−10 μM), N5 -OH-L-ornithine-HCl (5 mM, 
saturating), hemin (0.5−100 μM), and Tris-HCl (50 mM, pH 8.0). The hemin:enzyme ratio was 
maintained in each assay at 10:1. The reaction mixture was incubated at 22 °C for 10 min before 
the substrate was added. At 30, 60, and 90 s, an aliquot was removed from the mixture and 
quenched with an equal volume of 6% sulfosalicylic acid for protein precipitation and sample 
acidification. The cloudy mixture was centrifuged at 21000g for 5 min, and the supernatant was 
analyzed by LC−MS/MS for Piz as described above. The rate of Piz formation was divided by 
the enzyme concentration to obtain kcat. The apparent Km was calculated from reaction progress 
curves using DynaFit32 (Figure S9A).  
Coupled PzbA/B End Point Assays.  
SfaB/C enzyme assays were set up with the following components: His6-SfaB (10 μM), SfaC-
His6 (50 nM), L-ornithine-HCl (1 mM), hemin (0.5 μM), FAD (50 μM), NADPH (2 mM), and 
Tris-HCl (50 mM, pH 8.0). PzbAB (M. tulbaghiae) enzyme assays were set up with the 
following components: PzbAB-His6 (5 μM), L-ornithine-HCl (1 mM), hemin (50 μM), FAD (50 
μM), NADPH (2 mM), and Tris-HCl (50 mM, pH 8.0). Prior to these assays being set up, the 
reaction buffer was vigorously shaken just prior to use to increase the level of dissolved oxygen. 
Reaction mixtures were incubated at 22 °C for 10 min before the substrate was added to allow 
304 
 
cofactor incorporation. Fifteen minutes after catalysis had been initiated with L-Orn, reactions 
were stopped with an equal volume of 6% sulfosalicylic acid. Mixtures were cleared via 
centrifugation at 21000g for 5 min, and supernatants were analyzed by LC−MS as described 
above.  
Characterization of Enzymatically Produced L-Piz. 
First, 200 μL SfaC reaction mixtures were set up as follows: 50 mM phosphate buffer (pH 8.0), 
SfaC-His6 (50 nM), hemin (500 nM), and N5 -OH-Lornithine-HCl (5 mM). After the solution 
had been mixed and the reaction allowed to proceed for ∼15 min, an equal volume of 6% 
sulfosalicylic acid was added to precipitate the protein and quench the reaction. The solution was 
centrifuged at 21000g for 5 min. The supernatant was diluted 1:10 with 20 mM acetic acid. For 
cation exchange purification, a Discovery DSC-SCX SPE column (500 mg, Sigma) was 
conditioned with 2 mL of methanol followed by 2 mL of 20 mM acetic acid. The sample was 
applied to the column and washed with 2 mL of methanol. L-Piz was eluted with 2 mL of 5% 
ammonium hydroxide in 80% methanol. The elution fraction was evaporated under vacuum and 
resuspended in 100 μL of LC−MS grade water for HRMS analysis (Figure S3).  
Marfey’s Analysis.  
Enzymatic Piz was derivatized with 1-fluoro2,4-dinitrophenyl-5-L-alanine amide (FDAA, 
Marfey’s reagent) to determine stereochemistry; 50 μL of 1% FDAA in acetone was added to a 
100 μL aqueous sample. The resulting yellow solution slowly became cloudy, and following 
incubation at 50 °C for 1 h, the solution turned orange. Then 100 μL of 1 M HCl was added to 
quench the reaction. Finally, 100 μL of MeCN was added to dissolve the precipitate. The 
supernatant was filtered (Agilent Captiva Econo Filter, 0.2 μm) before LC−MS/MS. Analysis 
was performed using a Phenomenex Luna C18 column (75 mm × 3 mm, 3 μm) using the 
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following method: T = 0, 10% B; T = 5, 10% B; T = 25, 100% B; T = 27, 100% B; T = 29, 10% 
B; T = 30, 10% B; A, water and 0.1% formic acid; B, MeCN and 0.1% formic acid; rate, 0.6 
mL/min. The stereochemistry was determined against FDAA-derivatized authentic ACS 
Chemical Biology Articles DOI: 10.1021/acschembio.8b01086 ACS Chem. Biol. 2019, 14, 
696−703 701 L-Piz and DL-Piz racemate controls via LC−MS at [M + H]+ m/z 383.1 and 340 
nm (Figure S5).  
L-Piz NMR.  
1 H NMR spectroscopy was carried out at the Washington University in St. Louis Chemistry 
NMR Facility. Spectra were recorded using an Agilent 600 MHz instrument with a DD2 console 
and an Agilent 600 HCN cold probe. L-Piz was purified from in vitro reactions via SAX 
chromatography prior to NMR and dissolved in D2O (Figure S4).  
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